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Ma le cose, dentro di noi, 
sono sempre maledettamente complicate; 
e tanto più inganniamo noi stessi, o tentiamo, 
quanto più evidente e immediato 
si presenta il disinganno.
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Summary!
Mesenchymal stem cells (MSCs) are uniquely capable of crossing germinative layers 
borders (these cell populations are able to differentiate towards ectoderm-, 
mesoderm- and endoderm- derived lineages) and are viewed as promising cells for 
regenerative medicine approaches in several diseases. 
Some undoubtedly limiting factors for the clinical use of MSCs, i.e. for the repair of 
bone defects, are related to many different problems, that only partially today can be 
overcome through ex-vivo expansion and cells modification strategies. 
Considering MSCs sources, the use of fetal annexes-derived MSCs, such as MSCs 
from Whartonʼ jelly of umbilical cord (WJMSCs), or the recruitment of MSCs from 
“stem cell niches” in adult discard tissues, like periodontal ligament (PDL) of 
extracted teeth (PDLMSCs), could be promising in compensating limits of MSCs 
traditional sources, i.e. Bone Marrow, like small cells number, high harvesting 
technique morbility, difficult cells commitment due to early senescence. 
Uniforming and investigating best cells culture conditions with in vitro different 
experimental conditions is useful in our job to understand and control differentiation 
mechanisms and finally to influence the yield and proliferation rate of these MSCs 
populations, together with their osteogenic potential. 
The aim of our study is briefly sumarized:
- To isolate and culture MSCs cells from human Umbilical Cord Whartonʼs Jelly and 
periodontal ligament;
- To compare characteristics between all samples recruited and to link them to 
clinical aspects of tissues donors;
- To characterise both MSCs population in regard to their proliferation and 
differentiation potential;
- To investigate their functional characteristics before and after alginate microbeads 
encapsulation;
VII
- To investigate effects of three-dimensional and microgravity on MSCs before and 
after differentiation.
WJMSCs and PDLSCs were analyzed for the expression of MSC markers, and then 
committed to osteogenic differentiation. Before and after differentiation, alkaline 
phosphatase (ALP) activity, the expression level of a specific osteoblast transcription 
factor (Runx2), and mineralization status were evaluated. The performance of 
WJMSCs and PDLSCs was then compared in 3-D culture systems (alginate beads 
and microgravity system) in terms of viability, proliferation, secretive profile, 
expression of markers and effectiveness of phenotype modulation. 
Characterization of MSCs population was succesfull for all samples investigated, and 
for largest samples cohort (WJMSCs) it was possible to correlate cells biochemical 
parameters to clinical donors features.These findings may help during selection of 
best donors to combine them with scaffolds and biomaterials to promote tissue 
regeneration.
For both MSCs populations, we demonstrated cells can live and grow in 3-D 
systems. All MSCs samples analyzed showed a substantial osteogenic potential, 
before and after encapsulation in alginate microbeads.
Modulation of cells culture conditions, with the use of nanotechnologies strategies or 
the use of bioreactors, like rotating bioreactor (HARV bioreactor, Synthecon, Inc., 
Houston, TX, U.S.A.) has been shown to be a useful and promising approach to 
investigate characteristics and environmental effects of cells/biomaterials 
combinations, in order to predict their effect and potential for regenerative medicine 
strategies.
Key words:
Mesenchymal stem cells, Whartonʼs jelly, Periodontal ligament, Osteogenic 
differentiation markers, Regenerative medicine.
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INTRODUCTION
Chapter 1
Mesenchymal stem cells (MSCs): isolation, characterization and 
differentiation potential.
The use of living cells as therapeutic agents for the maintenance, regeneration, or 
replacement of malfunctioning tissues has been proposed in last decades [Kirouac 
et al, 2008]. Stem cells are the basis for cell therapy. They are functionally 
undifferentiated cells that retain the ability to differentiate in one or more mature 
cell types under appropriate conditions, and to self-renew, representing a 
potentially inexhaustible cell source [Alberts et al, 2002].
Stem cells are defined simply as cells meeting three basic criteria:
- stem cells renew themselves throughout life, i.e., the cells divide to produce 
identical daughter cells and thereby maintain the stem cell population,
- stem cells have the capacity  to undergo differentiation to become specialized 
progeny cells [Burns et al. 2010],
- when stem cells differentiate, they may divide asymmetrically  to yield an iden- 
tical cell and a daughter cell that acquires properties of a particular cell type, 
- stem cells is that they may renew the tissues that they populate. All tissue 
compartments contain cells that satisfy the definition of “stem cells”, and the rate 
at which stem cells contribute to replacement cells varies throughout the body.
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List of abbreviation
ALP! ! ! ! Alkaline Phosphatase 
AML! ! ! ! Acute Myeloid Leukemia
BM-MSCs ! ! ! Bone Marrow Mesenchymal Stem Cells
BMP-2! ! ! Bone Morphogenetic Protein-2 
BSP! ! ! ! Bone Sialoprotein
CD 3! ! ! ! Cluster Of Differentiation 3
CD 14! ! ! Cluster Of Differentiation 14
CD 31! ! ! Cluster Of Differentiation 31
CD 34! ! ! Cluster Of Differentiation 34
CD 45! ! ! Cluster Of Differentiation 45
CD 73! ! ! Cluster Of Differentiation 73
CD 90! ! ! Cluster Of Differentiation 90
CD 105! ! ! Cluster Of Differentiation 105
CD 146! ! ! Cluster Of Differentiation 146
Col1a1! ! ! Collagen type I alpha 1
D-MEM HG ! ! ! Dulbeccoʼs Modified Essential Medium High Glucose
D-MEM LG! ! ! Dulbeccoʼs Modified Essential Medium Low Glucose
ECM ! ! ! ! Extracellular Matrix
EDTA!! ! ! EthyleneDiamineTetraacetic Acid
ESCs!! ! ! Embryonic Stem Cells
FBS! ! ! ! Fetal Bovine Serum
FCS ! ! ! ! Fetal Calf Serum
GSK3β! ! ! Glycogen Synthase Kinase 3 Beta
HA ! ! ! ! Hydroxyapatite
HUC ! ! ! ! Human Umbilical Cord
XI
HERS! ! ! Hertwigʼs Epithelial Root Sheath
HSCs ! ! ! Hematopoietic Stem Cells
HARV! ! ! High Aspect Ratio Vessel
Ibsp ! ! ! ! Integrin-binding Sialoprotein
M-CSF! ! ! Macrophage Colony-Stimulating Factor
MNC ! ! ! ! mononuclear cells
MSCs!! ! ! Mesenchymal Stem Cells
mRNA ! ! ! Messenger Ribonucleic Acid
NF-κB ! ! ! Nuclear Factor kappa B
OC ! ! ! ! Osteocalcin
OPN! ! ! ! Osteopontin
PDL! ! ! ! Periodontal Ligament
PDLABs! ! ! PDLMSCs alginate beads
PDLSCs! ! ! Periodontal Ligament Stem Cells
PDLMSCs! ! ! Periodontal Ligament Mesenchymal Stem Cells
PBS! ! ! ! Phosphate Buffer Solution
PTH! ! ! ! Parathyroid Hormone
RANK!! ! ! Receptor Activator For Nuclear Factor Κ B
RANKL! ! ! Receptor Activator For Nuclear Factor Κ B Ligand
RT-PCR! ! ! Reverse Transcription Polymerase Chain Reaction
Runx2! ! ! Runt-related Transcription Factor 2
RWV ! ! ! ! Rotating Wall Vessel
Spp1! ! ! ! Secreted Phosphoprotein-1
STRO-1! ! ! Stromal Factor-1
TCP ! ! ! ! Tricalcium Phosphate
UC ! ! ! ! Umbilical Cord
UCM! ! ! ! Umbilical Cord Matrix
UC-WJMSCs! ! Umbilical Cord Whartonʼs Jelly Mesenchymal Stem Cells
XII
WJ! ! ! ! Whartonʼs Jelly
WJABs! ! ! WJMSCs alginate beads
WJMSCs! ! ! Whartonʼs Jelly Mesenchymal Stem Cells
Wnt signaling! ! Wingless signaling pathway
To describe different culture conditions for cells encapsulated in alginate microbeads, 
combinations of some different abbreviations were choosen:
- To indicate  WJABs cultured in 6 well-plate (We):
-  “control” culture medium (CCM): WJABs/We/CCM
-  osteogenic differentiation medium (ODM): WJABs/We/ODM
- To indicate  PDLABs cultured in 6 well-plate (We):
-  “control” culture medium (CCM): PDLABs/We/CCM
-  osteogenic differentiation medium (ODM): PDLABs/We/ODM
- To indicate  WJABs cultured in rotating HARV bioreactor 10 ml vessels (HARV):
-  “control” culture medium (CCM): WJABs/HARV/CCM
-  osteogenic differentiation medium (ODM): WJABs/HARV/ODM
- To indicate  PDLABs cultured in rotating HARV bioreactor 10 ml vessels (HARV):
-  “control” culture medium (CCM): PDLABs/HARV/CCM
-  osteogenic differentiation medium (ODM): PDLABs/HARV/ODM.
XIII

Cell-based therapies use either autologous or allogeneic stem cells, depending if 
the recipient is the same as the donor or not, respectively. While autologous cell 
therapy has the advantage of complete immunological compatibility, there are 
many situations where allogeneic cell transplantation is necessary for therapeutic 
efficacy [Cortesini, 2005]. Therapeutic strategies that make use of stem cells have 
been proposed for many clinical applications including Parkinson's and 
Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, 
osteoarthr i t is, and rheumatoid arthr i t is ( for an updated l ist v is i t 
stemcells.nih.gov).
Stem cells that may differentiate into tissues derived from all three germ layers, 
ectoderm, endoderm, and mesoderm, are called “pluripotent” [Weiss & Troyer 
2006] (see FIGURE 1). 
Figure  1: Stem cell division. Green dots: stem cells; Orange dots: progenitor cell;  Light blue dots: 
differentiated cell;  1 - symmetric stem cell division; 2 - asymmetric stem cell division (Green dot  is still stem 
cells, while Orange dot goes on through differentition pathway); 3 - progenitor division and terminal 
differentiation.
Embryonic Stem Cells (ESCs) are the “de facto” pluripotent cells for biomedical 
research. In contrast, biomedical research with postnatally collected tissues and 
stem cells has generated less controversy and enjoyed more therapeutic 
applications to date. This is likely owing to the fact that blood and bone marrow 
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stem cells were found to rescue patients with bone marrow deficiencies [Weiss & 
Troyer 2006 (a)]. 
Many recent evidences demonstrated that in all organisms, stem cells live in 
specialized “niches,” microenvironments including stem cell support cells and 
extracellular matrix. The niche micro-environment regulates the growth and 
differentiation of stem cells [Xie et al. 2000; Shinohara et al. 2001; Shinohara et al. 
2002].
The definition of a mesenchymal stem cell would be “ the putative marrow cell that 
can self renew and give rise to a one or more mesenchymal tissues” [Friedenstein 
et al. 1968].  However, marrow stromal cells, the population of cells within which 
the mesenchymal stem cell is thought to exist, can also differentiate to tissues 
other than those that originate in the embryonic mesoderm, raising questions 
about the appropriate use of the term mesenchymal stem cell. 
In addition to hematopoietic stem cells (HSCs), the bone marrow contains 
mesenchymal stem cells (MSCs). These cells were first recognised by 
Friedenstein and colleagues more than 30 years ago, who identified a non-
phagocytic, adherent, fibroblast-like population that in vitro could regenerate bone, 
cartilage, adipose and stroma [Friedenstein et al. 1968]. 
The cells were thoroughly characterised in regard to their colony forming 
efficiency, strain generation and differentiation into bone, cartilage, adipose tissue 
and myelo-supporting stroma. After transplantation of these cells under the kidney 
capsule, they engrafted in and differentiated into different connective tissue 
lineages [Friedenstein et al. 1974], which indicates that a common progenitor cell 
exists that gives rise to these tissues.
These cells are multipotent stem cells that can differentiate into a variety of cell 
type, such as osteoblasts, chondrocytes, adipocytes, myocites [Wobus 2008; 
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Kadiyala et al. 1997; Dennis et al. 1999; Bruder et al. 1997; Jaiswal et al. 1997; 
Ferrari et al. 1998; Gang et al. 2004; Young et al. 1998] (see FIGURE 2). 
Figure 2: Mesenchymal stem cells can differentiate into several mesenchymal tissues such as bone, cartilage, muscle, 
bone marrow stroma, adipose tissue and tendon.
The term Mesenchymal Stem Cell is descriptive for:
- Mesenchymal status: from Mesenchyme, the embryonic connective tissue that is 
derived from the mesoderm and that differentiates into hematopoietic and 
connective tissue, whereas MSCs do not differentiate into hematopoietic cells.
- Stemness: stem cells are capable of dividing and renewing themselves for long 
periods, they are unspecialised and they can give rise to specialised cell types. 
Their self-renewal potential ensures that they are available for the demands over 
a normal adult lifespan. 
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- Lack of specialisation: a stem cell is that it does not have any tissue-specific 
structure, so they can give rise to specialised cells. 
- Potential: three major classes of stem cells are now recognised: totipotent, 
pluripotent and multipotent stem cells. Multipotent cells, like hematopoietic and 
mesenchymal stem cells, are committed to give rise to cells that have a particular 
function.
MSCs can undergo over 25 passages in vitro (more than 50 cell doublings). This 
demonstrates a high capacity for self-replication; they can be generated frequently 
from a small amount of starting material and they donʼt seem to show signs of 
senescence and apoptosis until 50 population doublings [Campagnoli et al. 2001 
Bruder et al. 1997; Digirolamo et al. 1999; Conget & Minguell 1999]. An overview 
of MSCs hallmark are sumarized in Table 1. MSCs are identified through a 
combination of physical, phenotypic, and functional properties [Giordano et al. 
2007]. The classical assay utilized to identify MSCs is the colony forming unit 
(CFU). This assay identifies adherent spindle shaped cells that proliferate to form 
colonies and can be induced to differentiate into adipocytes, osteocytes, and 
chondrocytes [Prockop, 1997; Bianco & Gehron Robey 2000; Beyer Nardi & da 
Silva Meirelles 2006; Sethe et al. 2006; Pountos & Giannoudis 2005].
Isolation                                                                              Differentiation
Bone marrow
Trabecular bone
Periosteum
Articular cartilage
Synovium
Synovial fluid
Muscles
Adipose tissue
Tendons
Blood
Blood vessels
Umbilical cord vessels
Fetal tissues
Spleen and Tymus
Skin
Mesenchymal stem cells
Osteoblasts
Chndrocytes
Adipocytes
Cardiac myocytes
Fibroblasts
Myofibroblasts
Skeletal myocytes
Pericytes
Tenocytes
Retinal cells
Neural cells
Astrocytes
Hepatocytes
Pancreatic cells
Hematopoetic supporting stroma
Table 1: Sources and cell types derived from MSCs (all references in: Pountos & Giannoudis. Injury 2005;36 Suppl 3:S8-
S12.)
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Great effort has been applied to identify specific surface markers on MSCs for 
definition and identification of the cells in vivo and in vitro. The in vivo phenotype of 
MSCs has not been entirely  established. However, MSCs expanded in vitro do not 
express the hematopoietic or endothelial surface markers CD11b, CD14, CD31, 
CD34 or CD45 but are positive for CD29, CD44, CD73, CD105 and CD166 
[Pittenger et al. 1999; Conget & Minguell 1999; Haynesworth et al. 1992; Noort et 
al 2002]. Molecules suggested to be specific for primitive MSCs and their more 
differentiated progeny are STRO-1, CD63, CD49a and CD166 [Stewart et al. 
2003].
1.1! MSCs from different sources
Human MSCs were first identified in postnatal bone marrow and later in a variety 
of other human adult tissues, including muscle, connective tissue, skin, adipose 
tissue, perichondrium, trabecular bone [Young et al. 2001; Zuk et al. 2002; De 
Ugarte et al. 2003; Arai et al. 2002; Sakaguchi et al. 2004]. 
Bone marrow-derived stem cells (BM-MSCs) are reported to be more difficult to 
extract from the marrow cavity in normal aging because the red marrow space 
changes to a yellow marrow (fat-filled) as a consequence of aging [Weiss & Troyer 
2006 (a)]. Optimal stem cell aspirates from the marrow are found in young donors. 
Although BM-MSCs become senescent (cease to divide in vitro) by passage 6–10. 
Moreover MSCs take part in matrix remodelling and possess paracrine activity 
particularly in the environment of a wound [Fathke et al. 2004; Neuss et al. 2009]. 
These characteristics make them an interesting tool for wound healing 
applications. However, any medical application is hampered by the low amount of 
MSC in bone marrow, in particular in older patients, as well as the high cell 
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senescence, limited proliferation and differentiation capacity of these cells [Bruder 
et al. 1997; Mendes et al. 2002].
It is generally thought that stem cells derived from “younger” tissues, for example, 
tissues derived from the early embryo or fetus, would have longer telomeres and 
have the capacity for extended expansion in culture prior to becoming senescent 
(see FIGURE 3).
In the last 10 years, umbilical cord blood has been shown to be therapeutically 
useful for rescuing patients with bone marrow- related deficits and inborn errors of 
metabolism. Umbilical cord blood offers advantages over bone marrow because 
cord blood does not require perfect human leukocyte antigen (HLA) tissue 
matching, has less incidence of graft vs host disease, and may be used 
allogenically [Weiss & Troyer 2006 (b)].
MSC-like cells can be isolated from so many different tissues discard at the 
moment of delivery, and they could be considered as young as the new born. The 
collection of MSC-like cells from tissues that are discarded at birth is easier and 
less expensive than collecting MSCs from a bone marrow aspirate. During the 
collection of these tissues, there is no health impact on either the mother or the 
newborn. At least these cells may be stored frozen and then thawed to provide 
stem cells for therapeutic use decades after cryogenic storage. 
Fetal annexes, such as UC, UC  blood, placenta, amniotic fluids, have been shown 
to be good MSCs sources [Romanov et al. 2003; Sarugaser et al. 2009; Soncini et 
al. 2007]. They can also be isolated from several fetal tissues, such as blood, bone 
marrow and liver, kidney, lung, spleen, pancreas, blood and brain [Yu et al. 2004; 
Campagnoli et al. 2001; in 't Anker et al. 2003; Yu et al. 2003; Airey et al. 2004 
Kægler G & Wernet P 2006].
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Figure 3: Adult and fetal stem cells can be considered “multipotent”.
The differentiative capacity of fetal and adult MSCs may vary. D'Ippolito et al. 
examined the osteogenic differentiation of postnatal MSCs of different age and 
found that younger individuals exhibit increased osteogenic potential than older 
individuals [D'Ippolito et al 1999]. Also, MSCs from various fetal tissues exhibit 
diverse differential potential; osteogenic differentiation was reduced in MSCs 
derived from liver and adipogenic differentiation was less in spleen-derived MSCs, 
compared to bone marrow and lung- derived MSCs [in 't Anker et al. 2003].
It has been shown, that in contrast to its adult bone marrow (BM) counterpart, the 
stem cell compartment in CB is less mature [Kægler G & Wernet P 2006]. 
Considering adipose tissue and his procurement, it can be considered a discard 
tissue, but its procurement from living patients involves an invasive and painful 
surgical procedure [Seshareddy et al. 2008].
Contrarily MSCs can be isolated from UC without any risk for both patients, mother 
and newborn, avoiding morbility  and senecence problems related to different 
MSCs sources.
Different works demostrated that the ontological and anatomical origins of MSCs, 
i.e. Bone Marrow Mesenchymal Stem Cells (BM-MSCs) compared to UC MSCs or 
mandibular-derived MSCs, have influence on the differentiation capacities and 
behaviour both in a 3-dimensional matrix or in monolayer [Schneider et al. 2010; 
Aghaloo et al. 2010].
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MSCs are low-immunogenic both in vitro and in vivo [Horwitz 2001; Newman 
2009], suggesting their utility for autologous as well as allogeneic transplantations.
Most of these data have been carried out in vitro and as of yet, MSCs have not 
been completely shown to be capable of regeneration or maintenance of a tissue 
in vivo.
Differences between fetal and adult MSCs
Several differences between fetal MSCs and adult MSCs were noted:
- fetal MSCs appear to have greater expansion capacity  in vitro and faster 
doubling times than adult MSCs and this may be due to their having longer 
telomeres than adult MSCs [Guillot et al. 2007];
- fetal MSCs appear to lack some of the immune suppression properties 
observed in adult MSCs [Gotherstrom et al. 2003]. 
- fetal MSCs appear to lack HLA class II, in contrast to adult MSCs [Gotherstrom 
et al. 2003] 
- fetal MSCs appear to synthesize HLA- G, which is absent in adult MSCs 
[Gotherstrom et al.2003]. 
- fetal MSCs express slightly  different cytokine profile than adult MSCs. In 
summary, primitive MSCs have a greater ability to expand in culture perhaps 
due to their relative youth and have different physiology that is likely due to their 
naïve status. 
These differences are similar those observed between umbilical cord blood and 
adult peripheral blood [Troyer & Weiss 2008].
Considering markers expression, WJ cells are CD45, CD34 and HLA class II 
negative; CD73, CD90, CD105 can HLA-class I positive. Similar to early  passage 
both adult MSCs and WJC cells, they grow robustly, can be frozen/thawed, and 
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engineered to express exogenous proteins [Troyer & Weiss 2008]. Thus, the 
similarities of WJ cells and MSCs can be summarized as follows: WJ cells share 
the basic criteria used to define adult-derived MSCs. Additionally, stromal support, 
specific immune properties of low immunogenicity and immune suppression and 
the ability to migrate to pathology are taken to be properties of adult MSCs. These 
properties are observed in WJC cells too [Troyer & Weiss 2008].
1.1.1 ! Adult MSCs 
Adult stem cells have been isolated from different tissues, such as bone marrow, 
brain, liver, skin, skeletal muscle, gastrointestinal tract, pancreas, eye, dental pulp, 
appendix, peripheral blood, blood vessels, teeth, heart, gut, liver, ovarian 
epithelium, and testis [Atala et al. 2007; De Coppi et al. 2006]. They are thought to 
reside in a specific area of each tissue (called a "stem cell niche"). Stem cells may 
remain quiescent (non-dividing) for long periods of time until they are activated by 
a normal need for more cells to maintain tissues, or by disease or tissue injury. 
Scientific interest in adult stem cells has centered on their ability  to divide or self-
renew indefinitely, and generate all the cell types of the organ from which they 
originate, potentially regenerating the entire organ from a few cells (for an updated 
list visit stemcells.nih.gov). 
The use of adult stem cells in research and therapy is considered to be non-
controversial as they are derived from adult tissue samples.  Their use avoid all 
the ethical problems associated with ESCs and so far they have been the only 
stem population to be employed in the clinical setting [Segers & Lee 2008]. 
Typically, there is a very small number of stem cells in each tissue, and once 
removed from the body, their capacity to divide is limited, making generation of 
large quantities of stem cells difficult. Scientists in many laboratories are trying to 
find better ways to grow large quantities of adult stem cells in cell culture and to 
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manipulate them to generate specific cell types so they can be used to treat injury 
or disease. Some examples of potential treatments include regenerating bone 
using cells derived from bone marrow stroma, developing insulin-producing cells 
for type 1 diabetes, and repairing damaged heart muscle following a heart attack 
with cardiac muscle cells.
Although there are several reports of pluripotent cells being isolated from adults, 
this work is in need of verification [Young et al. 1999; Young et al. 2001; Jian et al. 
2002; Reyes et al. 2001; Kogler et al. 2004]. Such verification is important 
because an alternative source of pluripotent cells, cells derived from adults, offers 
the best of both worlds: pluripotent cells for therapeutics and cells that are 
collected with consent from adults (no controversy there).
1.1.2! Fetal MSCs
MSCs represent a minor fraction in bone marrow and other tissues. The exact 
amount is difficult to calculate since different methods used to collect the bone 
marrow affect the harvest, but it is estimated that MSCs comprise 0.001% to 
0.01% of the total bone marrow, [Caplan 1994; Pittenger et al. 1999]. Furthermore, 
the prevalence of MSCs declines with advancing age. In the marrow of a newborn, 
one MSC is found among 10,000 nucleated marrow cells, as compared to one 
MSC per 250,000 nucleated marrow cells in the adult bone marrow and one per 
2×106 in a 80-year old [Caplan 1994]. In 1st trimester fetal blood, one MSCs is 
found among 3000 nucleated cells and frequency declined with advancing 
gestation. [Campagnoli et al. 2001]. The amount of MSCs in different fetal tissues 
also varies. In 2nd trimester fetal tissues, one MSC is estimated to be present 
among 400 cells in the bone marrow, 1/700 in lung, 1/600 in spleen and 1/3500 in 
liver [in 't Anker et al. 2003]. The decrease of circulating MSCs in fetal blood during 
gestation and the higher frequency of MSCs in the 2nd trimester bone marrow 
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might be related to their migration from one hematopoietic site to another in the 
developing fetus. Different fetal tissues have been shown rich sources of MSCs 
and useful for therapies.
Itʼs nevertheless  true that cells residing in fetal organs (liver, lung, brain, etc.) are 
impossible to collect without causing serious health complications for the fetus/
baby/mother, so they have to be carefuly considered as interesting from the 
practical point of view. 
Human ESCs and stem cells derived from human fetal tissues have raised moral/
ethical concerns that have yet to be adequately discussed and addressed by our 
society [Weiss & Troyer 2006]. So many different and useful sources which do not 
affect baby or mother can be considered, as fetal annexes, like cord blood, 
amniotic fluid,  umbilical cord and placenta [Weiss & Troyer 2006].
1.2! Umbilical Cord Whartonʼs Jelly MSCs
Umbilical Cord tissues overview
The UC represents the link between mother and fetus during all pregnancy. It is 
composed of a special embryonic mucous connective tissue, called Whartonʼs jelly 
(WJ), lying between the covering amniotic epithelium and the umbilical vessels. 
The main role of this jelly-like material is to prevent the compression, torsion, and 
bending of the enclosed vessels, two arteries and one vein, which provide blood 
flow between fetal and maternal circulation [Can & Karahuseyinoglu 2007].
The human UC weighs approximately 40 g, its length reaches to approximately 60 
cm, and it has a mean diameter of 1.5 cm at term [Raio et al. 1999; Di Naro et al. 
2001]. It is covered by a single/multiple layer(s) of squamous-cubic epithelial cells 
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[Copland et al. 2002; Mizoguchi et al. 2004] called amniotic epithelium. Those 
epithelial cells display ultrastructural and functional characteristics to those seen in 
keratinocytes [Sanmano et al. 2005] and were shown to possess stem cell 
characteristics [Miki et al. 2005].
The inner tissue architecture includes a mucous connective tissue comprised of 
specialized fibroblast-like cells and occasional mast cells embedded in an 
amorphous ground substance rich in proteoglycans, mainly  hyaluronic acid. 
Neither capillaries nor lymphatics are found in the UC (see FIGURE 4). 
Figure 4: The umbilical cord (UC) in cross section.(modified from http://www.med.uio.no/dlo/mikro/Images/img03748.jpg)
MSCs isolation from Umbilical cord compartments: Whartonʼs Jelly MSCs
MSCs can be isolated from UC blood, placenta, perivascular areas, amniotic fluid, 
and from the tissue surrounding the UC vessels, the WJ [Weiss & Troyer 2006]. 
Different groups focused on different extraction protocols for MSCs from UC. As a 
result of short enzymatic digestion, Romanov et al. obtained cell populations 
positively differing from similar cell populations isolated from other sources 
alternative to bone marrow, like lipoaspirate [Romanov et al. 2003]. They reported 
only one contaminating cell type present (endothelial cells) that essentially does 
not affect the final outcome, while  other cellular components of the venous wall or 
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Whartonʼs jelly were reported to be absent in the cell suspensions, due to the short 
time of incubation with collagenase [Romanov et al. 2003].
In 2006 several groups demonstrated that cells from UCʼs WJ share properties of 
MSCs, like similar surface phenotype and differentiation capability  [Weiss & Troyer 
2006; Conconi et al. 2006; Lu et al. 2006]. Moreover these cells are more similar 
to fetal MSCs in terms of their in vitro expansion potential.
While MSCs have been isolated from several UC compartements [Weiss et al. 
2006 (a); Can & Karahuseyinoglu 2007; Secco et al. 2007], the choice of focusing 
on only one of them, the mesodermal one, could provide a purer derived 
population, avoiding any contamination and selecting a source embryologically 
nearer to MSCs tissue of origin [Baksh et al. 2007; Secco et al. 2007].
WJ is named for the English physician and anatomist Thomas Wharton 
(1614-1673) who first described it in his publication Adenographia, or "The 
Description of the Glands of the Entire Body", first published in 1656 (see FIGURE 
5).
Figure 5: Thomas Wharton.
Due to many reports and careful examination of cellular and ECM components, 
human UC shows a tissue compartmentalization in which cellular characteristics 
and ECM elements differ from each other. 
 Mesenchymal stem cells (MSCs): isolation, characterization and differentiation
14
In past five years three different research labs have published on the isolation and 
characterization of cells from the Whartonʼs jelly: Dr. Weissʼ lab  at the Kansas 
State University, Dr. Daviesʼ lab  at the University of Toronto and Dr. Y. S. Fu at the 
National Yang-Ming University, Taipei [Weiss et al. 2006 (a); Sarugaser et al. 2005; 
Fu el al. 2006]. All three groups reported that Umbilical Cord Matrix (UCM) cells 
are MSC-like cells and are robust. These cells can be isolated easily, frozen/
thawed, clonally expanded, engineered to express exogenous proteins, and 
extensively expanded in culture. In addition, human UCM cells express a marker 
of neural precursors, nestin, without exposure to differentiation signals [Weiss et 
al. 2006 (a); Fu el al. 2006]. 
Whether UCM cells are MSC-like or fit into a unique niche is currently not clear. 
It has been demonstrated  that UCM cells express the pluripotency gene mar- kers 
Oct-4, nanog, and Sox-2 at low levels relative to ESCs [Carlin et al. 2006].  On the 
other hand, these findings may serve as evidence that the cord matrix cell 
population has a subset of primitive stem cells. 
From these findings, it is suggested that UCM cells offer advantages over stem 
cells as a source of therapeutic cells. First, UCM cells are derived from a 
noncontroversial, inexhaustible source, and can be harvested noninvasively at low 
cost. Second, unlike human ESCs, UCM cells did not induce teratomas or death 
after 1 × 106 to 6 × 106 human UCM cells were transplanted either intravenously or 
subcutaneously into severe combined immunodeficient mice [Weiss et al. 2006 
(b)].
A major potential application of these cells in medicine is for “tissue engineering,” 
in which the ultimate goal is to provide “off-the-shelf tissues” and organs. UCM 
cells demonstrate excellent cell growth properties on bioabsorbable polymer 
constructs [Kadneret al. 2004]. 
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In recent years, several investigators published protocols for isolating MSCs from 
the UC tissue [Karahuseyinoglu et al. 2007; Lund et al. 2007]. Basically, the 
isolation procedure starts with the removal of umbilical vessels. The cord is then 
cut down to smaller segments or chopped into small pieces which are 
subsequently  enzymatically digested [Fu et al. 2006]. Alternative isolation methods 
without removal of vessels and without enzymatic digestions or explant cultures 
have also been described [Moretti et al. 2010]. To isolate cells from the 
perivascular tissue or the subendothelium of the umbilical vein, further methods 
have been established [Sarugaser et al. 2005].
Moretti et al. have used a protocol without enzymatic digestion and without 
removal of umbilical vessels to isolate MSC-like cells from whole UC  tissue in an 
explant culture approach [Moretti et al. 2010]. 
Technical procedures to isolate MSCs from the WJ are still poorly investigated and 
vary  dramatically depending on the authors [De Bruyn et al. 2010]. Trypsin or other 
enzymes such as hyaluronidase have been frequently but not systematically 
added to the collagenase, and the incubation time also varies from 4 to >24h. 
Moreover, some authors have removed the cord vessels by stripping them 
manually before enzymatic treatment. Several groups do not use enzymatic treat- 
ment, but most of them dissected the cord segment into very  small pieces (1–3 
mm3), with or without discarding the cord vessels [De Bruyn et al. 2010].
Furthermore, UC-derived cells could be efficiently cryopreserved and revitalized. 
Using  a cryo-medium containing 80% human serum, 10% culture medium, and 10 
% DMSO Moretti et al. reported cell survival rate after rapid thawing at 37°C  of 75 
+12.8% [Moretti et al. 2010].
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UC stromal cells characterization
In contrast to other progenitor cell populations, such as, for instance, 
hematopoietic stem cells, there is currently  no specific marker available defining 
human MSCs.  Several authors have contributed to the definition of markers useful 
for BM-MSC immunophenotyping. Several recent reports have extended the range 
of markers that help  characterize and identify MSC from different sources. In 
particular, WJ-derived MSC  have undergone an unprecedented characterization 
process further extending the similarities (and differences) with respect to other 
MSC populations [Anzalone et al. 2010].
The expression of a set of markers combined with the demonstration of in vitro 
multi-lineage differentiation potential is necessary  to identify MSCs in UC- derived 
cell populations [Dominici et al. 2006].
The surface antigen CD105, CD73, and CD90 are widely used for the identification 
of UC-derived stromal cells, as these markers are proposed by the ISCT as 
positive markers for human MSCs [Dominici et al. 2006].
However, these epitopes are also expressed by hematopoietic and endothelial 
cells, which are two potential contaminants in UC-derived cell populations. 
Consequently, it is necessary  to carefully exclude cells from hematopoietic or 
endothelial origin using surface markers, such as CD45, CD34, or CD31. UC-
derived stroma cells were found positive for pluripotency markers usually 
expressed by ESCs such as Sox-2, which underlines their primitive nature [Moretti 
et al. 2010]. With growing evidence that MSC-like cell population isolated from UC 
tissues are rather heterogeneous, at least in regard to primitive marker expression, 
the identification of a universal marker defining primitive human MSCs remains 
challenging (see Table 3). The most convincing biological property for the 
identification of MSCs remains the capability to differentiate into mesodermal 
lineages.
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Markers BM-MSCs WJ-MSCs
CD10 + +
CD13 + +
CD14 - -
CD29 + +
CD31 - -
CD33 - -
CD34 - -
CD44 + +
CD38 - -
CD45 - -
CD49e + +
CD51 + +
CD54 + NA
CD56 + -
CD59 + NA
CD68 NA +
CD71 + NA
CD73 + +
CD79 - NA
CD80 - +
CD86 - -
CD90 + +
CD105 + +
CD106 - +/-
CD117 - +
CD163 NA -
CD166 + +
CD235a - NA
HLA-A + +
HLA-B + +
HLA-C + +
HLA-DR - -
HLA-G + +
HNF-4α NA +
Vimentin + +
Sox2 + +
Nestin + +
Gd2 + +
STRO-1 - +/-
NA: not applicable
Table 3: Intra- and extra-cellular markers of BM- and WJ- derived MSCs are reported. (all references in: Anzalone et al. 
Stem Cells Dev 2010; 19:423-38; Moretti et al. Adv Biochem Eng Biotechnol 2010;123:29-54)
UC stromal cells differentiation
The differentiation repertoire of stroma cells derived from UC tissue reported in the 
literature till July 2009 is summarized in Table 4.
 Mesenchymal stem cells (MSCs): isolation, characterization and differentiation
18
Cell type
Mesodermal lineage Adipocyte
Chondromyocyte
Osteocyte
Cardiomyocyte
Skeletal myocyte
Endothelial myocyte
Ectodermal lineage Neuronal cells
Endodermal lineage Islet-like cells
Immature hepatocyte
Table 4: Differentiation potential of stroma cells derived from human umbilical cord tissue reported in the literature till July 
2009 (all references in: Moretti et al. Adv Biochem Eng Biotechnol. 2010;123:29-54).
As the UC stromal cells originated from extraembryonic mesoderm, adipogenic, 
chondrogenic, osteogenic, cardiomygenic, and skeletal myogenic inductions have 
been the most studied cell lineages with in vitro and in vivo studies [Beyer Nardi & 
da Silva Meirelles 2006; Can & Karahuseyinoglu 2007; Weiss & Troyer 2006; 
Weiss et al. 2006 (a); Troyer & Weiss 2008]. Some of these findings are 
summarized in Table 5.
Differentiation type Cell type
In vitro Adipocyte Chondrocyte Osteocyte Cardiomyocyte
Skeletal myocyte Neuronal/glial precursor 
Dopaminergic neuron Endothelial cell
In vivo* Dopaminergic neuron 
Photoreceptor rescue 
Endothelial cell
Skeletal myocyte
* in rodents
Table 5: In vitro and in vivo differentiation competence of the human umbilical cord stromal cells (all references in: Can & 
Karahuseyinoglu Stem Cells 2007;25:2886-2895.)
Increasing evidence, indeed, indicates that MSC  populations are heterogeneous 
with coexisting subsets having varying potency; this applies to bone marrow MSCs 
as well as to MSCs from other tissues. I.e. Karystinou et al. reported that human 
synovium-derived clonal MSCs were all capable of osteogenic and chondrogenic 
differentiation although with varying potency, but only 30% of the clonal 
populations tested were able to differentiate into adipocytes [Karystinou et al. 
2009].
Considering UC stromal cells, most studies agree that WJ-MSC can be suc- 
cessfully induced toward connective tissue phenotypes (osteoblasts, adipocytes, 
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and chondrocytes), thus opening new paths in regenerative medicine 
applications , i.e., to the musculoskeletal system [Anzalone et al. 2010]. 
Cells isolated from perivascular tissues of the umbilical vein showed a high 
osteogenic potential with spontaneous formation of bone nodules [Sarugaser et al. 
2005], which was even evaluated higher than the potential of bone-marrow MSCs 
in a comparative study [Baksh et al. 2007]. Recently, two sub-populations were 
evidenced in cultures of WJ-derived MSCs with regard to the expression of 
vimentin and pan-cytokeratin filaments [Karahuseyinoglu et al. 2007].
In 2003, Mitchell et al. reported that UCM cells can be induced in vitro to become 
cells with morphological and biochemical characteristics of “neural-like” cells 
expressing neuron-specific enolase, as well as other neural cell markers [Mitchell 
et al. 2003]. The multilineage potential of UCM stem cells was also verified by 
induction in vitro into chondrogenic, osteogenic, and adipogenic lineages [Wang et 
al. 2004; Fu et al. 2006]. Differentiation to cardiomyocytes was also reported but 
remains controversial. I.e. Wang et al. demonstrated for instance that WJCs could 
be induced to cells exhibiting cardiomyocyte morphology and expressing specific 
markers (N-cadherin and cardiac troponin) using 5-azacytidine or cardiomyocyte- 
conditioned medium [Wang et al. 2004]. I.e. Kadner et al. minced either UC 
vessels or whole cord to derive an autologous cell source of myofibroblasts for 
cardiovascular tissue engineering [Kadner et al. 2002], and WJ cells as well were 
described as “smooth muscle cells”, and named “myofibroblasts” after in situ 
labeling of vimentin, desmin, α-actin, and myosin [Kadner et al, 2004]. Sarugaser 
et al. investigated human umbilical cord perivascular cells, which were discarded, 
or not specifically isolated, in the previous studies, but they identified it as a 
subpopulation that, when isolated, would be capable of exhibiting a functional 
mesenchymal phenotype [Sarugaser et al. 2005].
In addition, it has been shown that UC-MSCs can successfully differentiate i.e. to 
endothelial cells after addition of VEGF and b-FGF [Kestendjieva et  al. 2008] and 
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can form vessel-like structures in matrigel cultures [Kestendjieva et  al. 2008; 
Chen et al. 2009]. For instance, WJ cells (WJCs) could be induced to skeletal 
myocytes when placed in myogenic medium [Conconi et al. 2006]. 
Different reports about trans differentiation of UCB cells into neural cells aroused 
great interest for investigators for their clinical implication and significance in 
central nervous system, and pushed them to focus on UC  stromal cells as source 
for isolation, expantion and differentiation into neural cells [Jeong et al. 2004; Ma 
et al. 2005]. WJ MSCs after induction expressed nestin, beta-tubulinIII, 
neurofilament and glial fibrillary acidic protein [Ma et al. 2005]. 
Several attempts have been made to use stem cells from different origins, 
including bone marrow stem cells, neuroepithelical stem cells, fetal neural stem 
cells, and umbilical cord blood cells, for treatment of focal ischemia [Jomura et al. 
2007]. Therapeutic effects of rat umbilical cord matrix cells transplantation in 
treating cerebral global ischemia were evaluated using a reproducible model in 
rats, with promising results (indirect reduction of the percentage of damaged 
hippocampal neurons after cardiac arrest and resuscitation) [Jomura et al. 2007]. 
Mitchell et al., using a similar approach, reported that the fibroblast-like cells of WJ 
could be induced to differentiate into “neural-like” cells expressing neuron-specific 
enolase, as well as other neural cell markers. 
Transplanted human umbilical cord (HUC) MSCs migrated towards the ischemic 
boundary zone and differentiated into glial, neuronal, doublecortin+, CXCR4+, and 
vascular endothelial cells to enhance neuroplasticity in the ischemic brain. In 
addition, HUCMSCs transplantation promoted the formation of new vessels to 
increase local cortical blood flow in the ischemic hemisphere [Ding et al. 2007].
Recent findings suggest that UC-MSCs can differentiate into endodermal lineages. 
Campard et al. reported that UC-matrix cells constitutively expressed markers of 
hepatic lineage, such as albumin, alpha-fetoprotein, cytokeratin-19, connexin-32, 
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and dipeptidyl peptidase IV. After in vitro hepatic induction, cells exhibiting a 
hepatocyte-like morphology with hepatic features such as specific markers up-
regulation and urea production were observed. However, the authors pointed out 
that their cells lack important characteristics of functional liver cells and thus 
conclude that UC-matrix cells can be differentiated at least to immature 
hepatocytes [Campard et al. 2008]. 
At present time, results of studies comparing the differentiation potential of UC-
derived MSCs with other sources should be carefully interpreted. More work is 
needed to attest whether cells isolated from a defined compartment of the UC is 
more suitable for a specific differentiation lineage. This information would be of 
tremendous importance for clinical applications of UC-derived MSCs, WJ cells too.
1.3! Periodontal Ligament MSCs
Periodontal Ligament overview
Periodontium refers to the specialized tissues that both surround and support the 
teeth, maintaining them in the maxillary and mandibular bones (see FIGURE 6). 
The periodontal ligament (PDL) is a connective tissue attached to tooth and 
alveolar bone. The alveolar process is the thickened ridge of bone that contains 
the tooth sockets on bones that bear teeth. It is also referred to as the alveolar 
bone. Bundle bone is a histologic term for the portion of the bone of the alveolar 
process that surrounds teeth and into which the collagen fibers of the periodontal 
ligament are embedded. It can also be referred to as alveolar bone proper 
[Mörmann & Ciancio 1997; Beertsen et al.1997].
Teeth are epithelio-mesenchymal organs developing and functioning in intimate 
coordination with periodontal tissues and bone [Fleischmannova et al 2010]. The 
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tooth-alveolar bone complex develops in the context of continuing epithelio-
mesenchymal interactions between the oral ectoderm and the mesenchymal cells 
of neural crest origin. 
Figure 6: Periodontal ligament anatomy (modifed by: http://www.studiodentaire.com/en/glossary/tooth.php) 
Tooth development starts with a locally  circumscribed thickening of the oral 
ectoderm that induces condensation of the local neural-crest-derived 
mesenchyme. Subsequently, at the bud stage, the odontogenic potential shifts to 
the dental mesenchyme, and signals from the dental mesenchyme induce 
formation of the epithelial signaling center regulating the bud-to-cap transition, the 
primary enamel knot [Jernvall et al., 1998]. During the bell stage, mesenchymal 
cells in contact with the dental epithelium differentiate into dentin- producing 
odontoblasts, and the adjacent layer of inner enamel epithelium cells differentiates 
into enamel-producing ameloblasts. The most superficial mesenchymal part of the 
tooth germ, the dental follicle surrounding the tooth epithelium and mesenchymal 
papilla, gives rise to periodontal structures: cementum, PDL and alveolar bone. 
During the eruption process, tooth roots are formed, and molecular interactions 
between tooth root epithelium and the dental follicle mesenchymal cells direct 
periodontium formation [Fleischmannova et al 2010] (see FIGURE 7).
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Signaling interactions between dental follicle cells and the  Hertwigʼs epithelial root 
sheath (HERS) result in the development of periodontium cementoblasts, 
osteoblasts, and fibroblasts from the mesenchymal cells of the dental follicle 
[Nakatomi et al. 2006]. Fibroblasts give rise to periodontal ligament fibers that are 
embedded in cementoblast-produced cementum at the side adjacent to the root 
dentin and in alveolar bone produced by  dental follicle osteoblasts at the side 
adjacent to the jawbone. 
Figure 7: Tooth development is traditionally considered a series of stages that reflect key processes.
Cementoblasts are believed to differentiate from dental follicle cells migrating 
through the increasing space between the HERS cells during HERS fenestration 
[Diekwisch 2002]. Between cementoblasts and osteoblasts of the alveolar bone, 
the PDL is maintained. The PDL is highly  vascularized and innervated region with 
heterogeneous populations, as well as a source of signaling factors and immature 
cells for periodontal homeostasis and regeneration. 
Different periodontal structures develop from initially homogenous mesenchymal 
cells of the dental follicle. The tightly balanced interaction in the development and 
maintenance of the tooth-periodontium-bone complex can be shown by  how the 
failure of one component affects the others [Blair et al., 2008]. Disturbances in 
bone homeostasis causing decreased systemic or periodontal bone mineralization 
(periodontitis, osteoporosis, osteolysis) may result in premature tooth loss. 
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Periodontal ligament stem cells
Human periodontal ligament stem cells (PDLSCs) are a unique population of 
MSCs which demonstrate the capacity  to generate cementum- and periodontal 
ligament-like structures in vivo. As such, PDLSCs represent a promising cell-
based therapy in reconstructive dentistry  for the treatment of periodontal disease. 
[Mrozik et al. 2010]
The presence of multiple cell types (fibroblasts, cementoblasts, and osteoblasts) 
within the postnatal periodontal ligament suggests that these cells may share 
common ancestors. The possibility that progenitor cells might exist in the postnatal 
periodontal ligament has been recognized but not even demonstrated in the past 
[Melcher et al. 1985]. Anyway these cells were believed to provide a renewable 
cell source for normal tissue homeostasis and periodontal wound healing [Pitaru el 
al. 1994; Gould et al. 1980].
Recently, multipotent stem cell populations, named periodontal ligament stem cells 
(PDLSCs), have been isolated from the periodontal ligament of extracted human 
third molar teeth [Seo et al. 2004]. These PDLSCs have been shown able to get 
rise to adherent clonogenic clusters that resemble fibroblasts; to be capable of 
developing into adipocytes, osteoblast- and cementoblast-like cells in vitro; to be 
capable of producing cementum- and periodontal ligament-like tissues in vivo [Seo 
et al. 2004; Gronthos et al. 2006; Shi et al. 2005]. PDLSCs express an array of 
cementoblast and osteoblast markers as well as several bone marrow-derived 
mesenchymal stem/stromal cell associated markers [Gronthos et al. 2000; 
Trubiani et al. 2005]. The similarity between PDLSCs and bone marrow MSCs 
suggested that PDLSCs represent another MSC-like population. On the other 
hand also research efforts to identify markers uniquely expressed by PDLSCs has 
been useful to discriminate these cells from other types of MSC-like cells in dental 
tissues [Chen et al. 2006].
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The first reported isolation and identification of MSCs in human periodontal 
ligament was in 2004 [Seo et al. 2004]. Since then, there has been considerable 
activity  trying to understand the function of these cell populations and their 
interactions with each other with a view to laying the fundamental groundwork for 
clinical applications in regenerative periodontics. A number of studies have now 
been carried out to confirm the presence of MSC-like cells in the periodontal 
ligament. These have not been limited to human but also include mouse, rat, and 
sheep [Gronthos et al. 2006; Trubiani et al. 2005; Nagatomo et al. 2006; Jo et al. 
2007; Ivanovski et al. 2001; Luan et al. 2006; Techawattanawisal et al. 2007]. All of 
these studies have confirmed the multipotent nature of PDLSCs, and while the 
initial studies indicated this to include an ability  to differentiate into osteoblast, 
cementoblast, or adipogenic phenotypes, at least one recent study has indicated 
an ability of these cells to also differentiate into neuronal precursors 
[Techawattanawisal et al. 2007]. Importantly, cryopreservation does not seem to 
alter the functional properties of PDLSCs [Seo et al. 2005]. This will have 
significant relevance should “banking” of these cells become a clinical necessity.
Identification of stem cells in postnatal dental tissues has presented exciting 
possibilities for the application of tissue engineering as well as gene- and cell-
based therapies in reconstructive dentistry. The use of stem cells with these 
technologies may constitute novel strategies for regenerative periodontal therapy. 
Periodontal diseases are infectious diseases characterised by irreversible 
destruction of supporting tissue for tooth, including periodontium, cementum, 
alveolar bone, and gingiva [Seo et al. 2004; Philstrom et al. 2005]. These changes 
often lead to an aesthetically  and functionally compromised dentition. Thus, 
regeneration of these tissue lost through periodontitis is the ultimate goal of 
periodontal therapy [Yang et al. 2010]. Periodontal regeneration can be defined as 
the complete restoration of the lost tissues to their original architecture and 
function by recapitulating the crucial wound healing events associated with their 
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development [Polimeni et al 200; Lin et al. 2008]. The isolation of adult stem cells 
from human periodontal ligament has presented new opportunities for tissue 
engineering [Gronthos et al. 2006; Nagatomo et al. 2006] (see FIGURE 8).
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Figure 8: Strategies to promote periodontal regeneration and possible differentiating directions of adult bone.
Periodontal ligament stem cells characterization and differentiation
The interest in dental stem cells has risen during last years and several reports on 
characterisation and differentiation of dental stem cells from different sources have 
been published [Lindroos et al. 2008]. To date, the surface marker expression data 
published on dental stem cells do not allow extensive comparison between other 
sources of stem cells in the body. 
The FACS analysis demonstrated that PDLSCs showed positive expression for the 
putative stem cell marker STRO-1; adhesion molecules CD9, CD29, CD49d, 
CD105, CD106, and CD166; receptor molecule CD44; surface enzymes CD10 
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and CD13, extracellular matrix protein CD90; complement regulatory protein 
CD59; and hFSP. PDLSCs lacked expression of CD31 and CD45, suggesting lack 
of cells of haematopoietic and angiogenic lineages [Lindroos et al. 2008].
PDLSCs have the capacity to commit to the cementoblastic, osteoblastic, and 
adipogenic lineages [Seo et al. 2004; Jo et al. 2007]. 
Ex-vivo expanded PDLSCs formed mineralized nodules with the presence of 
calcium in the extracellular matrix and expressed an array  of cementoblastic/
osteoblastic markers, including alkaline phosphatase, MEPE (matrix extracellular 
phosphaglycoprotein), bone sialoprotein, osteocalcin, and TGFβ receptor type I. 
Moreover, PDLSCs cultured with an adipogenic inductive cocktail could 
differentiate into Oil red O-positive lipid-laden fat cells, and this was correlated with 
an upregulation in the expression of two adipocyte specific transcripts—PPRAγ2 
and lipoprotein lipase, as detected by Reverse trancriptase-polymerase chain 
reaction (RT-PCR) [Silverio et al. 2008; Jo et al. 2007].
To explore the role for enamel matrix proteins in periodontal regeneration, the 
effect of enamel matrix derivative (EMD) on PDL cells in vitro was' e x a m i n e d 
largely [Gestrelius et al. 1997; Lyngstadaas et al 2001]. EMD in vitro formed 
protein aggregates, providing a unique environment for cell-matrix interaction. 
Under these conditions, BMD enhanced proliferation of PDL cells, and promoted 
mineral nodule formation [Gestrelius et al. 1997; Lyngstadaas et al 2001].
Through in vivo experiments, PDLSCs transplanted into immunocompromised 
mice and rats were shown off to be able to promote tissue regeneration and 
periodontal repair [Morsczeck et al. 2008]. 
Different studies have shown also that human periodontal ligament cells produce 
NGF and express trkA mRNA [Kurihara et al. 2003]. These findings suggest that 
NGF modulates the differentiation and proliferation of periodontal ligament cells by 
paracrine and autocrine functions in vitro and in vivo. RT-PCR showed that NGF 
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increased mRNA levels ALP, bone morphogenetic protein (BMP-2), and 
osteopontin (OPN), which are involved in periodontal tissue regeneration [Kurihara 
et al. 2003].
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Chapter 2
MSCs and osteogenic differentiation
Bone is a hallmark of all vertebrates and absolutely essential in terms of organ 
protection and support, brain and lung function, locomotion, support of 
haematopoiesis in the bone marrow, storage of minerals (i.e. calcium, phosphate) 
and providing attachment to muscles [Proff & Römer 2010]. Bone tissue is largely 
composed of type I collagen amounting to about 90% of total bone protein. The 
remaining organic component consists of non-structural proteins like growth 
factors, blood protein, osteonectin and osteocalcin (see FIGURE 1). 
The inorganic phase of bone is mainly composed of mineral hydroxyapatite (Ca10
(PO4)6(OH)2). Due to its material consistency, bone has a relatively flexible 
character as well as compressive strength. The mature bone is composed of two 
different types of tissue:
- cortical bone:  responsible for the stability  of the skeleton, it appears smooth, 
white and solid. The cortical bone contains osteons (Haversian systems), which 
are composed of a central canal (Haversian canal) surrounded by lamellae of 
bone matrix. Within the lamellae, there are osteocytes embedded in tiny  spaces 
(lacunae). The Haversian canal encompasses blood vessels and nerve cells 
throughout the bone and communicates with osteocytes in lacunae through 
canaliculi. Moreover, the corticalis has an outer membrane, the periosteum. The 
periosteum consists of an outer fibrous layer and an inner one that has 
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osteogenic potential and enables the bone to enlarge [Katagiri & Takahashi 
2002].
- cancellous bone: the inside of bone is assembled by a trabecular network 
(spongiosa) and harbours bone marrow or embryonic connective tissue. The 
spongiosa ensures elasticity and stability  of the skeleton and accounts for the 
main part (about 70%) of bone metabolism [Neumann & Schett 2007].
Figure 1: Bone shematic rapresentation (modified by http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/
1129.jpg)
Under control of specific growth and transcriptional factors, mesenchymal stem 
cells differentiate toward osteogenic lineage during a number of developmental 
stages, starting from commitment to osteoprogenitors, through preosteoblasts and 
osteoblasts and finally osteocytes or lining cells [Long 2001]. 
It is thought that during the early stages, commitment osteoprogenitors maintain 
certain degree of plasticity allowing de- and trans- differentiation to other 
mesenchymal lineages, whereas osteoblasts and osteocytes represent a terminal 
differentiation stage as they become specialized functional cells [Rottmar et al. 
2010]. However, it has also been suggested that even mature osteoblasts are 
being able to transdifferentiate to other phenotypes [Aubin 1998].
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2.1 Bone modeling and remodeling
In order to maintain stability and integrity, bone is constantly undergoing 
remodelling, with about 10% of bone material being renewed each year [Lerner 
2006]. 
Bone remodelling is a complex process that involves bone resorption performed 
by osteoclasts, followed by bone formation carried out by osteoblasts. In this 
process, these cells closely  collaborate in basic multicellular units (BMU) 
[Hadjidakis & Androulakis 2006; Hill 1998]. The bone remodelling cycle involves 
different sequential steps, namely resorption, reversal and formation [Hadjidakis & 
Androulakis 2006; Hill 1998; Neumann & Schett 2007]. Different cells populations 
are involved (see FIGURE 2):
- Osteoblasts: Active osteoblasts are cuboidal, polarized bone matrix producing 
cells. Similar to fibroblasts, myoblasts, chondrocytes and adipocytes, osteoblasts 
originate from MSCs located in the bone marrow, endosteum and periosteum. 
During differentiation of multipotent mesenchymal cells into several lineages, the 
progenitors of these lineages acquire specific phenotypes under the control of 
regulatory factors of the restricted lineages [Karsenty & Wagner 2002, Rosen & 
Spiegelman 2000, Arnold & Winter 1998]. Osteoblasts deposit osteoid, the 
unmineralized extra cellular matrix (ECM), which subsequently becomes 
calcified. 
- Osteocytes: During bone formation process, a proportion of cells becomes 
trapped within the lacunae of the matrix and are termed osteocytes. Osteocytes 
are connected by  a system of canaliculi, and their proposed function is to 
regulate the response of bone to mechanical stimuli [Ehrlich & Lanyon 2002]. 
- Lining cells: The other proportion of osteoblasts becomes bone-lining cells, which 
are flat cells lining the surface of bone [Aubin 1998].
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- Osteoclasts: bone resorbing cells belong to the family of monocyte/macrophage 
lineage. Osteoblasts express in vivo the receptor for activation of nuclear factor 
kappa B (NF-κB) ligand (RANKL) and macrophage colony-stimulating factor (M-
CSF) , which in turn activate a number of signaling pathways in osteoclasts, such 
as NF-κB pathway [Teitelbaum & Ross 2004].
Figure 2: Overview of bone remodelling. During resorption phase osteoclasts degrade old bone matrix;  after bone removal, 
osteoclasts undergo apoptosis and osteoblasts become activated and lay down new bone material in the trench. With the 
replacement of old bone by new one, the osteoblasts form resting flattened lining cells on the surface of bone, while the 
embedded in bone matrix one evolve to osteocytes.
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2.2 MSCs osteoblast differentiation: different signalling pathways.
The population of cells that is committed to the osteoblastic phenotype are called 
osteoprogenitors. Such cells divide and differentiate into osteoblasts forming bone. 
Analysis of fetal rat calvaria-derived osteoblast cultures (RC cells) has indicated 
that less than 1% of cells are actually destined to form bone [Aubin et al. 1995; 
Malaval et al 1999].
Continuous recruitment, proliferation and differentiation of cells within bone tissue 
is regulated by  the expression of genes providing the characteristics to the bone 
phenotype. A precise pattern for the expression of marker genes encoding the 
osteoblast phenotype has been shown [Calvi et al. 2003; Heino & Hentunen 2008; 
Lo Celso et al. 2009], which can be subdivided in three chronologically related 
distinct stages:
- proliferation phase: high mitotic activity that is accompanied by the expression of 
cell-cycle genes, such as those encoding for histones, and cell growth genes, 
such as C-myc, C-fos, and C-jun. During this period, genes associated with the 
formation of ECM, such as collagen type I, osteopontin (OPN), and fibronectin 
are actively  expressed, then gradually down regulated; following the down-
regulation of the proliferation genes, an increase in ALP activity is evident. 
- matrix development phase: composition and organization of the ECM is greatly 
modified, providing an environment favourable for mineralization; an increase in 
ALP activity is still evident. 
- mineralization phase: coordinated by the osteoblasts and involves the deposition 
of a calcium phosphate apatite within an organic framework.
Commitment of bone marrow originated MSCs to tissue-specific cells is 
orchestrated by transcriptional and biochemical regulators [Marie 2008; Katagiri & 
Takahashi 2002]. Osteoblast differentiation, recruitment, function and maturation is 
tightly promoted and regulated by the secretion of lipid-modified glycoproteins of 
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the wingless (Wnt) family, BMP-2 and several transcription factors [Proff & Römer 
2010]. An overview of these modification is represented in Figure 3. 
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Figure 3: Markers modification during MSCs differentiation through osteoblast lineage.
 A central regulator of bone formation is Runx2, also known as Core-binding factor 
α1 (Cbf α1), a member of the Runx (Runt-related factors) family of transcription 
factors. The family members, Runx1 (Acute myeloid leukemia gene (AML) -1), 
Runx2 (AML3), and Runx3 (AML2), are encoded by distinct genes but share a 
common DNA recognition motif. Runx2 activates the OCN and collagen type I- α 1 
genes [Komori 2008], and serves as an initial marker of the osteogenic cell lineage 
[Franceschi 2007]. Runx2 is abundantly expressed in calcified cartilage and bone 
tissues and is transcribed from two separate promoters. The upstream promoter 
drives the expression of osteoblast-specific isoforms, whereas the second 
promoter drives the expression of isoforms that are mainly expressed in T-cells, 
but they can be found also in osteoblasts and other mesenchymal cells [Xiao et al. 
1998; Ogawa et al. 2000]. 
During osteoblast differentiation, RUNX2, and canonical Wnt signaling play 
essential roles in the commitment of pluripotent mesenchymal cells to the 
osteoblastic lineage [Komori et al. 2006]. After commitment into the osteoblastic 
lineage, the osteoblasts express bone matrix protein genes at various expression 
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levels depending on the maturation level of the cells. Immature mesenchymal cells 
and preosteoblasts weakly  express Col1a1, and its expression is upregulated in 
immature osteoblasts [Aubin & Triffitt 2002; Inada et al. 1999]. Immature 
osteoblasts express Spp1 and then Ibsp, and maturated osteoblasts strongly 
express Bglap  (bone gamma-carboxyglutamate [gla] protein/ osteocalcin) [Aubin & 
Triffitt 2002; Maruyama et al. 2007]. Mature osteoblasts are embedded into the 
bone matrix and finally  become osteocytes, which express Dmp1 (dentin matrix 
protein 1) [Toyosawa et al. 2001] (see FIGURE 4).
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Figure 4: RUNX2 directs pluripotent mesenchymal cells to the osteoblast lineage, increases the number of immature 
osteoblasts, but inhibits osteoblast maturation. Preosteoblasts express Runx2. Immature osteoblasts express Runx2 and 
Spp1. Mature osteoblasts Runx2 expression is down-regulated. Osteocytes express Dmp1+. The transition of immature 
osteoblasts to osteocytes occurs at an early stage of bone development.
Targeted disruption of Runx2 results in the complete lack of bone formation by 
osteoblasts, revealing that Runx2 is essential for both endochondral and 
intramembranous bone formation [Komori 2008]. 
Runx2 has been designated as the most pleiotropic regulator of skeletogenesis 
[Karsenty & Wagner 2002], it functions as an inhibitor of proliferation of progenitors 
[Pratap et al. 2003], and is also required for osteoblast function beyond 
differentiation [Ducy et al. 1999; Liu et al. 2001].
Even if several findings support this biochemical function of Runx2, the number of 
Runx2-modulated genes that have been identified thus far is limited [Lambertini et 
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al. 2007]. Bone is also a specific estrogen target tissue. Both isoforms of estrogen 
receptors alpha and beta (ERα and ERβ), through which estrogen is involved in 
the regulation of factors associated with bone formation were detected in 
functional osteoblasts [Sutherland et al. 1996; Sasaki-Iwaoka et al. 1999; Nilsson 
et al. 2009].
2.3 MSCs and tooth tissue development.
Facial bone and dental development
Teeth are generated through highly orchestrated mutual inductive interactions 
between stomodeal ectoderm and cranial neural crest-derived ectomesenchyme 
cells [Koussoulakou et al. 2009]. Genes encode transcription factors that regulate 
the synthesis of various signaling factors [Thesleff et al. 1995]. 
Proper development of all tooth-periodontium-alveolar complex structures is 
achieved by reiterative temporo-spatially well-coordinated signaling interactions 
[Thesleff & Sharpe, 2006; Hu & Simmer, 2007]. 
These signaling factors mediate inductive interactions between the odontogenic 
tissue layers and affect cell multiplication, cell death and cytodifferentiation 
[Matalova et al. 2004].
Interestingly, genes and signaling factors playing leading roles in teeth 
morphogenesis are also involved in the development of many other organs 
[Koussoulakou et al. 2009; Matalova et al. 2004].
The plethora of molecules involved [e.g., fibroblast growth factors (FGFs), bone 
morphogenetic proteins (BMPs), sonic hedgehog (SHH), wingless integrated 
(Wnts)] and the complexity of interactions (e.g., activation, inhibition, regulatory 
loops) inevitably lead with some frequency to homeostatic disorganization, which 
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results in congenital abnormalities, such as tooth agenesis, which is the most 
commonly inherited disorder [Line 2003; Kapadia et al. 2007]. Most human 
congenital teeth malformations are caused by mutations in develop- mentally 
regulated genes [Smith & Coates 1998]. The fact that, an embryonic tooth bud can 
develop in vitro indicates that the expression of teeth-related genes is not 
restricted only in vivo [Thesleff et al. 1995]. Mutations that alter teeth act at many 
levels of control, i.e., the development of the embryonic bud, the morphogenesis of 
the bell stage, the production of enamel and dentin and the forma- tion of the roots 
[Townsend et al. 2008]. 
Tooth morphogenesis starts with an epithelial thickening at the areas that have 
been pre-patterned as odontogenic. Paracrine growth factors—mainly from the 
hedgehog, Wnt (wingless-type MMTV integration site gene), BMP and FGF 
families—homeobox transcription factors, and extracellular matrix molecules are 
activated to control tooth bud formation, and the development of the tooth cap  and 
bell [Fleischmannova et al 2010]. 
Differentiation of dental hard tissue producing odontoblasts and ameloblasts is 
directed by reciprocal interactions between inner enamel epithelium (future 
ameloblasts) and the mesenchymal cells directly facing inner enamel epithelium 
(future odontoblasts), mediated mainly by  molecules from Wnt, Runx2, and Tgf 
(transforming growth factor) protein families [Bègue-Kirn et al., 1994].
The RANK/RANKL/OPG (receptor activator of NFκB/ RANK ligand/
osteoprotegerin) signaling pathway seems to pro- vide temporo-spatial 
coordination of tooth-bone development. Expression of Rankl in the early alveolar 
bone ossification cen- ters is a critical contributor to tooth development 
[Fleischmannova et al 2010].
The presence of RUNX2 in fully differentiated cells supports the concept that 
RUNX2 is also required in maintaining fully functional cells, at least in bone [Ducy 
et al. 1999; Quack et al. 1999].
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RUNX2 has also been identified as essential for tooth formation [Ducy et al. 1999; 
DʼSouza et al. 1999] (see FIGURE 5). 
Figure 5: Patterns of Runx2 expression (red areas). (A) Initiation stage. Expression is induced in the mesenchyme by the 
odontogenic epithelium. (B) Bud stage. Expression is maintained around the ingrowing dental epithelium. (C) Cap stage. 
Expression is sus- tained in the mesenchyme and the dental follicle. RUNX2 is necessary for Sonic Hedgehog (Shh) 
expression and for formation of the enamel knot. (D) Bell stage. In this stage, expression is down-regulated in the dental 
papilla but is maintained in the dental follicle and surrounding mesenchyme.
Type II Runx2 is also expressed in periodontal ligament (PDL) fibroblasts, 
although BSP, a marker of osteoblast differentiation and biomineralization, is not 
[Jiang et al. 1999]. The action of RUNX2 seems to be suppressed by a 
mechanism designed to maintain PDL width [Saito et al. 2001]. However, these 
cells maintain the potential to differentiate to osteoblasts under certain conditions, 
such as mechanical stress [Yang et al. 2006]. 
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Figure 6: Preodontoblasts differentiate from neural-crest-derived pluripotent mesenchymal cells. RUNX2 is essential for 
differentiation of pluripotent mesenchymal cells into preodontoblasts. RUNX2 also probably induces the differentiation of 
preodontoblasts into immature odontoblasts at an early stage but is inhibitory at a late stage. Preodontoblasts express 
Runx2, immature odontoblasts express Dspp and Nes but Runx2 weakly, and mature odontoblasts express Dspp and Nes 
but not Runx2. Runx2 expression is downregulated during odontoblast differentiation, and RUNX2 inhibits terminal 
differentiation of odontoblasts. (Dspp dentin sialophosphoprotein, Nes nestin)
In mouse embryonic mandibular first molar tooth
germs, Runx2 expression is initiated by FGF produced
by the odontogenic epithelium, shortly after com-
mencement of epithelial thickening, and is followed by
expression of RANKL in the early alveolar bone ossifi-
cation centers and that of its receptor, receptor activator
of nuclear factor kappa B (RANK) and OPG in tooth
bud epithelium and mesenchyme. Thus, Runx2 is not
involved in the initiation of tooth formation, but is
intimately involved in regulating the expression of
mesenchymal molecules that act reciprocally the
epithelium to control the histo- and morpho-differe ti-
ation of the enamel organ (6, 82, 83).
Runx2–/– mouse molars show arrested development at
the bud stage, whereas incisors, which develop earlier,
progress to the bell stage and show dentine formation,
although odontoblasts are abnormal and no enamel is
formed (6, 84).
Enamel knot marker genes, including cyclin-dependent
kinase inhibitor 1A (p21), Fgf4, ectodysplasin A receptor
(Edar) and Bmp4, are down-regulated in Runx2–/– lower
molars, but are expressed normally in the upper molars.
Sonic Hedgehog (Shh) is completely absent in Runx2–/–
lower molars, while weak signals remain at the tip of the
tooth bud in the upper molars (83).
Lower molars are more severely affected than upper
molars in Runx2–/– mice, and incisors are less affected
than molars. Hence, RUNX2 may have different down-
stream target genes in different regions of the jaws.
Similar regional differences in molecular regulation is
evident in relation to other genes, notably Dlx (85) and
ActivinbA (86). The different origins of the neural crest
cells populating the maxillary and mandibular primordia
may explain their different behavior (87). However, the
developmental profiles of Runx2 expression in odonto-
blasts and osteoblasts, both derived from mesenchyme, is
also different (6), suggesting that the gene may also be
differentially regulated in these cells.
Runx2 is thus essential for tooth development up to
the bell stage, being necessary for the formation of the
enamel knot, which controls growth and folding of the
enamel organ epithelium. Whether Runx2 is essential for
the later stages of tooth development is still unknown, as
Runx2–/– mice do not survive beyond birth.
Prior to crown development, Type II Runx2 is
strongly expressed in dental papilla mesenchyme, which
gives rise to the pulpal cells and odontoblasts. Type II
Runx2 is markedly down-regulated at the bell stage in
the dental papilla, after morphogenesis is complete.
Expression continues, albeit at a lower level, in the cells
of the dental papilla, particularly near the apical por-
tion, as well as in the odontoblasts lining the pulp
chamber. Expression is evident throughout the further
development of the tooth and at all stages of root
formation, including formation of the periodontium.
Cementoblasts, cementocytes, periosteal tissue, osteo-
blasts, and osteocytes all showed expression of Type II
Runx2. No expression was found in osteoclasts. The
forming periodontium contains a decreasing gradient of
transcripts and immunostaining from crown to the root
tip (88) (Figs 7, 8).
Ameloblasts
Runx2 expression controls downstream factors acting on
the development of the enamel organ epithelium. The
importance of Runx2 in amelogenesis is evidenced by the
lack of enamel in the incisor tooth germs of Runx2–/–
mice. RUNX2 is also present in late secretory- and
maturation-stage ameloblasts (6).
AMBN is an extracellular matrix protein that may
play a role in enamel crystal formation in the developing
dentition. It is used as an ameloblast-specific gene mar-
ker. The murine Ambn promoter contains two RUNX2-
binding sites. RUNX2 interacts with functionally
important regions of the Ambn promoter, and mutations
of the Ambn promoter’s RUNX2-binding sites diminish
promoter activity. This indicates that RUNX2 possesses
an important function in transcription of the Ambn gene
(89). Runx2 Type II mRNA remains strongly expressed
in both immature and mature ameloblasts (81). Thus,
Fig. 7. Patterns of Runx2 expression. (A) Initiation stage.
Expression is induced in the mesenchyme by the odontogenic
epithelium. (B) Bud stage. Expression is maintained around the
ingrowing dental epithelium. (C) Cap stage. Expression is sus-
tained in the mesenchyme and the dental follicle. RUNX2 is
necessary for Sonic Hedgehog (Shh) expression and for for-
mation of the enamel knot. (D) Bell stage. In this stage,
expression is down-regulated in the dental papilla but is
maintained in the dental follicle and surrounding mesenchyme.
Fig. 8. Runx2 mRNA expression in the secretory stage.
Pre-ameloblasts show no expression; however, this is strongly
up-regulated in maturational phase cells. There is diffuse
expression throughout the dental papilla, with up-regulation in
pre-odontoblasts. Differentiated odontoblasts, however, show
no expression. The periodontal ligament shows strong expression
as do cementoblasts and cementocytes. d, dentine; e, enamel;
od, odontoblasts; ma, maturational amleoblasts; p, dental
papilla; pa, pre-amleoblasts; pdl, periodontal ligament.
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Wnt signaling plays a fundamental role in facial and tooth development [Galli et al 
2010]. Several Wnt genes and Lef1 are expressed in the dental epithelium and in 
the immediately adjacent mesenchyme [Kratochwil et al. 1996; Dassule & 
McMahon, 1998; Chen et al. 2009], and the control of their expression yields 
dramatic effects on tooth formation: inhibition of Wnt signaling in explants from 
mandibular arch primordia by deletion of β-catenin in tooth mesenchyme [Chen et 
al., 2009] or in dental epithelium [Liu et al. 2008] blocked tooth development.
Besides playing a fundamental role in tooth morphogenesis, however, Wnt 
canonical signaling has also been demonstrated to be active in adult periodontal 
fibroblasts and con- tributes to periodontal tissue growth and remodeling during 
tooth eruption [Rooker et al. 2009]. Moreover, this signaling cascade can 
orchestrate the activity of several cell types in tooth and periodontal tissues, 
because it can up-regulate the proliferation and decrease the differentiation of 
cementoblasts [Nemoto et al. 2009], while it negatively  controls the odontoblastic 
differentiation of dental pulp stem cells [Scheller et al. 2008]. Amelogenin, a critical 
pro- tein for the formation and mineralization of tooth enamel, is also capable of 
stimulating β-catenin/TCF signaling in human periodontal ligament cells and in 
mouse calvaria osteoblastic cells [Matsuzawa et al. 2009].
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Chapter 3
MSCs for bone tissue regenerative medicine
Due to their abilities (steamness and self-renewal properties) and because MSCs 
can be isolated and expanded ex vivo without modification in the phenotype or 
loss of function, MSCs are considered to be very important for the development of 
cell-based therapies and tissue repair in regenerative medicine.
3.1 ! Bone repair
After completion of the bone remodeling cycle, most osteoblasts undergo 
apoptosis [Clines 2010]. Some cells will remain at the bone surface to form lining 
cells that may serve as osteoprogenitors or even prepare bone for osteoclast 
attachment [Everts et al. 2002]. A few osteoblasts become encased in their own 
matrix to become osteocytes, the most prevalent cell in bone. 
After a bone fracture, both endochondral and intramembranous ossification re-
emerge. This process of fracture repair begins with the immediate formation of a 
hematoma at the fracture site. Through release of cytokines, cells are recruited to 
the fracture site that marks the site for repair. Hypoxia and vascular disruption at 
the fracture site are stimuli for chondrocyte recruitment and initiation of 
endochondral ossification. Adjacent to the fracture, fibroblastoid periosteal bone 
lining cells differentiate into osteoblasts and begin the process callus formation. 
MSCs for bone tissue regenerative medicine
43
The fracture gap is eventually filled with immature woven bone that is remodeled 
over time to more structurally sound lamellar bone [Clines 2010]. 
Fracture repair in most situations is a predictable process. However, the risk of 
fracture repair failure increases with aging, diabetes and smoking [Clines 2010]. 
Osteoporosis, from estrogen deficiency, glucocorticoids or inflammatory states, 
can also be viewed as a condition whereby bone fails to optimally ossify. Anti-
resorptive agents such as bisphosphonates are effective in reducing fracture risk 
but potential side effects have recently gained more attention [Khosla et al. 2007]. 
Conventional treatment for bone fracture is to join or fixate the fractured ends and 
allow physiologic ossification and remodeling to occur. The application of BMP-2 
or biodegradable scaffolds enhances repair times. However, failure of fracture 
repair is still common, especially when associated with chronic disease [Clines 
2010]. 
Several types of approach are of a particular interest in improving bone repair (see 
FIGURE 1).
Figure1: Different strategies can be used and combined to treat diseases that weaken bones. Bone formation can be 
activated (i) by enhancing osteoblasts (Obs) activation (ii) by suppressing the activity of osteoclasts (Ocs) (iii) by adding 
growth factors and hormones (so called “inducers molecules”). Osteoprogenitors cells (like MSCs) within bone defects can 
be added with or without the use of biomaterial (synthetic biomaterials, demineralized bone). (modified by: Deschaseaux et 
al. 2009 Trends Mol Med. 15:417-29)
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 One  approach involves strategies to target molecular pathways to increase the 
number of osteoblasts or their maturation. The US Food and Drug Administration 
approved the use of parathyroid hormone (PTH) as a highly efficient anabolic 
agent for osteoporosis. Although the exact mechanisms underlying these effects of 
PTH are unknown, experiments have shown that intermittent injection of PTH 
increased the number of osteoblasts and their maturation, probably through 
different molecular pathways [Datta et al. 2009]. However, recent data suggest 
that PTH administration in rats can generate osteosarcoma [Tashjian et al. 2008]. 
Whether such an adverse effect could occur in humans remains undetermined.
An other clinical condition that results in altered bone metabolism is rheumatoid 
arthritis (RA). RA is a chronic debilitating autoimmune disease that results in 
inflammation and structural destruction of the joints. A hallmark of RA 
pathogenesis is an imbalance of the osteoblast–osteoclast axis driven by 
inflammatory processes, resulting in elevated bone resorption by osteoclasts. 
Current therapies used to treat this disease have focused on inhibition of synovitis, 
but such treatments do not adequately repair damaged bone. A key pathway of 
osteoclast formation involves the receptor activator of NF-κB ligand pathway 
acting on myeloid progenitor cells [Choi et al. 2009]. The Wnt pathway has been 
shown to be important for the differentiation of osteoblasts from mesenchymal 
lineage precursors, and endogenous Wnt inhibitor, such as sclerostin might have 
important roles in osteoclast dysregulation in RA.
Targeted deletion of sclerostin in mice results in increased bone volume, bone 
mineral density and bone strength compared with wild type controls [Choi et al. 
2009]. Sclerostin-deficient animals had increased osteoblast activity as well as 
increased serum levels of osteocalcin, an osteoblast marker.
The use of molecules to intervene in the Wnt pathways as anabolic agents seems 
to be more complex because their activities depend on differentiation stage of cells 
and their concentration. Furthermore, this pathway is extensively described as 
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being involved in tumorigenic processes. Nevertheless, targeting the Wnt pathway 
offers several options to treat bone diseases [Deschaseaux et al. 2009].
Initially  used in patients with bipolar disease, lithium was found to be a Glycogen 
synthase kinase 3 beta (GSK3β) inhibitor. Surprisingly, in such bipolar patients, 
oral lithium treatment was shown to be associated with a lower risk of fracture, 
although 25% of patients treated with lithium developed parathyroidism and 
hypercalcemia [Chen & Alman 2009]. Other Wnt antagonists are being studied 
such as sclerostin proteins. Sclerostin was found to be a Wnt pathway inhibitor; 
bone mass, bone formation and bone strength are increased in rats treated with 
anti-sclerostin antibody. Clinical trials in post-menopausal women are under 
investigation [Li et al. 2009]. However, in addition to cancer, long-term activation of 
the Wnt/β-catenin path- way can have other drawbacks because osteoarthritis 
symptoms and osteophytes were observed in animal models [Deschaseaux et al. 
2009].
The osteogenic potential of MSCs has been well defined, as evidenced by bone 
formation following transplantation of MSC in vivo. Moreover, in vitro experiments 
demonstrate the formation of mineralized nodules, along with elevated production 
of alkaline phosphatase, osteopontin, bone sialoprotein, osteocalcin, types I and III 
collagen, and generation of PTH and estrogen receptors, during the differentiation 
of MSC into osteoblasts [Tsuchida et al. 2003]. Although there is enthusiasm for 
attempting to utilize MSC  stherapeutically, methods, either in vitro or in vivo, which 
provide an adequate commitment to direct MSC differentiation into osteoblastic 
cells need to be defined. Different groups has shown the chance of transfering the 
gene for BMP-2  into bone marrow MSC and mesenchymal progenitor cells via 
recombinant adenovirus. These gene-engineered cells continuously expressed 
BMP-2 protein both in vitro and in vivo, and facilitate cell differentiation into cells of 
the osteoblast lineage [Cheng et al. 2001]. 
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Considering others molecular pathways, and the chance to “inhibit or enhance 
them”, several studies have shown that Wnt proteins inhibit the ability  of human 
MSCs to differentiate to osteoblasts [Boland et al. 2004; de Boer et al. 2004], while 
others show the opposite [Luo et al. 2004, Bain et al. 2003]. In the absence of ß-
catenin, osteoprogenitors differentiate into chondrocytes [Hill et al. 2005], thus ß-
catenin seems to be required for osteoblast differentiation at a very early stage.
The bone repair process in adults closely resembles the normal development of 
the skeleton during embryogenesis, even though some aspects differ. After injury, 
hypoxia and inflammation induce vascularization, and in vessels growing within 
injured tissue, perivascular MSCs populate the wound site under hypoxic 
conditions [Deschaseaux et al. 2009]. MSCs proliferate and then differentiate 
along a cartilaginous or an osteogenic lineage in response to growth factors and 
cytokines released by platelets, inflammatory cells, and neighboring cells and 
tissues. Nowadays crucial data regarding the native properties of MSCs and 
osteoblasts and osteoclasts progenitors too are still needed to elucidate the 
mechanisms of bone formation and bone remodeling.
3.2 Dental tissue disease and regeneration
Disturbances in bone homeostasis causing decreased systemic or periodontal 
bone mineralization (periodontitis, osteoporosis, osteolysis) may result in 
premature tooth loss [Fleischmannova et al 2010]. 
Periodontal diseases are infectious diseases characterised by destruction of 
supporting tissue for tooth, including periodontium, cementum, alveolar bone, and 
gingiva [Seo et al. 2004; Philstrom et al. 2005]. Thus, regeneration of these tissue 
lost through periodontitis is the ultimate goal of periodontal therapy [Yang et al. 
2010] (see FIGURE 2).
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When PDL tissues loss occurs, because of inflammatory disease or traumatic 
reasons,  dental root  ankylosis and root resorption occur both [Nyman et al. 1980; 
Andreasen & Kristerson, 1981]. 
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Figure 2: Periodontal tissue damage and healing strategies. Within population some patients 
develop periodontitis. Regenerative approach has the aim to rebuilt all tissues lost (hard and soft 
too), instead of achieving only reparation of tissues.
Periodontitis is an inflammatory disease caused by  bacterial infection, mainly 
Aggregatibacter actinomycetemcomitans or Porphyromonas gingivalis. 
Characteristic of periodontitis are periodontal pocket formation and excessive 
alveolar bone resorption, followed by tooth loss. Chronic inflammation is, in many 
cases, coupled with excessive bone resorption, most likely  resulting from up-
regulation of RANK/RANKL signaling. Other studies showed that not only bone 
resorption but also new bone production are affected by P. gingivalis infection. 
Bacterial lipopolysaccharide was reported to increase the proliferation of 
progenitor cell populations, however, delaying their subsequent dif- ferentiation, 
which may potentially  be reflected in alveolar bone extracellular matrix formation 
[Roberts et al. 2008]. Additionally, premature tooth loss may be associated with 
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generalized bone density  disorders resulting from both congenital genetic defect 
and disease. Several studies have reported that post-menopausal women without 
estrogen substitution therapy have more teeth missing than do women with 
estrogen substitution therapy. Moreover, syndromes such as familial expansile 
osteolysis or Pagetʼs disease, caused by RANKL pathway defects resulting in high 
activity  of osteoclasts that predominantly  affect long bones, often involve loss of 
dentition [Fleischmannova et al 2010].
At the present time, periodontal regeneration, considered as the the formation of 
new bone and new cementum with supportive periodontal ligament [Iwata et al. 
2010], is a process achieved only if some conditions, local and sistemic, are 
present at the moment of healing.
Considering tissue engineering field, it has been defined as “understanding the 
principles of tissue growth, and applying this to produce functional replacement 
tissue for clinical use” [MacArthur & Oreffo 2005].  After tooth loss, this 
therapeutical approach offers a new hope to both patients who suffered it and who 
is involved in treating the disease  as well [Peng et al. 2009]. 
All these findings support the hypothesis that it would be conceivable to use 
PDLSCs for in vivo regeneration of the periodontium in patients with periodontal 
destruction [Arnold et al. 2010].
Between healthy donors, it could be also useful to develop  selective strategies 
based on predictable elements, such as clinical and biological paramenters, to 
discriminate cells with most promising regenerative potential, as done before with 
different cells donors.
The development of tooth tissue engineering strategies and cell therapy mainly 
focuses on three aspects: seeding cells, scaffolds and biomolecules (see FIGURE 
3).
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Figure 3: cells/biocomponents combinative options and their implication in experimental strategies.
Traditional 2-D culture well were chosen first to test PDLSCs osteogenic 
differentiation potential.
Analysis of bone markers ALP and Runx-2, OC, and OP showed PDL as reliable 
source of osteogenic progenitors [Lekic et al. 2001; Lindroos et al. 2008], and well 
staining revealed presence of sparse calcified nodules after 21 days osteogenic 
differentiation [Seo et al, 2004]. 
Both mineralized tissues, bone and cementum, reconstitution  is necessary to 
achieve complete periodontal regeneration, and it is known that some progenitor 
cells niches, scattered in the whole tissue, possess the ability to differentiate, 
when properly  stimulated, in osteoblasts, fibroblasts and cementoblasts [Bartold et 
al. 2006; Seo et al. 2004; Pitaru et al. 1994].
To overcome some problems connected to the small amount of MSCs in the adult 
tissue, and the difficult recruitment of them during healing processes, due to 
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inflammation and microenvironement, all knowledge and mechanisms 
comprehension, only cells ex vivo expansion protocols and biomaterials 
combination have been shown useful for both tesearch and devepoling therapies. 
Combining traditional culture conditions and different new technologies or 
biomolecular approach, cells phenotype enhancement can be achieved through in 
vitro and in vivo experiments, as seen for BM MSCs [Park et al. 2005]. 
Some molecules family, such as amelogenin-like molecules and bone 
morphogenetic proteins (BMPs) have been demonstrated having a critical role in 
controlling periodontal tissue development  first and  after tissue damage, in 
periodontal regeneration [Foster & Somerman 2005].
Although their role in this mechanism is not well understood, there are evidences 
of how their presence could provides an environment that enables PDL cells to 
speed up their metabolism, growth rate and growth factors release [Lyngstadaas 
et al. 2001; Duan el al. 2011].
Instead of molecular environment modification, physical and mechanical 
modification have been proposed to modify cells proliferation, differentiation and 
molecular pattern expression.
Osteoinductive medium combined with HA-containing composite microsphere 
material affected encapsulated cells and allowed their differentiation into 
osteoblastic lineage in vitro, both under 2D and 3D culture conditions [Inanç et al. 
2007]. 
When ex-vivo expanded and transplanted in immunocompromised mice with 
hydroxyapatite/tricalcium phosphate carrier particles, PDLSCs generated a typical 
cementum/PDL-like structure [Seo et al. 2004].
Some promising results come also from clinical outcome of patients previously 
treated with autologous PDLPs combined with bone grafting material [Feng et al. 
2010]. 
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Chapter 4
MSCs culture systems: 2-D vs. 3-D
The main drawback in MSCs transplantation is sometimes the low quantity of 
MSCs. Since the biology of MSCs and their microenvironment are not totally 
understood it has not been easy to overcome this issue. Ex vivo expansion of 
MSCs from UC or other sources became an alternative to increase the cell-dose 
available for transplants and to further research on MSCs. There is evidence that 
even if short-term expansion may modify MSCs properties, it is strongly probable 
that the engraftment characteristics remain unaltered [Zhai et al. 2004].
The differentiation of MSCs has been extensively  studied, using mainly  well-
established in vitro assays with culture-expanded MSCs. Findings, therefore, have 
the caveat that they may not always be reliable and fully reproducible because of 
the vast heterogeneity  of in vitro culture conditions and MSC  types [Augello & De 
Bari 2010]. The in vitro-obtained data are overly dependent on culture conditions 
for derivation and expansion of MSC populations and, therefore, are unlikely to be 
extrapolated to the native cells. 
MSCs also interact physically  with the surrounding environment. The first line of 
interaction for MSCs is with the extracellular environment, be it plastic, a 
resorbable bioscaffold, or a more rigid structure [Augello & De Bari 2010]. 
Evidence of how the extracellular matrix can control stem cell fate, inducing 
seeded MSCs toward osteogenesis or chondrogenesis depending on its physical 
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properties was reported [Engler et al. 2006]. These findings open up 
unprecedented avenues for the regulation of MSC differentiation in regenerative 
medicine using physical factors, avoiding or combining these conditions with the 
use of exogenous growth factors too (see FIGURE 1).
Figure 1: Modulation of cells phenotype could be reached at different levels through many different approaches, involving  
cell physical and biochemical environment modifications.
This knowledge leads to a new approach by researchers, of investigating all 
possible conditions in vitro that can simulate or mimic the in vivo ones.
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4.1 ! Static conditions
Static culture systems, such as polystyrene Petri dishes, multiwells, or flasks, have 
been the most widely used culture devices. MSCs are conventionally  cultured in 
these containers, and put inside a biological incubator, where two physical 
parameters are regulated: temperature and pH. Temperature is usually set at 
37°C, whereas pH control is performed by maintaining an atmosphere at 5% CO2 
concentration, which corresponds to the physiological pH of 7.2. The main sources 
of variability among different culture protocols reside in medium composition, cell 
seeding density, and time intervals between cell dilutions, called cell passages, 
and medium changes. Conventional cultivation methods are in need of both 
optimized protocols and ad hoc technology [Cabrita et al, 2003].
Classically, osteogenic differentiation of human MSCs requires incubation in fetal 
bovine serum containing medium supplemented with ascorbic acid, β-
glycerophosphate, and dexamethasone, resulting in an increase in alkaline 
phosphatase activity and calcium deposition [Augello & De Bari 2010]. The 
chondrogenic differentiation is performed with a high cell-density  pellet or 
micromass culture treated with transforming growth factor (TGF)-β in serum-free 
medium; this results in production of cartilage-specific, highly sulfated 
proteoglycans and type II collagen. For adipogenic differentiation, MSCs are 
treated with dexamethasone, insulin, isobutyl-methyl-xanthine, and indomethacin 
(added to medium containing fetal bovine serum), and the differentiation is 
revealed by  the detection of lipid vacuoles with oil red O staining [Augello & De 
Bari 2010]. 
Most investigators have used modified Dulbeccoʼs Medium  plus animal or human 
serum and combinations of cytokines. Alternatively, serum-free and animal 
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product-free media have been developed to avoid immunological issues affecting 
transplantation [Andrade-Zaldívar et al. 2008]. Different cytokine cocktails aim the 
proliferation of undifferentiated MSCs and the maintenance of their engraftment 
capacity. The optimal combination and concentration of growth factors to preserve 
the stem state has not been yet established.
When cells are cultured under static conditions, medium in the well is stagnant. 
Soluble factors are present in the medium, and are up  taken and released by the 
cells, depending if they  are exogenous or endogenous. The competitive processes 
in these culture conditions are transport by diffusion and cell uptake/release of 
soluble factors.
It is well known that bone biology basically depends on some molecular pivots that 
could represent disease targets as well as tools for new treatments [Deschaseaux 
et al. 2009] (see Table 1). 
Recognized molecular 
factors
Observations
PTHrP/PTH -Used for osteoporosis; efficient for increasing bone mass when intermittently administered
SDF1 -Allows MSCs homing both in vitro and in vivo
BMP 2 -Osteochondrogenic factor; might initiate bone formation and bone healing and can induce 
expression of other BMPs
-Used for spine fusion, bone nonunion and bone defects; clinically efficient for bone repair 
and regeneration; some adverse effects observed (osteolysis and ectopic bone formation)
BMP 7 -Osteogenic factor in vivo and in vitro; active on more mature osteoblasts
-Used for spine fusion and bone nonunion; clinically efficient for bone repair
Wnt–β-catenin -crucial for osteoprogenitor proliferation;
-LiCl used as a specific inhibitor of GSK3b to increase bone mass post-fracture and to 
diminish fracture risk:
-Bortezomib, proteasome inhibitor used in treatment of multiple myeloma (MM); also 
increases bone mass 
-Anti-DKK1 monoclonal antibody (BHQ880) used to inhibit osteolysis in MM or to increase 
BMD 
-Anti-sclerostin antibody used to increase bone mass
-GSK3b inhibitor (603281-31-8)
RANKL/OPG -Targeting RANKL to treat osteoporosis
Biphosphonates -Widely used for osteoporosis, bone necrosis, osteogenesis imperfecta and some osteolytic 
tumors (zoledronate, alendronate, risedronate); some adverse effects noted (osteonecrosis, 
inhibition of osteogenesis)
TGF β -Can induce osteoblast differentiation at the early stage of immature cells but can also inhibit 
osteogenesis in committed cells
-Used as a bone nonunion marker
Platelet-rich plasma (growth 
factor substitute)
-Used for bone defects treatment with or without biomaterials with or without 
osteoregenerative cells (randomized controlled trials still required)
Table 1: Key molecules involved in bone repair (complete references in: Deschaseaux et al. 2009 Trends Mol Med. 
15:417-29).
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In normal conditions, after damage or “de-novo”, bone formation begins when 
mesenchymal cells form condensations and in most condensations the 
endochondral process precedes bone generation. 
Like other tissues, bone responds to bone-specific soluble growth factors. It is 
therefore important to understand that the appropriate growth factors are required 
to discover the osteogenic potential of isolated progenitor cells populations.
TGF-β have been shown able to affect cell growth and differentiation during 
developmental processes such as embryogenesis and tissue repair [Long 2001].
Also a large number of BMP have been cloned and involved in osteogenic 
differentiation. Additional growth factors also regulate bone development, and their 
role in MSCs differentiation is being investigated.
Considering PDL cells, different molecular factors have a significant role in 
controlling the behavior of cells within the periodontium [Foster & Somerman 
2005]:
- BMPs
- Amelogenine-like molecules;
- Phosphate-regulating factors.
Several groups developed in vitro models for defining the role of PDL cells and 
cementoblasts [Zhao et al. 2002]. They combined and examined cells 
biomolecular interactions, focusing on molecules family above mentioned.
Results from numerous studies, in vitro and in vivo have shown that certain BMPs 
promote osteoblast maturation and induce mineral formation. In fact, recombinant 
human BMP2/absorbable collagen sponge was approved by  the FDA this year for 
treatment of bone fractures in the US [Foster & Somerman 2005].
Different studies focused on monolayer culture conditions modification, for 
example through well coating strategies. The increased attachment rate of PDL 
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cells growing on EMD demonstrates that this enamel protein based matrix mimics 
an extracellular matrix that facilitates rapid attachment of these cells [Gestrelius et 
al. 1997; Lyngstadaas et al 2001].
Data are accumulating to suggest that amelogenins can regulate the behavior of 
mesenchymal cells and thus act as signaling molecules. Regardless of the role 
such molecules play during development of periodontal tissues it is clear that cells 
within the periodontium respond to these factors [Foster & Somerman 2005]. 
Different groups have noted considerable alterations in periodontal tissues in mice 
having mutations in or knockout of genes associated with phosphate regulation , 
providing novel insights into mechanisms controlling mineralization [Foster & 
Somerman 2005; Zhao et al. 2002]. 
Due to the side effects of uncontrolled release of these factors in some culture 
conditions, like in static conditions, many studies have focused on the creation of 
appropriate delivery systems in the form of nanoparticles, microspheres, and 
scaffolds. Although their design and compositions are unique to each other, they 
share the same goal: how to deliver factors to target sites to meet their temporal 
and spatial need [Bae et al. 2010].
Among these candidates biodegradable polymeric microspheres (PMS) have been 
widely utilized as a favorable vehicle in delivering various cytokines and proteins. 
The encapsulation of various drugs, bioactive proteins, or other molecules within 
degradable polymers has long been recognized an effective way to control the 
release profile of the retained substances [Bae et al. 2010].
Many efforts have been done to identify new drug delivery systems able to 
enhance drug permeation and to control drug delivery release rate. In this context 
stricking advantages can be given by nanotechnology [Civiale et al. 2009]. 
Pharmaceutical nanotechnologies including nanosuspensions, solid lipid 
nanoparticles, liposomes and polymeric micelles can allow to overcome some of 
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the inconveniences of conventional drug delivery and sometimes improve water 
solubility of poorly soluble drugs and their chemical stability [Kayser et al., 2005]. 
Natural polymers, such as pectin and gelatin, can be used to produce biocompat- 
ible and biodegradable microparticles, obviating the toxicity  or biodegradability 
problems (i.e., formation of localized granulomatous inflammation) possibly related 
to the use of synthetic materials. Pectin in particular, due to its interesting features, 
such as hydrophilicity, biocompatibility, and biodegradability, has been proposed 
for the production of pharmaceutical formulations intended for controlled drug 
delivery [Esposito et al 2001].
Polymeric micelles are self-assembling colloidal systems obtained by assembling 
of block or graft amphiphilic copolymers. These systems seems to be very 
promising in drug delivery for many peculiarities, including their high kinetic and 
thermodynamic stability and able to give a slow drug release [Civiale et al. 2009].
Polyhydroxyethylaspartamide is a synthetic polymer having protein-like structure, 
obtained by the reaction of ethanolamine with polysuccinimide. It was largely 
investigated for ocular drug delivery also for its good biopharmaceutical properties 
as drug carrier material such as high water solubility, multifunctionality, 
biocompatibility, low cost of production [Civiale et al. 2009].
Alginate microspheres have been used for the encapsulation of a wide variety  of 
biologically  active agents, including proteins, antibodies, DNA and eventually cells 
[Capretto et al 2010].
Recently, the production of alginate microbeads was also accomplished by 
microfluidic procedures. Chang-Hyung and collaborators reported the preparation 
of alginate beads using a polydimethylsiloxane-based chip, including two injection 
lines for alginate solution and CaCl2, and an injection line for the cell suspension 
[Chang-Hyung et al. 2007; Capretto et al. 2010] (see FIGURE 2).
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Fig. 1. Schematic representation of the microfluidic system set-up for the preparation of polysaccharidic microbeads, including drawing of the multiphase flow generator by
the ‘‘Y” junction squeezing mechanism (upper panel). Microphotographs of the multiphase flow formation, bar = 300 lm (lower panel).
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Fig. 2. Dark field stereophotomicrographs of polysaccharidic microbeads. (A) Alginate microbeads prepared by ‘‘external gelation” procedure; (B) microbeads consisting of
(B) 9:1, (C) 4:1, (D) 1:1, w/w alginate/agarose blends. Alginate/agarose (1:1 blend, w/w) microbeads containing SC (E). In the insets are reported dark field
stereophotomicrographs showing, at higher magnification, the microbeads surface and morphology. Bars correspond to 400 lm (A–D) and 150 lm (E).
L. Capretto et al. / Acta Biomaterialia 6 (2010) 429–435 431
Figure 2: Schematic representation of the microfluidic system set-up for the preparation of polysaccharidic microbeads, 
including drawing of the multiphase flow generator by the ʻʻY” junction squeezing mechanism (upper panel). 
Microphotographs of the multiphase flow formation, bar = 300 μn (lower panel) (from Capretto et al. 2010).
All these strategies try to obtain controlled and predictable factors delivery, 
targeting sites or cells in a temporal and spatial optimized condition. Considering 
static experimental conditions, the problem of the limited interactions of cells with 
the extra cellular matrix or environment is not overcame.
 
4.1.1 Scaffolds overview and alginate bead dissertation
Mammalian tissues rank among the most difficult tissues to grow in vitro conditions 
because of their important nutrient needs, their sensitivity  to nitrogenated wastes 
and their high fragility to shear stresses. The exact requirements in nutrients, 
waste elimination, and shear stress also vary widely  for the different types of 
tissues  [Martin & Vermette 2005]. 
The first cultures of MSCs were performed in classic static culture dishes. 
However, static cultures do not provide the proper three-dimensional (3D) 
environment. Therefore, new strategies have been designed. 
The microenvironment of MSCs has been mimicked with 3D-scaffolds. 
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Cells are often combined with artificial structures capable of supporting three-
dimensional tissue formation structures, typically called scaffolds. 
Scaffolds usually serve at least one of the following purposes:
- Allow cell attachment and migration
- Deliver and retain cells and biochemical factors
- Enable diffusion of vital cell nutrients and expressed products
- Exert certain mechanical and biological influences to modify  the behaviour of the 
cell phase.
A scaffold should provide chemical stability  and physical properties matching the 
surrounding tissue to provide cytocompatibility, adhesion support, proliferation and 
mechanical strength [Hollweck et al. 2010]. Scaffolds can be of biological origin, 
made of synthetic material or be some type of hybrid [Ahsan et al. 2005; Dawson 
et al. 2008]. Naturally occurring biomaterials may most closely  stimulate the native 
cellular milieu, but large batch-to-batch variations upon isolation from biological 
tissues and poor mechanical strength are the main limitations for i.e. cardiac 
applications. In addition, biopolymers are often denatured at rates not matching 
those for tissue formation and often require chemical modifications, which can lead 
to toxicity  [Vats et al 2003; Yang et al 2001]. Synthetic materials, like expanded 
polytetrafluoroethylene (ePTFE), confer non-biodegradability due to their highly 
crystalline nature. Additionally, these polymers are nonimmunogenic, 
antithrombotic, and easily available.
As both cell attachment and incorporation in vitro, as well as subsequent tissue 
maturation during in situ regeneration, are crucial features of tissue engineering, 
the amount of porosity  and the pore size of the supporting 3D structure are 
important features that need to be taken into consideration when designing tissue-
engineering scaffolds [Boyan et al. 1996].
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With respect to the scaffolds for bone engineering, calcium phosphate 
bioceramics, such as hydroxyapatite (HA) and tricalcium phosphate (TCP), have 
been intensively investigated due to their similarity in composition to bone matrix, 
bioactivity and osteo-conductivity [Legeros 2002].  
Numerous in vivo and in vitro assessments have reported that calcium phosphate 
materials, no matter of which form (bulk, coating, powder or porous) or phase 
(crystalline or amorphous), always support the attachment, differentiation and 
proliferation of relevant cells (such as osteoblasts and mesenchymal cells) [Brown 
2001]. Also developed ceramic/polymer composite materials are attractive as bone 
substitutes because the novel biomimetic strategy used to generate them provides 
properties similar to natural bone [Liao et al. 2004]. 
Schneider et al. study compared the cell-mediated remodelling of 3-D collagen I/III 
gels during osteogenic differentiation of BM-MSCs and UC-MSCs. Results 
indicate that both cells populations display all features needed for effective bone 
fracture healing [Schneider et al. 2010]. The expression of ECM differs in both cell 
types considerably, suggesting different mechanisms for bone formation and 
significant impact for bone tissue engineering [Schneider et al. 2010].
Experimental injection of MSCs into injured regions ensured delivery to the 
damaged area but was hampered by significant cell loss [Hollweck et al. 
2010].'An alternative approach to injection of isolated cells into the defect was to 
use artificially engineered tissues.
Recently, tissue engineering based on PDLSCs to enhance periodontal 
regeneration has been the focus of periodontal research. In situ engineered 
constructs containing in vitro expanded autologous cells have been used to 
regenerate periodontal defects [Li et al. 2009]. 
As an important biotechnology in tissue engineering, cell encapsulation has 
increasingly attracted interests in recent years [Abbah et al. 2008]. It promotes 
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tissue regeneration by  facilitating the localized retention of entrapped cells, as well 
as controlling the release of therapeutic agents to the host. Microcapsules are 
important components for prolonging the viability and therefore sustaining the 
functions of confined cells [Abbah et al. 2008].
Also the protection of implanted cells from the hostʼs immune response is of 
primary importance. Encapsulation protocols have also been proposed to maintain 
the cell phenotype longer than in monolayer, to prolong the cell viability and 
therefore to sustain cell function [Penolazzi et al. 2010]. 
Living cells embedded in microbeads, acting as scaffolds, have found application 
in many different fields, including cell culture, cell-based therapy and tissue 
engineering [Wang et al. 2003].
The main advantage of these devices is represented by  the presence of an 
immunoisolating membrane, which enables the transplantation of non-self cells 
and tissues without the need for immunosuppressive regimens [[Abbah et al. 
2008 ; Capretto et al 2010].
Successful clinical use of encapsulated cells strongly depends on a number of 
crucial characteristics:
- the morphological and dimensional properties;
- mechanical stability; 
- biocompatibility; 
- molecular exchangeability of microbeads. 
As scaffold materials, polysaccharides have largely been used. Polysaccharides 
(such as alginate, agarose or chitosan) indeed possess adequate mechanical 
properties, permit the exchange of molecules and can be transformed into 
spherical gelled solid particles by mild procedures, preserving the cell viability 
[Capretto et al 2010].
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Several groups showed that human MSCs encapsulated showed a higher 
proliferation rate than those seeded on scaffolds, and alginate beads were also 
tested to study the chondrogenesis of human MSCs [Yowa et al. 2009; Ma et al. 
2000].
The use of alginate microbeads showed excellent biocompatibility and 
immunoprotection of embedded cells [Luca et al. 2005; Luca et al. 2007]; Abbah et 
al. showed that calcium cross-linked alginate microbeads can act as a scaffold for 
MSCs proliferation and osteogenic differentiation and has potential for use as 3D 
degradable scaffold [Abbah et al. 2008]. 
Despite static cultures have shown expansion of MSCs, the scaling-up  represents 
a major problem because more volume means less oxygen flow and less nutrient 
availability in the system. Several dynamic models that incorporate gas flow have 
been used to overcome this problem [Andrade-Zaldívar et al. 2008]. Diverse 
bioreactors with specific characteristics have been designed for MSCs expansion 
since the 1990s. In addition, the latest designs have served as well to study the 
MSCs biology. 
Differences between tissues suggest that reactor design considerations and 
operating conditions can be different when dealing with a specific tissue. However, 
every type of tissue beneficiates from controlled shear stresses and optimal 
nutrient availability and wastes elimination [Martin & Vermette 2005].
The term “bioreactor” has been frequently  used, but often to mean different things. 
Bioreactors can be defined ʻʻas devices in which biological and/or biochemical 
processes develop under closely monitored and tightly controlled environmental 
and operating conditions (e.g., pH, temperature, pressure, nutrient supply, and 
waste removal)ʼʼ. Different bioreactor systems matching this definition are currently 
being used in a wide range of biotechnological applications including industrial 
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fermentation processing, wastewater treatment, food processing, and 
manufacturing of biopharmaceuticals. However, many systems encountered in the 
tissue-engineering literature are composed of vessels of few milliliters, which, 
under many aspects, do not fit in the presented definition of a bioreactor [Martin & 
Vermette 2005].
Dynamic bioreactor culture systems are essential for the in vitro cultivation and 
maturation of bone tissue engineering grafts, especially for larger grafts where the 
core of the scaffold is more than 200 mm from the surface [Chen et al. 2006]. 
Bioreactors improve the mass transport of nutrients and allow the diffusion 
limitation of traditional static culture, which is generally taken to be around 200 
mm, to be overcome [Ishaug et al. 1997; Martin et al. 1999]. In addition, the 
dynamic media flow applies a mechanical stimulus to the cells, enhancing cellular 
osteogenesis and mineralization through triggering of mechano-transduction 
signaling pathways [Gomes et al. 2003; Chen et al. 2006]. 
Currently, several types of bioreactors have been developed for bone tissue 
engineering applications, providing truly  microgravity environement (see FIGURE 
3). 
This includes the Spinner Flask bioreactor, Perfusion bioreactor, Biaxial and 
Rotating Wall Vessel (RWV) bioreactor, all of which have been shown to be useful 
to expand MSCs as well as to study their in vitro biology, and to promote cellular 
osteogenic differentiation  [Gomes et al. 2003; Martin et al. 2004; Stiehler et al. 
2008]. 
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Figure 3: designs of bioreactor systems.
Microgravity  is any condition equivalent to experiencing little or no acceleration or 
gravitational attraction, e.g., far from a planet, star, or other massive body. The 
term microgravity  is used to describe a condition where gravity is not small, but 
appears to be small. This occurs on an orbiting spacecraft, such as the 
International Space Station (ISS), and all objects in free-fall. NASA used a variety 
of facilities to create microgravity conditions. The most famous way is by aircraft 
flying in parabolic arcs to create microgravity for tests and simulations that last 
!"#$%&'(#$)
BIAXIAL ROTATING 
BIOREACTOR
SPINNER FLASK 
BIOREACTOR
PERFUSION 
BIOREACTOR
ROTATING WALL 
VESSEL BIOREACTORS
tested for ALP activity using SensoLyte! pNPP Alkaline Phosphatase Assay Kit
(AnaSpec USA) and the ALP activities were normalized to the total protein content
determined using the Bradford assay (Bio-Rad Laboratories, US) as previously
described [15].
2.6.2. von Kossa staining
hfMSC cellular scaffolds were stained with von Kossa at week 4. Brieﬂy samples
were gently rinsed twice with PBS then ﬁxed in 10% formalin for 1 h, and washed in
water. Finally, they were stained with freshly made 2% silver nitrate in water (w/v)
for 10 min in the dark and expose to sun light for 3 h.
2.6.3. Calcium content assay
The calcium content of the hfMSC cellular scaffolds at week 1, 2 and 4
(n ¼ 3) were assayed as previously described [15]. Brieﬂy, the calcium deposition
is dissolved in 0.4 ml 0.5 N acetic acid and determined by a colorimetric assay
using calcium assay kit (BioAssay Systems, USA). Control cell-free empty scaf-
folds cultured as above (n ¼ 3) were used as a negative control to offset the
elution of calcium from the tri-calcium phosphate component in the PCL-TCP
scaffold.
2.6.4. Scanning electron microscope (SEM) and energy dispersive X-ray
spectrometer (EDX) analysis
Cellular scaffolds were dehydrated, gold sputtered, viewed under the SEM and
element component of crystal-like structure inside the samples was analyzed by
EDX as previously described [15].
2.7. Statistical analyses
All the data have been represented as mean " SD, and compared using
either two-way ANOVA or student t-test. A value of P < 0.05 was taken as
signiﬁcance.
3. Results
3.1. Characterization of hfMSC
hfMSC isolated from the bone marrow grew as spindle-
shaped cells as monolayers. They expressed a typical MSC
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element component of crystal-like structure inside the samples was analyzed by
EDX as previously described [15].
2.7. Statistical analyses
All the data have been represented as mean " SD, and compared using
eith r two-way ANOVA or student t-test. A valu of P < 0.05 w s taken as
signiﬁcance.
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hfMSC isolated from the bone marrow grew as spindle-
shaped cells as monolayers. They expressed a typical MSC
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tested for ALP activity using SensoLyte! pNPP Alkaline Phosphatase ssay Kit
(AnaSpec USA) and the ALP activities were normalized to the total protein content
determined using the Bradford assay (Bio-Rad Laboratories, US) as previously
described [15].
2.6.2. von Kossa staining
hfMSC cellular scaffolds were stained with von Kossa at week 4. Brieﬂy samples
were gently rinsed twice with PBS then ﬁxed in 10% formalin for 1 h, and washed in
water. Finally, they were stained with freshly made 2% silver nitrate in water (w/v)
for 10 min in the dark and expose to sun light for 3 h.
2.6.3. Calcium content assay
The calcium content of the hfMSC cellular scaffolds at week 1, 2 and 4
(n ¼ 3) were assayed as previously described [15]. Brieﬂy, the calcium deposition
is dissolved in 0.4 ml 0.5 N cetic acid and determined by a colo imetric assay
using calcium assay kit (BioAssay Systems, USA). Control cell-free empty scaf-
folds cultured as above (n ¼ 3) were used as a negative control to offset the
elution of calcium from the tri-calcium phosphate component in the PCL-TCP
scaffold.
2.6.4. Scanning elec ron microscope (SEM) and energy dispersive X-ray
spectrometer (EDX) analysis
Cellular scaffolds were dehydrated, gold sputtered, viewed under the SEM and
element component of crystal-like structure inside the samples was analyzed by
EDX as previously described [15].
2.7. Statistical analyses
All the data have been represented as mean " SD, and compared using
either two-way ANOVA or student t-test. A value of P < 0.05 was taken as
signiﬁcance.
3. Results
3.1. Characterization of hfMSC
hfMSC isolated from the bone marrow grew as spindle-
shaped cells as monolayers. They expressed a typical MSC
Fig. 1. (continued).
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20-25 seconds. The facilities most-likely to be misconstrued as “anti-gravity 
chambers,” are NASAʼs drop towers. 
It has long been established that cells and tissue growing in microgravity  - the 
weightless condition obtained in space - can grow and mutate in ways different 
than on Earth. A perpetual challenge for the experimental study of these 
phenomena has been simulating the conditions of space so that complete 
laboratory studies can be done by  numerous investigators on Earth. The simulated 
growth of mammalian cells in tissue culture needed to duplicate the quiet 
conditions of orbital free-fall in a way that allowed for maintaining fresh media and 
oxygenation (see FIGURE 4). To solve the problem, NASA in the 1980s developed 
the bioreactor, a can-like vessel equipped with a membrane for gas exchange and 
ports for media exchange and sampling.
Figure 4: Cell constructs grown in a rotating bioreactor on Earth (left) eventually become too large to stay suspended in the 
nutrient media. In the microgravity of orbit, the cells stay suspended. Rotation then is needed for gentle stirring to replenish 
the media around the cells.
As the bioreactor turns, the cells continually fall through the medium yet never hit 
bottom. Under these quiet conditions, the cells "self- assemble" to form clusters 
that sometimes grow and differentiate much as they would in the body [Unsworth 
et al. 1998].
It has been well established that a number of cell types grow in the bioreactor on 
Earth for extended periods in ways that resemble tissue-like behavior. For this 
reason, the bioreactor also provides cell culture studies with a new tool for the 
study of three-dimensional (3-D) cell growth and differentiation. Bioreactors have 
10
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are feasible. The space-grown tissue, when compared to the control experiment on Earth, also revealed someinteresting differences. The cells from both the space and control experiments were healthy, but the tissuethat grew in microgravity was mechanically weaker and smaller than the tissue that formed in the groundexperiment. Freed explained that the space-grown tissue contained less of a key component,glycosaminoglycan, that the cells secrete. Vunjak-Novakovic said that this clue may help them to understandnot only the weakening of tissue experienced by astronauts but also similar diseases experienced by peopleon Earth. Freed reported that they have already received calls to their lab from people who suffer fromcartilage problems. "They are waiting for what we aredoing in the lab to be ready for them," she said. "It isalways hard to explain that research goes very slowlyand that we are working as hard and as fast as wecan." Freed and Vunjak-Novakovic share the dreamthat tissue may one day be engineered for replacementof damaged or congenitally defective tissue. Theirresearch is bringing the realization of that big momentever closer.
Turning a Problem on Its SideIt has long been established that cells and tissuegrowing in microgravity - the weightless conditionobtained in space - can grow and mutate in waysdiffere t than on Earth. A perpetual challenge for theexperimental study of these phenomena has beensimulating the conditions of space so that completelaboratory studies can be done by numerousinvestigators on Earth. The simulated growth ofmammalian cells in tissue culture needed to duplicatethe quiet conditions of orbital free-fall in a way thatallowed for maintaining fresh media and oxygenation.To solve the problem, NASA in the 1980s developedthe bioreactor, a can-like vessel equipped with amembrane for gas exchange and ports for mediaexchange and sampling. As the bioreactor turns, thecells continually fall through the medium yet neverhit bottom. Under these quiet conditions, the cells "self-assemble" to form clusters that sometimes grow anddifferentiate much as they would in the body.
Standard cell culture in 1g
5 min. 30 min. 5 hours
Standard cell culture in µg
5 min. 30 min. 5 hours
Cell constructs grown in a rotating bioreactor on Earth
(left) eventually ecome too large to stay susp nded in
the nutrient media. In the microgravity of orbit, the cells
stay suspended. Rotation then is needed for gentle
stirring to replenish the media around the cells.
Activity Five: Group students in pairs and require them to look up personalities such as
those found at:  http://www.spacetoday.org/History/SpaceWomen.html
or http://observe.arc.nasa.gov/nasa/ootw/1998/ootw_980211/ob980211.html
or http://microgravity.nasa.gov/WOMEN/ or http://www.jsc.nasa.gov/Bios/
The students should write a report and plan a presentation preferably using PowerPoint or
their own drawings on poster board. (For assessment tips see Teacher Notes).
A ground-test model of th  NASA Bioreactor shows the
key element, a rotating plastic cylinder enclosing a tubular
membrane that infuses growth media and oxygen and
removes wastes.
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been used aboard the Mir Space Station to grow larger cultures than even 
terrestrial-bioreactors can support. Several cancer types, including breast and 
colon cancer cells, have been studied in this manner [Ingram et al. 1997].
A cell suspension bioreactor is a closed stirred vessel where it is possible to inline 
monitor and control some culture parameters, and to take samples from the vessel 
without disrupting culture conditions. It can be run in different configurations, such 
as batch, fed-batch, and in perfusion mode, with a system to prevent cell wash-out 
[Cabrita et al, 2003]. The main advantage of a suspension bioreactor is related to 
the reduction of spatial gradients. The homogeneity in the vessel ensures more 
defined and repeatable culture conditions, making easier the scale-up  of the 
process with a consequent cost reduction. Other advantages are the possibility to 
control the process inline, and to obtain higher cellular densities, because, as cells 
are suspended, the culture becomes three-dimensional [Blanch et al, 1997].
One approach to maintain homogeneous environment with low stress, is the use 
of rotating wall vessels (RWV). 
The RWV has proven beneficial not only to microgravity  sciences but also to the 
field of tissue engineeing. The reconstituted tissue formed in the RWV is 
characterized by more extensive 3D growth, tissue differentiation, and cell-cell and 
cell-matrix interactions than can be achieved in conventional bioreactors [Muhitch 
et al. 2000]. Multicellular aggregates of human prostate tumor cells were more 
differentiated in terms of mor- phology and cytokeratin expression when grown in a 
RWV than control cultures in a spinner flask or static Transwell [Clejan et al., 
1996]. Likewise, reconstituted cartilage prepared from RWV cultures of 
chondrocytes had a higher content of matrix glycosaminoglycans relative to 
spinner-flask controls [Freed & Vunjak-Novakovic, 1995].
Liu et al. designed a RWV bioreactor to culture total mononuclear from UCB [Liu et 
al. 2006]. Cells were cultured at an increasing rotating speed from 0 to 6 rpm. The 
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RWV achieved large expansion of mononuclear from UCB. The authors suggested 
that the multi-step  RWV bioreactor could expand a single cord blood to reach 1.2 x 
109 mononuclear from UCB [Liu et al. 2006].
The National Aeronautics and Space Administration (NASA) developed two RWV 
bioreactors for tissue mass culture [Martin & Vermette 2005]. The slow turn lateral 
vessel (STLV) bioreactor has been used to culture several kinds of cells both on 
Earth and in space. The STLV was operated at 15–30 rpm on Earth and slower in 
space allowing a free-fall state, reducing the shear stress.
Gas exchange is provided by a 31.4 cm2 gas exchange membrane at the inner 
concentric cylinder. On Earth, this reactor is often rotated at a speed of 
approximately  15–30 rpm as the tissues grow, so the constructs in the reactor are 
maintained ʻʻstationaryʼʼ in a state of continuous free-fall. Solid body rotation of the 
constructs at higher rotating speeds is also reported in space and Earth 
experiments. Both the inner and outer cylinders can be independently rotated 
[Martin & Vermette 2005].
The high aspect ratio vessel (HARV) is similar to the STLV, but its design lowers 
the speed necessary to maintain the constructs stationary (typical speeds of 12–
15 rpm) and enhances gas exchange. It is enhanced by the presence of a 78.5 
cm2 gas exchange membrane at one end of the vessel, the area for exchange 
being more than twice as large than the one in the STLV [Prewett et al.1993]. The 
principle of operation of this reactor is identical to that of the STLV. Both the STLV 
and HARV are commercialized by Synthecon Inc. (http:// www.synthecon.com/, 
Houston, TX) [Schwarz & Wolf 1991; Schwarz et al. 1991] (see FIGURE 5).
Both systems were used in the space and on earth to culture human embryonic 
stem cells (hESC), showing that STLV reduced the aggregation of hESC and they 
attained a 4-fold increase in productivity respect to the Petri dish cultures 
[Gerecht-Nir et al. 2004]. The NASA- RWV systems have been used to study the 
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effects of microgravity on murine HSC and evaluating the hematopoietic 
homeostasis during long space expeditions [Ohi et al. 2004].
Earthʼs gravity provides additional shear to cell aggregates in the vessel as cells, 
which are about 4% denser than the fluid media, fall through the fluid at their free-
fall terminal velocity  (i.e., drag and gravitational forces on the constructs are equal 
but opposite).
Figure 5: NASA-RWV bioreactors. High aspect ratio vessel: (a) side view (b) front view (adapted from Gerecht-Nir et al. 
2004).
Rotating-wall reactors have also been shown to attenuate heart tissue 
development by disturbing the cytoskeleton–cell surface–ECM interface of 
embryonic cells [Lwigale et al. 2000]. The HARV reactor, while not altering the 
morphology of the cells, significantly decreased the number of contracting heart 
cells and the quantity of fibronectin relatively  to a control culture. Fibronectin is a 
glycoprotein responsible in part for linking cells cytoskeleton to the ECM. Bone 
tissue cultured in the rotating-wall reactor also presented major differences 
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compared to a control culture, noticeably in the expression of many proteins [Teti 
et al. 2002]. The growth rate was found to be non-uniform across the faces of the 
cell carriers [Lappa et al. 2003]. 
Li et al. investigated the biological effect of three-dimensional dynamic simulated 
microgravity  induced by rotary cell culture system on human periodontal ligament 
stem cells in vitro. PDLMSCs were carried on Cytodex 3 micro-carriers and 
cultured in HARV vessels. Dynamic simulated microgravity  affected the biology of 
cells as indicated by promotion of proliferation and viability, alterations of 
morphology and disorganization of microfilament system. Besides, simulated 
microgravity  treated cells presented increased matrix mineralization and up-
regulated expression of mineralization associated genes after incubation in 
osteogenic medium [Li et al. 2009]. 
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AIM
Aim of work
• To isolate and culture MSCs cells from human Umbilical Cord Whartonʼs Jelly 
(WJMSCs) and periodontal ligament (PDLMSCs);
• To compare characteristics between all samples recruited and to link them to 
clinical aspects of tissues donors;
• To characterise both MSCs population in regard to their proliferation and 
differentiation potential;
• To point out culture strategies in order to modify osteogenic cells 
differentiation pattern;
• To investigate their functional characteristics before and after alginate 
microbeads encapsulation
• To investigate effects of alginate microbeads encapsulation on MSCs 
osteogenic differentiation potential, in different culture conditions (out and 
within rotating vessel bioreactor).
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Experimental strategies
Cells Characterization
All experiments were performed after ex-vivo expansion and mesenchymal 
characterization of WJMSCs and PDLMSCs. 
- WJMSCs and PDLMSCs were analyzed for mesenchymal hallmarks;
- WJMSCs: in order to find predictable criteria in selection of WJMSCs were 
cultured in 6,12 or 24 well-plate in control and osteogenic conditions (2-D stiren 
adhesion culture condition) and analyzed for clinical obstetric parameters of 
donors. Viability, markers expression and Calcium deposition ability were tested;
- PDLMSCs: in order to find culture conditions able to optimize osteogenic 
differentiation, PDLMSCs were cultured in 6,12 or 24 well-plate in control and 
different osteogenic conditions (2-D stiren adhesion culture condition, in presence 
of Polymeric Micelles (PMs) osteogenic inductors complexes or in presence of 
traditional osteogenic inductors). Viability, citotoxicity and Calcium deposition 
ability were tested.
Alginate beads encapsulation and different culture systems
WJMSCs and PDLMSCs were encapsulated in alginate beads after ex-vivo 
expansion. 
- WJMSCs alginate beads (WJABs): viability, citotoxicity, markers expression and 
beads secretive profile were tested before and after cells encapsulation;
- WJMSCs and alginate beads (WJABs) and PDLMSCs alginate beads (PDLABs): 
Beads were split and cultured in 6 well-plate (We) or poured in rotary cells culture 
system (RCCS-4TM Bioreactor, Synthecon, Inc., Houston, TX, U.S.A.), in High 
Aspect Ratio Vessel (HARVTM). Viability, markers expression and Calcium 
deposition ability were tested after cells encapsulation, in two different culture 
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conditions: “control” culture medium (CCM) and osteogenic differentiation 
medium (ODM).
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MATERIALS AND METHODS
Cells characterization
Methods for the isolation, ex vivo expansion and characterization of WJMSCs from 
umbilical cord and PDLMSCs from human periodontal ligament are described. 
Isolation of MSCs populations from Whartonʼs Jelly
Samples
In the obstetric department, UC  were collected only after having obtained informed 
consent from the mother. Following delivery  of the baby, the UC were collected 
from the into special bags containing sterile phosphate-buffered saline (PBS). 
WJMSCs cultures were initiated directly  from UC  samples, with a total generation 
frequency of 90%. 
Human umbilical cords were collected after surgical and natural full-term deliveries 
with informed consent of the mothers. Long segments from 10 to 20 cm were 
sectioned and conserved at 4° C into sterile PBS until they were used in the 
laboratory (within 4h). Ethics approval was obtained from the institutional ethics 
committee.
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Isolation and culture of WJMSCs
MSCs culture medium
-  Dulbeccoʼs Modified Essential Medium Low Glucose
-  10% (v/v) fetal bovine serum
-  penicillin 100 mg/mL 
-  streptomycin 10 mg/mL
Protocol choosen followed several steps:
1. The umbilical cord segments were sectioned longitudinally to expose the WJ. 
Some incisions were made on the matrix with a sterile scalpel to expose a wider 
area of tissue. Forceps provided the isolations of vessels, both vein and 
arteries. 
2. The WJ was minced into very fine pieces from 1 to 2 mm3 avoiding any 
endothelial and epithelial contamination, mantaining all vessels integrity.
3. Small pieces were directly  plated in T-25 cm2 culture flasks, in Dulbeccoʼs 
modified Eagleʼs medium low-glucose (D-MEM LG), supplemented with 10% 
fetal calf serum (Euroclone S.p.A., Milan, Italy), 1 mM L- Glutamine and 
antibiotics (penicillin 100 mg/mL and streptomycin 10 mg/mL).
4. Cultures were maintained in a humidified atmosphere with 5% CO2 at 37°C. At 
subconfluence (80–90%) cells were scraped off by 0.05% trypsin/ethylene 
diamine tetraacetic acid (EDTA) (Gibco, Grand Island, NE) (2min), washed, 
counted by hemocytometric analysis, assayed for viability, and thereafter used 
for in vitro experiments or encapsulation procedures.
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Isolation of MSCs populations from periodontal ligament (PDL)
Samples
Following informed consent, teeth with healthy periodontal ligament were obtained 
as a result of tooth extraction for orthodontic purposes or removal of totally bone 
impacted lower or upper third molars.
All patients selected were healthy  patients with clinically healthy periodontium. The 
extent of experiments was explained to all patients and informed consent was 
obtained according to the Helsinki Declaration. 
PDL tissue were all processed within 4 h from extraction. 
Before each surgical procedure, each patient underwent to 60” clorexidine 0,12% 
mouthrinse to avoid any bacterial field contamination.
After surgical incision, flap elevation and surgical osteotomy, teeth were collected 
with proper forceps and put into 15 ml tube with sterile PBS avoiding any contact 
with oral cavity. 
Isolation and culture of PDLMSCs
MSCs culture medium
-  Dulbeccoʼs Modified Essential Medium Low Glucose
 10% (v/v) fetal bovine serum
 penicillin 100 mg/mL 
 streptomycin 10 mg/mL
MATERIALS AND METHODS
79
Protocol choosen followed several steps:
1. In sterile laboratory conditions, teeth were washed several times and PDL 
samples were obtained from the mid-third of roots of extracted third molars.
2. Gently  PDL was separated from the middle third of the tooth root surface using 
forceps and a size 15 surgical blade in a 10-cm tissue culture dish containing 
PBS.
3. Then PDL tissue was washed for 30”, 5 times in culture medium, Dulbeccoʼs 
modified eagle medium (DMEM) (Invitrogen, Carlsbad, CA, USA) containing 
10% (v/v) fetal bovine serum, penicillin (100 mg/mL)  and streptomycin (10 mg/
mL)
4. PDL tissue was cut into small pieces (approximately 2 mm2) and placed in 6-
well culture dishes with 1mL culture medium. After 5 days of incubation, culture 
medium was gently  changed and cell culture was continued with medium 
changes every 3 days until PDL cells were subconfluent. After reached 
subconfluency, cells were passaged using 0.05% trypsin– 0.1% EDTA solution 
(Invitrogen) and expanded in T-25 cm2 flasks. 
5. At subconfluence (80–90%) cells were scraped off by 0.05% trypsin/ethylene 
diamine tetraacetic acid (EDTA) (Gibco, Grand Island, NE) (2min), washed, 
counted by hemocytometric analysis, assayed for viability, and thereafter used 
for in vitro experiments or encapsulation procedures.
Cryopreservation of Ex Vivo-Expanded MSCs
For all samples the same protocol for cryopreservation was chosen:
1. suspensions of culture-expanded MSCs were prepared by 0.05% trypsin/0.02% 
EDTA digestion and cells were enumerated. Viability  was assessed using 0.4% 
trypan blue/PBS as described above. Cells were centrifuged and resuspended 
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in 0,9 mL of FBS and kept on ice. Cells were then resuspended in a 90% FBS, 
10% dimethyl sulfoxide (DMSO) solution (Sigma Aldrich, St Luis, MO, USA). 
2. Cryovials were placed at –20◦C for 1 hr, –80◦C overnight before transferring the 
cryovials into liquid nitrogen for long-term storage.
3. Recovery of the cryopreserved stock was achieved by rapidly  thawing the cells 
in a 37◦C water bath. The cells were resuspended in 45 mL cold MEDIUM and 
and spin at 1500 rpm for 5 min.
4. Viability of cells was assessed  using 0.4% trypan blue/PBS.
Flow cytometric analysis
Homogeneous populations of PDLMSCs and WJMSCs were analyzed for markers 
expressed on the cell surface. 
WJMSCs were fixed in 4% paraformaldehyde and incubated at 4°C for 30ʼ with 
5μg/ml of the following monoclonal antibodies: anti-human-CD3, -CD34, -CD45, 
(DAKO Cytomation, Glostrup, Denmark), CD31 (Chemicon International, 
temecula, CA), -CD73, -CD90, -CD146 (Becton Dickinson, Mountaine View, CA), -
CD105 (produced from the hybridoma cell line, clone SH2, ATCC, Rochville, MD). 
The cells were washed twice and incubated with 2.4 μg/ml of a polyclonal rabbit 
anti-mouse immunoglobulins/FITC conjugate or with 8 μg/ml  of a polyclonal rabbit 
anti-rat immunoglobulins/FITC conjugate or with 1μg/ml  of a polyclonal swine anti- 
rabbit immunoglobulins/FITC conjugate (DAKO Cytomation) at 4°C for 30 min. 
After two final washes, the cells were analysed using a FACStar plus Cytometer 
(Becton Dickinson). For isotype control, FITC-coupled non-specific mouse IgG 
was substituted for the primary antibody.
MATERIALS AND METHODS
81
The PDLMSCs were analyzed for expression of MSC surface marker molecules, 
by direct immunofluorescent staining. Briefly, cell pellets were resuspended in PBS 
and incubated with fluorescein iso-thiocyanate (FITC)– or phycoerythrin (PE)–
conjugated mouse anti-human antibodies CD45-PE, CD34-FITC, CD90-FITC, 
CD105-PE and Stro-1-FITC (DakoCytomation; Dako, Glostrup, Denmark) for 
15min at 4°C. Monoclonal antibodies with no specificity were used as negative 
control.
Antibody-treated cells were then washed with PBS and spinned down. Cell pellets 
were resuspended in 400mL of PBS and analyzed by FACS Scan (Becton 
Dickinson, Franklin Lakes, NJ). For each sample, 20,000 events were acquired 
and analyzed using the CellQuest software (Becton Dickinson European HQ, 
Erembodegem Aalst, Belgium).
Viability analysis of MSCs populations
Before and after all experiments, the viability of the cells was analyzed by double 
staining with propidium iodide (PI) and Calcein-AM according to the 
manufacturerʼs instructions. For the PI and Calcein-AM analysis, cells were 
visualized under a fluorescence microscope (Nikon, Optiphot-2; Nikon 
Corporation, Tokyo, Japan) using the filter block for fluorescein. Dead cells stained 
red, while viable ones appeared green.
Adipogenic differentiation
To induce adipogenic differentiation, cells were treated with adipogenic medium for 
three weeks with medium changes twice a week. The adipogenic medium 
consisted of DMEM supplemented with 1 μM dexamethasone (Sigma Aldrich, St. 
Louis, MO, USA), 5 μg/mL bovine insulin (Sigma Aldrich, St. Louis, MO, USA), 0.5 
MATERIALS AND METHODS
82
mM 3-isobutyl-1- methyl-xanthine (IBMX) (Sigma Aldrich, St. Louis, MO, USA), 60 
μM indomethacin (Sigma Aldrich, St Louis, MO, USA) and 10% FCS. On the 21st 
day the cells were fixed in 10% formalin neutral solution (Merck, Darmstadt, 
Germany) for 30 min and stained with fresh 0.6% oil red O solution to show lipid 
droplets in induced cells.
Cytotoxicity studies
The cytoxicity analysis was done on in vitro cultured MSCs before and after 
experiments. Determination of viable cells was done with [3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) colorimetric assay 
(thiazolyl blue). MTT assay is based on the conversion of the yellow tetrazolium 
salt MTT to purple formazan crystals in the mitochondria of living cells [Denizot et 
al. 1986]. MTT provides a quantitative determination of viable cells. 
After 72 hrs of treatments in triplicate, 200 μL of a solution of MTT (5 mg/ml) was 
added to each well of cells, and the plate was incubated for 2 hr at 37°. The 
medium was removed, and the MTT crystals were solubilized with 50% 
dimethylformammide (DMF). Spectrophotometric absorbance of each sample was 
measured at 570 nm. 
Alkaline phosphatase analysis
For alkaline phosphatase staining, the Alkaline phosphatase (ALP) Leukocyte kit 
(Sigma) was used. To perform the test, prefixed mono-layered cells were 
incubated at room temperature in a solution containing naphthol AS-BI phosphate 
and freshly prepared fast blue BB salt buffered at pH 9.5 with 2-amino-2-
methyl-1,3-propanediol (AMPD). The presence of sites of ALP activity appeared as 
blue cytoplasmatic staining. 
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ALP activity, before and after osteogenic induction, was evaluated inMSCs 
population by the hydrolysis of p-nitrophenylphosphate (PNPP), according to 
literature [Ibbotson et al. 1986]. Cells enzime activity (expressed as U(nmol/min)/
μg of protein) was evaluated before and after osteogenic differentiation. One unit 
was defined as the amount of enzyme which hydrolyzed 1 nmol/PNPP per minute. 
Cell protein was determined according to the Lowry method [Waterborg et al. 
1994]. 
Alizarin Red staining
The extent of mineralized matrix in the plates was determined by Alizarin Red S 
staining (AR-S, Sigma) at different time, and before and after osteogenic induction. 
Cells were fixed in 70% ethanol for 1 h at room temperature, washed with PBS, 
and stained with 40 mM AR-S (pH 4.2) for 10 min at room temperature. Next, cell 
preparations were washed five times with deionized water and incubated in PBS 
for 15 min to eliminate non-specific staining. The stained matrix was observed at 
different magnification using a Leitz microscope. 
Oil Red O Staining
Lipid vacuole formation in the adipogenic cultures was determined by Oil Red O 
(Sigma- Aldrich) staining on day 14. The cells were gently rinsed with PBS and 
fixed with 4% paraformaldehyde in PBS for 1 hour, rinsed with H2O, and incubated 
with 60% isopropanol for 5 minutes, and stained with the Oil Red O working 
solution (30 ml of 3 mg/ml Oil Red O/isopropanol stock solution plus 20 ml H2O) 
for 5 minutes at room temperature. After rinsing with water, the cultures were 
counterstained with haematoxylin for 1 minute at room temperature, rinsed again, 
and observed with phase contrast microscopy (Nikon TS100).
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Immunocytochemistry
Cells grown in chamber slides were fixed in 4% PFA for 20 minutes at room 
temperature, washed twice in PBS, treated with 3% H2O2  (in PBS) and incubated 
in 2% normal horse serum (S-2000, Vector labs, CA, USA) for 15 min at room 
temperature. After the incubation in blocking serum, the slides were incubated with 
monoclonal antibody anti-human-STRO1 FITC conjugated (Santa Cruz biotec) for 
1 hour at room temperature. The slides were washed three times with PBS 1X  
and then were visualized under a fluorescence microscope (Nikon, Optiphot-2, 
Nikon Corporation, Japan) using the filter block for fluorescein; cells were also 
counterstained with DAPI.
Real-time quantitative RT-PCR
Cells from wells were harvested and total RNA was extracted using an RNeasy 
Mini Kit (Qiagen GMBH, Hilden, GM) according to the manufacturerʼs instruction. 2 
micrograms of total RNA were reverse transcribed with the improm II RT system 
(Promega, WI, USA).
Real-time PCR was carried out using the ABI PRISM 7700 Sequence Detection 
System (Applied Biosystems Inc, Foster City, CA, USA), TaqMan technology, and 
the Assays-On-Demand kit for human Slug and Runx2. The mRNA levels of target 
genes were corrected for GAPDH mRNA levels (endogenous control). All PCR 
reactions were performed in triplicate for each sample and were repeated three 
times. All experimental data were expressed as the mean ± S.E.M.
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Scratch Wound Migration Assay
24 h before siRNA transfection, PLDMSCs and WJMSCs were seeded in 12 well 
plates in duplicate at density  of  15x103/cm2 in DMEM supplemented with 10% 
FCS. Cells were transfected with 30 nM siRNA using Lipofectamine RNAiMAX 
(Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturersʼ 
instructions. After 24 hours a scratch was introduced to the cell monolayer using a 
sterile 200 ml pipette tip. Transfected cells were incubated for 6 days at 37°C. As a 
negative control for the siRNA treatment, PDLMSCs and WJMSCs were seeded in 
DMEM with 10% FCS. Scratch wound modifications were observed at 0, 24 and 
48 h. Knockdown of Slug expression was verified by Real-Time RT-PCR.
Encapsulation of MSCs in alginate microbeads and bioreactor culture
Encapsulation of MSCs
Monodisperse alginate beads containing cells were prepared using an 
encapsulation device that is based on a vibrating nozzle (Encapsulator Research 
Inotech, Dottikon, Switzerland). The encapsulator is composed by a 2-L glass 
reaction vessel with stainless steel top  and bottom plates. The top plate contains a 
feed-line connected to a syringe and a vibrating nozzle. A  nozzle with an internal 
diameter of 300mm was used. The flow of alginate to the nozzle is achieved by a 
precision syringe pump. The production of WJMSC-filled alginate microcapsules 
was optimized by changing the following experimental parameters: vibrational 
frequency, vibrational amplitude, alginate pumping rate (pump), and distance 
between the nozzle and the surface of the gelling bath (height) (see Table 1). 
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Parameter Abbreviation Meaning Range
frequency freq frequency of the vibration of the nozzle 100.0-140.0 hz
amplitude amp amplitude of vibration of the nozzle 1.0-6.0 mm
pump pump polymer pumping rate 7.5-9.5 mL/min
height height distance from nozzle to surface of gelling bath 100.0-140.0 mm
Table 1: Production of alginate microcapsules by vibrational encapsulation procedure: the 
investigated experimental parameters and their range of variation.
Before encapsulation, WJMSCs were suspended in a 1.5% (w=v) aqueous 
solution of highly purified sodium alginate (Stern Italia, Milano, Italy) at a 
concentration of 8–12x106 cells=mL. The generated microdroplets were dropped 
into an isotonic barium chloride solution (1.2%; w=v); after gelation (3 min), the 
microbeads were washed twice with saline and cultured in 10% fetal calf serum 
(Euroclone S.p.A.) Dulbeccoʼs modified Eagleʼs medium supplemented with 
antibiotics' (penicillin 100 mg/mL and streptomycin 10 mg/mL) at 37◦C in an 
humidified atmosphere of 5% CO2.
Dimensional and morphological characterization of microbeads
The morphology of Ba–alginate microbeads was evaluated by optical 
stereomicroscopy (Nikon SMZ 1500 stereo micro- scope, Tokyo, Japan). 
Microbead size and size distribution were determined by photomicrograph 
analyses (Eclipsenet version 1.16.5; Laboratory Imaging s.r.o. for Nikon Italia, 
Firenze, Italy). Microbead samples, immediately after preparation and at intervals 
after storage under different conditions, were deposited onto a microscope slide 
and examined microscopically. A sample of 100–300 beads was examined, and 
the mean size was determined.
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Determination of MSCs encapsulated and free secretory pattern by Bio-Plex® 
analysis
After 72h of in vitro cell culture, the medium from MSCs growing as monolayer and 
embedded in Ba–alginate microbeads was collected and analyzed for a set of 
selected proteins. To compare and normalize the data of adherent and 
encapsulated MSCs, the microbeads were washed twice with PBS before the 
analyses and incubated at 37◦C, for 15min, with 500μL of 50mM EDTA (Sigma, St. 
Louis, MO) in PBS buffer. EDTA was then neutralized with additional 10mL PBS, 
and cells were collected by  centrifuging at 400 g for 15 min. Pellets obtained from 
MSCs growing as monolayer and embedded in Ba–alginate microbeads were 
lysed with 50 μL buffer (NaCl 150mM; Tris-HCl pH 7.4 20mM; EDTA 1mM; 
ethylene glycol tetraacetic acid (EGTA) 1mM; Triton X-100 1%; Na3VO4 0.1mM; 
phenylmethanesulphonyl fluoride (PMSF) 1 mM; proteinase inhibitory cocktail 
(PIC) 0.1% v=v). About 10 μL of each sample was tested with the Bradford method 
to determine proteins content. Concentrations of interferon- alpha2 (IFN-a2), 
interleukin-1alpha (IL-1a), IL-2 receptor a, IL-3, IL-12 (p40), IL-16, IL-18, 
cutaneous T-cell-attracting chemokine (CTACK), growth regulated oncogene-a 
(GRO-a), hepatocyte growth factor (HGF), intercellular adhesion molecule-1 
(ICAM-1), leukemia inhibitory factor (LIF), monocyte chemotactic protein-3 
(MCP3), macrophage colony  stimulating factor (M-CSF), macrophage migration 
inhibitory factor (MIF), monokine induced by IFN-Gamma (MIG), β-nerve growth 
factor, stem cell factor, stem cell growth factor-β  (SCGF-β), stromal cell-derived 
factor 1a (SDF-1a), tumor necrosis factor-β, tumor-necrosis-factor related 
apoptosis inducing ligand (TRAIL), and vascular cell adhesion molecule-1 
(VCAM-1) were simultaneously evaluated using a commercially available multiplex 
bead–based sandwich immunoassay kit (Human 23-plex; Bio-Rad Laboratories, 
Milano, Italy). Bio-Plex® analysis was performed following the manufacturerʼs 
instructions. About 23 distinct sets of fluorescently  dyed beads loaded with capture 
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monoclonal antibodies, specific for each cytokine, were used. Secretion and 
standard samples (50 μL/well) were incubated with 50 μL of premixed bead sets in 
a prewet 96-well microtiter plate. After incubation and washing, 25 μL of 
fluorescent detection anti-body mixture was added and left to react for 30 min 
under gentle shaking; samples were then washed and resuspended in the assay 
buffer. Standard calibration curves for each protein were used, ranging from 2 to 
32000pg/μL; the minimum detectable dose was 2pg/μL. The formation of the 
different immunocomplexes was measured by the Bio-Plex® Protein Array  System 
(Bio-Rad Laboratories). A 50 μL volume sample was withdrawn from each well, 
and the fluorescent signal of a minimum of 100 beads per region (chemokine/
cytokine) was measured. To compare directly  secretive content of adherent and 
encapsulated MSCs, all values were normalized with respect to the total protein 
amount.
Bioreactor setup
Three-dimensional dynamic culture experiments were performed in Rotary Cell 
Culture SystemTM (RCCS-4TM bioreactor, SyntheconTM, Inc., Houston, TX, U.S.A.), 
with High Aspect Ratio Vessel (HARVTM).
For all experiments 10 ml HARVTM vessels were used.
RCCSTM is a technology for growing either a chorage dependent or suspension 
cells in laboratory. Two basic type of RCCS vessels are manifactured by 
SyntheconTM, Inc.:
- Slow Turning Lateral Vessel (STLVTM) is tubular shaped and has central gas 
transfer core;
- High Aspect Ratio Vessel (HARVTM) has a disc shaped culture chamber with the 
oxigenator membrane forming the iside wall of the vessel. 
MATERIALS AND METHODS
89
HARVTM vessel consists of a horizontally rotated culture chamber, where the 
alginate beads were suspended, and a perfusion system with media continuously 
flowing through the culture chamber. The culture chamber can rotate in the X-axis 
at certain speed to suspend the cellular scaffolds in a free floating culture 
condition.  Rotating-wall reactor need control systems to vary  the rotation speed of 
the vessel in function of the cells culture system size (i.e. scaffold, tissue mass). 
When the rotation velocity is maintained constant, the cells/beads will see its 
terminal free-fall velocity to increase.
Alginate microbeads were inserted in each HARVTM 10 mL vessel filled with basal 
medium. 50 to 60 beads  were used in each vessel. 
After alginate microbeads insertion, HARVTM vessels were filled with basal 
medium, and all air bubbles were removed from the culture chamber. Then 
HARVTM vessels were located into incubator at 37°C and 5% CO2 with the whole 
RCCS-4TM. Cells were rotated at 25 rpm for all the experiment duration. Medium 
was replaced in vessel every three days.
Osteogenic differentiation
The ability of WJMSCs and PDLMSCs to differentiate into osteblastic cell lineages 
in vitro can be investigated by culturing under inductive conditions.
Osteogenic differentiation of WJMSCs and PDLMSCs
WJMSCs Differentiation medium:
- Dulbeccoʼs Modified Essential Medium High Glucose
- 10% (v/v) fetal calf serum
- 1× L-glutamine 
- 1× penicillin-streptomycin 
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-  0.1 μM dexamethasone 
-  10 mM β-glycerophosphate 
-  50 μg L-ascorbic acid-2-phosphate
PDLMSCs Differentiation medium:
- Dulbeccoʼs Modified Essential Medium High Glucose
- 10% (v/v) fetal calf serum
- 1× L-glutamine 
- 1× penicillin-streptomycin 
-  0.1 μM dexamethasone 
-  10 mM β-glycerophosphate 
-  50 μg L-ascorbic acid-2-phosphate
Culture protocol
1. In vitro-expanded MSCs were seeded 2 × 104 cells/cm2 D-MEM growth medium 
and incubate at 37◦C in 5% CO2 and >90% humidity.
2. Cells adhered well overnight in tissue culture incubator. 
3. After 24 h, the D-MEM growth medium was aspirated and add an equivalent 
volume of osteogenic inductive medium. 
4. the medium was changed twice a week. 
5. Cells differentiate up to 3 weeks.
Osteogenic and control culture conditions
Three different culture conditions were established: 
- two-dimensional culture as monolayer, in different osteogenic conditions. For the 
two-dimensional monolayer culture, confluent MSCs from the 2nd-4th passages 
were trypsinized and placed inside 6, 12 and 24-well plates. Cells were 
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maintained in the basal medium for 1–2 days until they reached confluence, and 
then the culture was continued with the osteogenic induction supplement-
containing medium. Medium changes were performed twice a week.
- three-dimensional static culture in alginate microbeads. Alginate microbeads for 
three-dimensional static culture were placed in 6-well plate with basal medium for 
48 h. Then, when encapsulated cells were induced to osteogenic differentiation, 
basal medium was removed and changed with osteogenic one. Osteogenic 
medium was used for the 21-days experimental period. Medium was changed 
twice a week, removing 2mL and adding 2 mL.
- three-dimensional dynamic culture in alginate microbeads using the RCCS-4TM 
(SyntheconTM, Inc., Houston, TX, U.S.A.), with High Aspect Ratio Vessel 
(HARVTM). For all experiments 10 mL HARVTM vessels were used. When 
osteogenic differentiation was performed, 48 hours after incubation the basal 
medium was changed with the osteogenic one in the vessel (an other vessel 
contained basal medium and beads as control). Medium was changed twice a 
week for the 21-days experimental period.
Batch Polymeric micelles (B-PMs) and Microfluidic Polymeric micelles (M-
PMs) for osteogenic inducers entrapment
Polymeric Micelles (PMs) were designed and prepared by Prof. Claudio Nastruzzi 
at the Department of Pharmaceutical Science, University of Ferrara, Italy.
PMs were prepared in batch systems (B-PMs) using Pluronic F127® solutions in 
DMSO at a concentration of either 1.5·10-2 M or 7.5·10-3 M. PMs were formed by 
pipetting the polymeric solutions into deionized water (with a polymer solution to 
water volume ratio, R, ranging from 0.03 to 0.13) and stirred using the pipette.
Microfluidic synthesis of PMs (M-PMs) was carried out in microreactors consisting 
of three inlets and one main reaction channel with an outlet. A  hydrodynamic flow 
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focusing configuration was created within the microreactor where the focused 
central stream of polymer-DMSO solution flowed along the main channel and met 
two lateral sheath streams of water side by  side. Volumetric flow rate ratios, R, of 
polymer solution to water were varied by  altering each streamʼs flow rate. The total 
flow rates for three  different microreactors were controlled at 2.00, 0.65 and 0.30 
mL/h. An inverted microscope (Olympus IX51, Japan) was used to monitor the 
flow within the microchannel. The product sample was collected from the reactor 
outlet (typically, 2 mL), and used for further analysis and size characterisation. 
DMSO was obtained by Sigma-Aldrich UK, and used as supplied. Polymer 
Pluronic® F127 was provided by BASF Chem Trade GmbH.
Following the preparation of PMs, water was added to the samples in order to 
have a comparable amount of solvent (3.2% v/v) in different samples. A 
nanoparticle. Tracking analysis (NTA) system NanoSight LM10 (NanoSight Ltd. 
Amesbury, UK) was used to measure the hydrodynamic particle diameter of the 
PMs. For each measurement, c.a. 300 μL of sample was loaded in the detection 
cell and five measurements were performed to give an average value using 
NanoSight NTA Analytical Software. For comparison with NTA system, also a 
classical Dynamic Light Scattering (DLS) was used to obtain the hydrodynamic 
particle diameter. Particle sizing was performed using dynamic light scattering with 
Zetasizer Nano ZS (Malvern Instruments Ltd., U.K.). For each measurement, c.a. 
200 μL or more volume of the sample was loaded in a disposable low-volume 
cuvette. Three measurements were performed on each sample. Size distributions 
and Z-average sizes were obtained by averaging over three measurements. 
For our experiments, specific PMs were prepared with the two aforementioned 
techniques by  Prof. Claudio Nastruzzi at the Department of Pharmaceutical 
Science, University of Ferrara, Italy.
- Batch PMs (B-PMs): 
- 0.1 μM dexamethasone;
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- 50 μg/mL L-ascorbic acid-2-phosphate;
- Working solution was 100 μL in 1 mL of culture MEM;
- Microfluidic PMs (M-PMs):
- 0.1 μM dexamethasone;
- 50 μg/mL L-ascorbic acid-2-phosphate,
- Working solution was 100 μL in 1 mL of culture MEM.
When ostegenic differentiation of MSCs was performed with PMs, different culture 
condition was tested. The use of micelles allowed to include dexamethasone and 
ascorbic acid, while 10 mM of β-glycerophosphate addition in medium was still 
necessary in a traditional solution.
Osteogenic Differentiation medium:
- Dulbeccoʼs Modified Essential Medium High Glucose
- 10% (v/v) fetal calf serum
- 1× L-glutamine 
- 1× penicillin-streptomycin 
-  10 mM β-glycerophosphate 
- PMs (for both PMs preparations, working solution was 100 μL in 1 mL of culture 
MEM).
Statistical analysis
Data are presented as the mean ±  SE from at least three independent 
experiments, where indicated. Statistical analysis was performed by  one-way 
analysis of variance followed by the Studentʼs t test. A P value <0.05 was 
considered statistically significant.
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RESULTS
Characterization of human MSCs from Whartonʼs Jelly umbilical cord and 
from periodontal ligament
Isolation of MSCs from the WJ
All umbilical cord samples were collected by Professor Fortunato Vesce, 
Department of Biomedical Sciences and Advanced Therapies, Section of Obstetric 
and Gynaecological Clinic, Azienda Ospedaliero-Universitaria S. Anna, Ferrara, 
Italy. As soon as possible the umbilical cords samples were delivered to the 
laboratory, and within 3-4 hours all samples were processed as described above. 
During time elapse between collection and process in laboratory cords were 
manteined in sterile PBS at 4° C. 
As previously reported [Secco et al. 2008] Whartonʼs Jelly  was chosen instead of 
the  whole cord (epithelium and vessels) to isolate a relatively homogeneous cell 
population, avoiding in this way any epithelial cell contamination.
Contrary to the majority of groups working on WJMSCs, we chose to process the 
WJ based essentially  on the capacity of MSCs to adhere to a plastic surface, 
without enzymatic treatment or stripping of vessels (see FIGURE 2).
After section of 5 cm umbilical cord segments, each part was washed several 
times to eliminate clots and cord blood (see FIGURE 2, A).
With a sterile scalpel longitudinal incisions were performed on cord epithelium 
carefully, to expose the underneath matrix (see FIGURE 2, B and C).
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While the presence of mesenchymal stem cells in umbilical cord blood is 
controversial, according to literature we were able to generate primary  cultures 
from all cord samples with a 100% yield .
Among all samples processed in our lab, 60 samples of umbilical cord were 
collected, processed and analyzed for obstetric factors.  For each mother and 
newborn, the clinical parameters reported in Table 1 were considered.
Sample Motherʼs age (ys)
Weeks of
pregnancy Mode of delivery Gender Birth weight (Kg)
1 26 29 CS F 1.25
2 31 32 CS M 1.74
3 30 40 CS F 3
4 30 32 CS M 1.9
5 30 32 CS M 1.91
6 37 40 SP F 3.59
7 21 41 SP F 3.75
8 35 40 SP F 3.17
9 33 42 SP M 3.05
10 31 40 SP M 3.69
11 38 38 CS F 3.32
12 38 38 CS F 2.6
13 38 39 SP M 3.45
14 36 40 SP F 3.6
15 29 40 CS F 3.22
16 33 38 SP M 3.7
17 34 38 CS F 3.45
18 35 35 CS M 3.31
19 34 40 SP M 3.21
20 35 40 SP M 3.18
21 32 38 CS F 3.6
22 33 35 CS M 2.41
23 33 35 CS M 2.53
24 40 40 SP F 3.75
25 38 39 SP M 3.36
26 29 37 CS F 3.62
RESULTS
98
27 29 40 SP M 3.4
28 39 39 CS M 3.62
29 33 40 SP F 3.12
30 32 35 SP F 3.17
31 29 37 CS M 2.14
32 37 39 CS M 3.37
33 20 40 SP F 3.02
34 41 39 CS F 2.73
35 35 37 CS F 2.77
36 34 38 CS F 2.9
37 38 38 SP F 3.05
38 34 40 SP M 3.7
39 32 36 SP M 2.93
40 27 38 SP M 3.1
41 30 34 SP M 2.6
42 31 41 SP F 3.25
43 27 33 CS M 1.915
44 27 33 CS F 2.005
45 26 39 SP M 3.35
46 34 42 CS M 3.51
47 23 37 CS F 2.95
48 30 39 CS M 4.24
49 33 39 CS F 3.3
50 37 39 CS M 2.84
51 33 39 CS M 3.27
52 32 40 CS M 3.9
53 31 37 CS F 1.98
54 35 40 SP M 3.95
55 23 37 SP M 3.11
56 40 38 CS M 2.85
57 37 39 CS F 3.3
58 25 35 CS M 3.57
59 25 35 CS F 2.38
60 27 29 CS M 2.1
F (female)  M (male) CS  (caesarian delivery) SP (spontaneous delivery)
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Table 1: The population examined for clinical parameters influence consisted of 60 healthy 
pregnant women successively enrolled voluntarly between February 1, 2008 and March 1, 2009. 
The recorded clinical parameters are: mother's age, weeks of pregnancy, mode of delivery, 
newborn gender and birth weight.
Although differences between each mother and newborn clinical parameter, cords 
were all easy to chop and scrape, to obtain only the jelly  mucoid connective tissue 
from each sample (see FIGURE 2, D).
As previously  described we placed small pieces (2-3 mm2) directly into 25-cm2 
flasks in 10% FCS D-MEM Low Glucose medium.
After 3 to 5 days cell colonies were observed adhering on plastic flask bottom. 
These colonies consisted of spindle-shape fibroblast-like cells. Sub confluent 
fibroblast-like cells were the only cell types growing under these conditions after 2 
weeks of culture. ~50-60% confluence was reached within 2 weeks (see FIGURE 
3, B and C).
After 2 weeks, the WJ tissue pieces were removed. At that time the adherent cells 
were expanded and the medium was renewed. These cells represented the so 
called “p 0”. 
This method for cell isolation was easy, fast, and reliable with low contamination 
risk.
Isolation of MSCs populations from periodontal ligament
The human PDL connective tissue (see FIGURE 4) attached to tooth and alveolar 
bone from different donors was collected, as adult source of MSCs in so called 
“stem cell niches”, and processed within 4 hours.
All PDL samples came from bone impacted lower or upper third molars of healthy 
patients.
The protocol chosen (total impacted teeth; clorexidine mouthrinse before surgical 
procedures) avoided any contamination by oral bacteria. In addition, scalpel was 
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chosen to detach gently the tissue from the root, avoiding any contamination by 
dental papilla or dental pulp (see FIGURE 5, B).
Then the tissue was cut into small pieces (approximately 2 mm x 2 mm) and 
placed at the centre of 6-well culture dishes.
The small amount of tissue for each patient was considered, so 6-well culture plate 
condition was chosen instead of 25 cm2 culture flasks to promote cells outgrowth 
and proliferation.
As done for UC samples, and contrary to different groups working on PDL tissue, 
we chose again to process the PDL based essentially  on the capacity  of MSCs to 
adhere to a plastic surface, without enzymatic treatment.
After 3 to 5 days outgrown cells were observed nearby tissue fragments. They had 
spindle and fibroblastic morphology (see FIGURE 5, C). 
A total of 20 teeth (19 wisdom teeth) were obtained from 20 patients consecutively 
selected among those treated at Dental Section, University (19-34 years of age) 
and clinical data were recorded (see Table 2).
Sample Age Gender Tooth Colonies Clinical Data Drugs
1 26 M 18 + - -
2 23 M 48 - - -
3 21 F 28 + asthma steroids o.n.
4 33 F 48 + - -
5 31 F 48 - - -
6 19 M 38 + - -
7 27 M 48 + - -
8 33 F 18 - - -
9 21 F 18 + - -
10 19 M 28 + - -
11 31 F 48 - - -
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12 28 F 38 + - Contracept.
13 24 M 38 + - -
14 34 M 28 + - -
15 23 F 48 + - -
16 24 M 38 + - -
17 26 M 48 + - -
18 23 F 38 - - Contracept.
19 34 M 38 + - -
20 22 M 48 + - -
Table 2: 20 healthy patients enrolled voluntarly between January 1, 2010 and 1, September 2010. 
All teeth were totally impacted.
15 primary human PDL cell populations were obtained on the basis of their ability 
to form well-defined colonies. All of them displayed a microscopically distinct 
spindle-shape fibroblast-like cells morphology (see FIGURE 5, C).
They grew rapidly  and were subcultured at about day 14, with medium changes 
every 3 days, to avoid over-confluence, especially around explanted PDL tissue 
(see FIGURE 5, D).
The success rate of cell expansion, without collagenase/dispase or trypsin/EDTA 
was more than 75%.
Flow cytometric analysis
MSC characteristics were evaluated by the immunophenotypic profile of adherent 
cells from each culture by testing a panel of surface markers using flow cytometry. 
The expression of phenotypical markers was evaluated by  the intensity of 
fluorescence of cells of the studied population.
Considering WJMSCs, samples were positive for mesenchymal cell markers 
including CD90 (Thy-1), CD73, CD105, CD146, CD44 (hyaluronan receptor), 
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CD29 (β-1 integrin), but negative for CD31 (endothelial cell marker), CD3, CD14, 
CD34, CD45 (hematopoietic cell markers). Also the expression of CD90, CD73 
and CD105 (SH2, endoglin) was significanlty  high, as for CD146 too (see FIGURE 
6, panel I).
Also adherent cells derived from PDL did not express hematopoietic/endothelial 
markers (CD34, CD45) analyzed by flow cytometry. In addition, the majority of 
cells expressed high levels of mesenchymal and adhesion markers such as CD90 
and CD105 (see FIGURE 7, panel I). 
Adherent cells derived from PDL were also positive for STRO-1 expression which 
was analyzed by  flow cytometric analysis and immunofluorescence (see FIGURE 
7 panel I, A).
Viability assay
Calcein-Propidium double stain was chosen as viability  assay to show at the same 
time the presence of living or dead cells for all experiments. WJMSCs and 
PDLMSCs obtained with the described procedure appeared always viable: a 
representative experiment is reported in FIGURE 6 panel I,  A  and FIGURE 7 
panel II, A.
Also microscopic observations in brightfield showed that cells owned the spindle-
shape fibroblast-like cells morphology (see FIGURE 6 panel I, B and C  and see 
FIGURE 7 panel II, B). These findings were recurrent during all experiments. This 
stainig allowed to follow during time cells viability also after encapsulation 
procedures, as mentioned successively.
Differentiation potential
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The isolated WJMSCs and PDLMSCs were tested for their potential to differentiate 
into osteogenic or adipogenic cells in the presence of specific inducing factors. For 
this purpose the cells at the 3rd to 4th passage at least, were committed to 
differentiate in presence of the specific differentiation inducers. Osteogenic 
differentiation was induced for 3 weeks with DMEM-HG for both WJMSCs and 
PDLMSCs, supplemented with 10% FCS, 0.1 mM dexamethasone, 10 mM β-
glycerophosphate and 50 μg/mL ascorbic acid. In both the control and 
differentiating cultures the medium was changed twice a week. Cells started to 
change morphologically as early as 5 days in an inducing culture medium; the 
cells lost their typical fibroblast appearance turning into wider polygonal cells. 
These changes became more evident with time and on the 21st day, when specific 
Alizarine Red staining was performed. The effectiveness of differentiation was 
assessed by  this assay for the identification of Calcium deposition in extracellular 
space. Terminal differentiation of the cells appeared as intense red staining (see 
FIGURE 8 panel I, B and panel II,  B). Another change observed was that, upon 
differentiation, the osteogenic cells continued to grow as a monolayer while the 
cells in control cultures preserved their fibroblast-like morphology (see FIGURE 8 
panel I, B and panel II, B). 
To assess adipogenic differentiation, WJMSCs and PDLMSCs were cultured in an 
adipogenic medium consisting of DMEM-LG or DMEM-HG for WJMSCs and 
PDLMSCs respectively, supplemented with 1 μM dexamethasone, 5 μg/mL bovine 
insulin, 0.5 mM IBMX, 60 μM indomethacin and 10% FCS for 21 days. After 14 
days tiny intracytoplasmic droplets can be observed; most cells became larger and 
had a round shape. The effectiveness of differentiation was assessed by 
histochemical staining for the identification of neutral lipid vacuoles by Oil red O 
staining. In the adipogenic differentiated cells, red stained intracellular vacuoles 
(see FIGURE 8 panel I, A and panel II, A) can be observed.
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Scratch assay
The scratch test was chosen as in vitro wound model to investigate WJMSCs and 
PDLMSCs migration ability  and its modulation after an artificially  induced 
detachement within the cell monolayer in presence of a specific biological 
response modifier.
This set of experiments had the aim to investigate the effectiveness of wound 
assay in pointing out effect of cells phenotype modification, through the direct 
observation of different cells behaviour when comparing treated cells to control. 
The wound healing and the ability to migrate was tested in the cells depleted of a 
critical transcription factor such as Slug after siRNA interference. Slug is involved 
in a broad spectrum of biological functions, such as cell differentiation, motility, 
cell-cycle regulation and apoptosis. 
Considering WJMSCs, cells were transfected, as described in the Material and 
Method section, for 3 days with siSlug or a nonrelevant siRNA as negative control. 
Knockdown of Slug expression was verified by Real-Time RT-PCR. RT-PCR 
results, after correction to GAPDH content, are expressed as siRNA/Slug2 over 
control ratio. 
Slug-silenced or untreated WJMSCs were cultured until they reached 100% 
confluence. Monolayers were then scratch wounded for both conditions. siSlug 
treated cells exhibited a reduced capacity to cover the scratch if compared to 
untreated just after 24 hours (see FIGURE 9 panel I, B). In fact, untreated 
WJMSCs exibited a rapid modification of wound margin, due to active proliferation 
and migration ability.
Considering PDLMSCs, the same Slug silencing protocol was performed to 
modulate cells behaviour in the same in vitro wound model created for WJMSCs. 
Slug expression was determined at mRNA level and knockdown of Slug 
expression was verified by Real-Time RT-PCR; expression of Slug was shown 
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significantly reduced, as reported  (see FIGURE 9 panel II, A). siSlug treated cells 
exhibited a reduced capacity to cover the scratch if compared to untreated (ctr). As 
done for WJMSCs, observations went on for more 24 hours, showing that 
PDLMSCsʼ Slug knockdown affected cells motility, avoiding any  closure of the 
wound. The results confirm the role of Slug transcription factor in the regulation of 
cell migration ability. In addition, these data demonstrated that both experimental 
models are sensitive to depletion of an important transcription factor such as Slug, 
and at the same time are suitable to study the functional effect of a specific gene 
expression modulation. 
Osteogenic potential of WJMSCs and variability between samples.
With the collaboration of Section of Obstetric and Gynaecological Clinic, Azienda 
Ospedaliero-Universitaria S, Anna, it was possible to obtain fresh samples of 
human umbilical cords, ready to be processed within few hours, as suggested by 
previous studies.
Among the collected samples, we selected the 20 most homogeneous ones 
considering the percentage of CD-90 presence and CD-45 absence (≥ 99%), and 
we analyzed for each one different obstetric parameters (see FIGURE  10 table 
A).
We conducted analyses adjusting for two specific markers of osteoblast 
differentiation: the activity  of Alkaline Phosphatase (ALP) and the expression 
levels of Runt-related transcription factor 2 (RUNX-2) which increases transcription 
of osteoblast specific genes. Focusing on basal levels of ALP and RUNX-2, it has 
been possible to demonstrate that these parameters can be predictive of 
osteoblastic potential of WJMSCs (see FIGURE  10 panel C). In fact, the samples 
with high basal levels of RUNX-2 and ALP are more prone to deposit mineral 
matrix if compared to WJMSC with low levels of these two proteins. 
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Next  we analyzed whether the basal levels of RUNX-2 and ALP correlate with the 
examined obstetrics factors (see FIGURE  10 panel C). We found that the infant 
gender and mode of delivery didnʼt significantly correlate (P> 0.05) with basal 
RUNX-2 expression and ALP activity. 
On the other hand, the age of the mother at delivery, has a significant impact on 
the basal ALP activity  but doesnʼt affect RUNX-2 expression level (see FIGURE 
11 upper graph). Samples collected from mothers which were <32 years old give 
origin to WJMSCs with high ALP activity. Interestingly, birth weight of the infant 
was shown to significatively  impact on RUNX-2 basal expression level which, (see 
FIGURE 11 lower graph), decreases with the decreasing of the babyʼs weight. The 
same relationship was found for the duration of pregnancy (see FIGURE 11 middle 
graph). In fact, it was found that WJMSCs from babies born before the 37 weeks 
of gestation express lower basal level of RUNX-2 than the full term borns. It is very 
likely  that WJMSCs recovered from premature birth contain a high number of 
undifferentiated cells with high plasticity, a condition which is not actually required 
for osteoblast differentiation. 
As a whole, these findings led us to focus on two parameters, weeks of pregnancy 
and consequently birth weight of the baby, and RUNX-2 basal levels, subdividing 
the collected samples in the two subgroups: subgroup  I, premature birth with low 
levels of RUNX-2, and subgroup  II, full term birth with high levels of RUNX-2 (see 
FIGURE  10 table A). The ability of the samples belonging to these two subgroups 
to complete the event of cellular maturation, that is the deposition of mineralized 
matrix, was then compared. Two representative samples of the two subgroups 
(see FIGURE 10 table A) demonstrate that, samples from subgroup I showed a 
null mineralization status also after 21 day  of cell culture in osteogenic medium, 
whereas samples from subgroup II showed a high level of mineralization beginning 
from day 14. Therefore, these findings suggest that maximal WJMSCs 
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osteoblastic potential can be obtained by primary cultures with RUNX-2 high basal 
levels, selected from the heaviest term babies. 
Another clinical observation that is important to do is that the cases below 37 
weeks of gestation were all treated with 24 mg of bethametasone two hours before 
delivery, therapy routinely given to all the pregnant women delivering prematurely, 
in order to prevent respiratory distress syndrome in the newborns. 
Absence of osteoblastogenesis could have been expected in the samples derived 
from women delivering prematurely. Since we observed a low or null 
mineralization status in WJMSCs from such patients (see FIGURE  10 panel B), it 
could be possible to point out a correlation between the two events. 
The analysis of the basal level of RUNX-2 and ALP activity  allowed to quickly test 
an high number of mesenchymal precursors cultured in vitro and select the ones 
with probably  higher osteogenic potential. Also our results suggest that it is 
preferred to recruit samples from full term borns without paying attention to 
motherʼs age.
The employment of Polymeric Micelles (PMs) to deliver osteogenic inducers. 
After osteogenic differentiation potential was investigated for PDLMSC  populations 
(see FIGURE 8 panel II), we chose these cells to investigate an in vitro different 
approach to induce osteogenic differentiation.
Polymeric Micelles (PMs) designed and prepared by Prof. Claudio Nastruzzi at the 
Department of Pharmaceutical Science, University  of Ferrara, Italy (see FIGURE 
12 panel I), were chosen to deliver in culture medium osteogenic inducers, instead 
of traditional solubilization with DMSO, which is already known to be cytotoxic. 
For our experiments, two different kind of PMs were tested, differing for generation 
techniques: Batch technique for PMs (B-PMs), that is considered the traditional 
method, and Microfluidic technique for PMs (M-PMs) (see FIGURE 12 panel II). 
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In order to investigate if PMs affect cell viability  MTT test (see FIGURE 13) was 
performed. PDLMSCs cultured in adhesion conditions were exposed to different 
conditions for 72 hours. The presence of formazan salts, marker of the viable cells, 
was reported in the graph as percentage of viable cells respect to control culture 
condition (rated to 100%).
The use of PMs allowed to include dexamethasone and ascorbic acid, while 10 
mM of β-glycerophosphate addition in medium was still necessary in a traditional 
solution. All different culture conditions exhibited no appreciable cytotoxicity (cells 
viability was higher than 75%) (see FIGURE 13). Comparing the results obtained 
with cells exposure to PMs produced in batch reactor (see FIGURE 13, grey 
column) or microreactors (see FIGURE 13, horizontal white stripes column), the 
effectiveness of the microfluidic technique to generate PMs instead of batch 
technique, in term of uniformity and no dispersion of solvents in culture medium, 
was observed. This characteristic resulted in lower cytotoxicity.
Afterwards, a set of in vitro experiments was performed to monitor effects of PMs 
for a 21-days period of time, in terms of cell viability  and osteogenic differentiation 
(see FIGURE 14).
Microscopic observations, Viability Assay and Alizarin Red Staining were 
performed at 7, 14 and 21 days. PDLMSC cells viability wasnʼt affected by 
presence of PMs, both M-PMs and B-PMs at 7, 14 and 21 days (see FIGURE 14, 
B-PMs and M-PMs columns on the right, 2nd, 4th and 6th lines) . 
At day  7, PMs conditions seemed to promote an earlier calcium deposition (see 
FIGURE 14, ODM and B-PMs columns, 1st line) when compared to traditional 
osteogenic condition (see FIGURE 14, ODM, B-PMs and M-PMs columns, 1st 
line).
After 14 or 21 days, Alizarin staining showed how this difference in promoting 
mineralization went on (see FIGURE 14, ODM, B-PMs and M-PMs columns, 3rd 
and 5th lines).
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With the use of M-PMs the same amount of mineral deposition that was carried 
out with  traditional osteogenic condition at day 21 was present at day 14 (see 
FIGURE 14, ODM column 5th line, M-PMs column, 3rd line respectively).
The results from this set of experiments confirmed the hypothesis that during in 
vitro experiments efforts to modify environment in terms of composition and 
soluble molecules could reveal the real osteogenic potential of each cell 
population, that sometimes is more affected by collateral events (i.e. culture 
medium flow inside the well, presence of higher concentration of toxic molecules 
than expected, like DMSO).
The use of the PMs here described  to control in terms of space and time the 
release of inducers, like dexamethasone, avoided uncontrolled presence of DMSO 
and all its well known side effects, resulting in different speed of differentiation for 
PDLMSCs. 
Encapsulation of WJMSCs and PDLMSCs in alginate microbeads
Alginate microbeads: preparation and characterization of beads
To overcome limits connected to the use of traditional 2D in vitro models, a first set 
of experiments was designed to study the behaviour of cells in three dimension 
conditions, considering WJMSCs as reliable cell population to set these 
conditions. Cells encapsulation was performed by  Prof. Claudio Nastruzzi at the 
Department of Pharmaceutical Science, University of Ferrara, Italy.
WJMSCs were embedded into alginate microbeads by an encapsulation device 
based on a vibrating-nozzle (see FIGURE 15). The encapsulation procedure was 
relatively simple and consisted of a limited number of steps. In order to achieve 
complete biocompatibility, indispensable for mammalian cells, the encapsulation 
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procedure was conducted at room temperature under physiologic pH and tonicity 
using a pyrogen-free alginate solution. 
A classical intuitive approach COST (Changing One Separate factor a Time) was 
employed to define the experimental set up, including the selection of the crucial 
experimental parameters. This approach was chosen in order to evaluate which 
factor(s) could mostly affect the morphology of the produced alginate microbeads 
in terms of general geometry, surface characteristics and dimensions. Following 
the above procedure, each experimental parameter was varied indipendently (see 
FIGURE 16, panel I), while all the others were maintained constant, to see direct 
effects on microbeads. Experiments were performed changing the following 
parameters: frequency of vibration (freq), amplitude of vibration (amp), polymer 
pumping rate (pump) and distance between the nozzle and the gelling bath 
(height). The frequency was calculated from a knowledge of the alginate solution 
viscosity for the nozzle diameter used, to obtain the desired microbeads size and 
morphology (mean diameter comprised between 550 and 650 μm with a spherical 
shape). The vibrating frequency of the nozzle was varied from 100.0 to 140.0 
Hertz while the rate of polymer pumping was investigated in the range 7.5-9.5 (mL/
min) (see FIGURE 16, panel II). The investigation of these parameters revealed 
that if the vibrating frequency was set too high (>200.0 Hertz) a progressive 
number of coalescences (formation of clusters of microbeads partially fused 
together) was detectable in the microbead population (data not shown). The 
amplitude of the vibration applied to the nozzle (varied in a range from 1.0 to 6.0 
mm) had only a slight effect on the microbead characteristics such as size, 
sphericity  and presence of coalescences. On the contrary, the distance between 
the nozzle and the gelling bath (range 100.0-140.0 mm) has a great effect on the 
microbead morphology. In fact, a distance of 100.0 or 120.0 mm caused the 
formation of microbead with an elliptic shape (formation of tails). Considering the 
results of this set of experiments (see FIGURE 16, panel II), among the 4 different 
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experimental variables, only the amplitude of the vibration has minor effect on the 
microbeads formation, while all the others exert significant morphological and 
dimensional changes on the alginate microbeads. The microbeads with the best 
morphology (see FIGURE 17, panel I, A and B) were produced by the following 
set up: a frequency of 150 Hz, an amplitude of 1.0 mm, a pump flow rate of 8.5 
mL/min and an height of 140.0 mm.
Once the instrumental set up  was achieved, we focused our attention on another 
important experimental parameter: the concentration of alginate solution. Different 
percentages were tested, ranging from 0.5 to 3.5% (w/v) and the effect on the 
production of microbeads was considered as well. As first observation, it should be 
mentioned that, using the automated vibrating nozzle instrument, we succeeded in 
obtaining microbeads using alginate concentration up  to 2.0% (w/v). On the 
contrary, using higher concentrations of alginate (>2.0%, w/v), the resulting 
solution was too viscous to be efficiently converted in microdroplets. Samples of 
microbeads produced with an alginate concentration of 0.5, 1.0, 1.5 and 2.0% 
were analyzed for morphology, size and size distribution. The results of the above 
experiment are showed (see FIGURE 16, panel II). Microbeads produced with an 
alginate concentration comprised between 1.0-2.0% (w/v) were spherical in shape 
and characterized by a smooth surface (see FIGURE 17, panel I,  A and B). 
Lowering the alginate concentration down to 0.5% (w/v) caused partial broke-up of 
microbeads resulting in particles with an irregular shape. This behaviour was 
attributed to the mechanical stress caused by the landing in the hardening barium 
chloride solution. Moreover, at the same concentration, some coalescences were 
detectable. We obtained alginate microbeads with a smaller mean diameter and 
homogenous dimensional distribution using a polymer concentration of 1.5% (w/v). 
Increasing the alginate concentration up  to 2% (w/v), the size distribution became 
broader and the mean diameter increased from 630 (in the case of an alginate 
concentration of 1.5%) to 645 μm (see dimensional distribution plots reported in 
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Fig. 3 E, F). On the other hand, alginate microbeads prepared with lower polymer 
concentrations (0.5 and 1.0%, w/v) formed some coalescences (see FIGURE 16, 
panel II), although the size distribution remained acceptably narrow.
Encapsulation of WJMSCs in alginate microbeads:a DoE approach
After performing the COST study, a “design of the experiments” (DoE) optimisation 
and screening of the experimental parameters were also conducted. The DoE 
reduces the number of experiments and provides statistical information about the 
effects of different variables and their possible interactions.
The parameters frequency, pump and height were chosen as variables and tested 
at three levels by Prof. Nastruzzi and his groups.
After investigation of the factors influence, the validity  and the significance of the 
model was estimated by analysis of variance (ANOVA). All the data obtained fitted 
well the model determining a good reproducibility of the studied model. 
Viability and proliferation of encapsulated WJMSCs 
A crucial issue that we investigated at the beginnig of embedding/seeding protocol 
for cell scaffolding, was the effect of the encapsulation procedure on the growth 
and the activity of cells.
With the aforementioned protocol set by Prof. Nastruzzi and his group, the 
resulting barium alginate microbeads were elastic, size uniform and transparent, 
facilitating the microscopic observation  of the WJMSCs viability  and morphology 
during the in vitro studies (see FIGURE 17, panel I, A-F). The hardening of 
alginate solution was accomplished by an ionic gelation procedure based on 
barium chloride. The use of barium ions (instead of more often used calcium ions) 
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resulted in the formation of mechanically  stable microbeads  preserving the in vitro 
and in vivo viability of the embedded cells (see FIGURE 17, panel I, C and D).
The viability of WJMSCs encapsulated in alginate microbeads was determined by 
the live/dead test. The observation of the fluorescent images recorded immediately 
after the encapsulation procedure at the typical excitation wavelengths, (see 
FIGURE 17, panel II, A and B) indicated that the cells were highly viable (>95%). 
In order to strengthen these data, the cell viability was determined after different 
length of culture time (up  to 6 days) by using two alternative procedures, namely, 
the double staining with a Calcein-AM cell viability  assay kit (see FIGURE 17, 
panel II,  C and D) and the MTT test (see FIGURE 17, panel II, F). About one 
hundred of alginate microbeads were incubated with thyazolyl blue, and the 
presence of formazan salts, marker of the viable cells, was reported in the graph 
as percentage of viable cells respect to day “0” (rated to 100%). At each day of 
measurement, we observed a steady but not significant (p> 0.05) decrease in 
formazan absorption during the first 10 days (see FIGURE 17, panel II, F).
Secretive profile: WJMSCs in alginate microbeads vs adherent WJMSCs 
The secretive profile of both adherent (free) and alginate-encapsulated WJMSCs 
was analyzed by multiplex bead-based sandwich immunoassay (shortly Bio-
Plex®). The panel of analyzed factors includes member of the family of 
interleukins, chemokines, growth factors and soluble form of adhesion molecules 
(see FIGURE 18). All the proteins analyzed had a molecular weight lower of the 
molecular weight cut off of the microbead membrane. Most of the protein analyzed 
were secreted both by the free and encapsulated cells, even if in a different extent. 
The levels of IFN-α, IL-2Rα, TRAIL, M-CSF, IL-12, ICAM-1, SCGF-β, CTACK, 
VCAM, SDF-1α, were higher in the supernatant from free cells. In particular, IFN-
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α, IL-2Rα, TRAIL, M-CSF, IL-12, ICAM-1, SCGF-β, were significantly higher in the 
supernatant from free cells (p<0.05). On the contrary, MCP3, GRO-α, MIF and 
HGF were found more abundantly  present in the supernatant from the 
encapsulated cells. In particular, MCP3 and GRO-α were significantly higher in the 
supernatant from from the encapsulated cells (p<0.05) when compared to free 
ones. Finally, some factors (IL-1α, IL-18, β-NGF, SCF, TNF-β LIF, MIG) were not 
detectable or detected at very low levels (IL-3, IL-16) in both situations. 
After encapsulation treatment, WJMSCs within alginate interacted with the 
surrounding environemet in an open-two-ways pattern of modifications. 
Alginate microbeads encapsulation of WJMSCs and PDLMSCs: induction of 
osteogenic differentiation
After all sets of experiments were succesfull for encapsulation of WJMSCs, also 
PDLMSCs were embedded in alginate microbeads.
Since WJMSCs have been proven, as well as PDLMSCs, to be able to 
differentiate in osteogenic lineage, the ability of the WJMSCs and PDLMSCs 
entrapped in alginate to differentiate in osteoblasts was assessed at day 21 of 
osteogenic induction  by a number of classical criteria and compared with 
WJMSCs and PDLMSCs entrapped in alginate in absence of osteogenic medium 
respectively.
To describe different culture conditions for cells encapsulated in alginate 
microbeads, combinations of some different abbreviations were chosen:
- To indicate WJMSCs in alginate microbeads: WJABs 
- To indicate  WJABs cultured in 6 well-plate (We):
-  “control” culture medium (CCM): WJABs/We/CCM
-  osteogenic differentiation medium (ODM): WJABs/We/ODM
- To indicate PDLMSCs in alginate microbeads: PDLABs
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- To indicate  PDLABs cultured in 6 well-plate (We):
-  “control” culture medium (CCM): PDLABs/We/CCM
-  osteogenic differentiation medium (ODM): PDLABs/We/ODM
The experimental protocol was the same for both cell population.
Considering WJABs, WJABs/We/CCM cells after 21 days of culture in control 
medium didnʼt show any change in beads morphology, size or shape.  WJABs 
were still transparent and easy to observe in brightfield (see FIGURE 19, A). On 
the other hand observation of WJABs/We/ODM revealed that beads in osteogenic 
medium turned darker and seemed less transparent (see FIGURE 19, B). The 
Calcein AM/Propidium iodide double staining assay at day 21 showed that cells 
were vital in both conditions (see FIGURE 19, C and D).
The mineral deposition within beads was measured by  Alizarin Red staining assay, 
that showed unstained WJABs in control conditions (see FIGURE 19, E), as well 
as red color was seen within WJABs after 21 days of osteogenic differentiation 
(see FIGURE 19, F).
Considering PDLABs, PDLABs/We/CCM cells after 21 days of culture in control 
medium didnʼt show any  change in beads morphology, size or shape, as well as 
for WJABs/We/CCM. Also PDLABs appeared transparent and easy to observe in 
brightfield (see FIGURE 20, A). Parallel observation of PDLABs/We/ODM revealed 
that beads in osteogenic medium turned darker and seemed less transparent (see 
FIGURE 20, B). A sort of brown shading characterized aspects of all PDLABs/We/
ODM. The Calcein AM/Propidium iodide double staining assay at day 21 showed 
that cells were vital in both conditions (see FIGURE 20, C  and D), as well as for 
WJABs.
The mineral deposition within beads was measured by  Alizarin Red staining assay, 
that showed unstained PDLABs in control conditions (see FIGURE 20, E), while 
intense red color was seen within PDLABs after 21 days of osteogenic 
differentiation (see FIGURE 20, F).
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Comparing results for WJABs and PDLABs in osteogenic conditions (see FIGURE 
19, F and 20, F respectively), both cell populations were able to differentiate in 
osteogenic lineage, with an increased mineralization for PDLABs samples. In 6-
well plate conditions, cells underwent osteogenic differentiation despite 
encapsulation.
Considering osteoblastic markers, WJABs and PDLABs showed an appreciable 
increase of ALP activity, an early marker for osteoblast differentiation, after 21 
days in osteogenic condition (see FIGURE 21, upper graph). WJABs and PDLABs 
showed also an increase of the expression of the bone-specific gene such as 
Runx2 analyzed by quantitative RT-PCR (see FIGURE 21, lower graph). 
In both cases, PDLABs osteoblastic markers showed higher increase if compared 
to WJABs, as well as RUNX2 modification wasnʼt significant (p> 0.05).
Therefore, even if further investigations are needed, these data suggest that the 
alginate microbeads here described provide a valuable support to osteogenic 
differentiation.
Alginate microbeads encapsulation of WJMSCs and PDLMSCs induced to 
osteogenic differentiation: effect of Rotary Cell Culture SystemTM  (RCCS-4TM  
bioreactor) with High Aspect Ratio Vessel (HARVTM)
Bioreactors have been proven to be able to provide cell a new tool for the study of 
three-dimensional (3-D) cell growth and differentiation. 
With the aim to verify if differentiation could be enhanced through the improvement 
of cells exchanges with culture environement, a set of experiments in different 
culture conditions (like the continuing culture medium flow, the enhanced gas 
exchange, or the gravity  modification) were performed in Rotary Cell Culture 
SystemTM (RCCS-4TM bioreactor, SyntheconTM, Inc., Houston, TX, U.S.A.) (see 
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FIGURE 22 panel I), with High Aspect Ratio Vessel (HARVTM) (see FIGURE 22 
panel II).
For all experiments 10 ml HARVTM vessels were used. For all experimental period 
(21 days) 10 ml HARVTM vessels were manteined in incubator, providing costant 
rotation speed (25 rpm) at 5% CO2 and 37°C (see FIGURE 22 panel III). 
As previously done, to describe different culture conditions for cells encapsulated 
in alginate microbeads, combinations of some different abbreviations were 
choosen:
- To indicate WJABs cultured in rotating HARV bioreactor 10 ml vessels (HARV):
-  “control” culture medium (CCM): WJABs/HARV/CCM
-  osteogenic differentiation medium (ODM): WJABs/HARV/ODM
- To indicate PDLABs cultured in rotating HARV bioreactor 10 ml vessels 
(HARV):
-  “control” culture medium (CCM): PDLABs/HARV/CCM
-  osteogenic differentiation medium (ODM): PDLABs/HARV/ODM
During this first set of experiments, culture conditions were maintained the same 
for 4 different samples: 2 WJMSCs populations and 2 PDLMSCs populations.
Representative experiments are shown in FIGURE  23 to 28.
We successfully cultured RCCS environment, and under the observation of phase 
contrast microscope, WJABs and PDLABs appeared vital also after 21 days of 
culture (see FIGURE 23, B, D, H, J and FIGURE 26, B, D, H, J).
Considering WJABs, WJABs/We/CCM, as well as WJABs/HARV/CCM cells after 
21 days of culture in control medium didnʼt show any change in beads morphology, 
size or shape. WJABs were still transparent and easy to observe in brightfield (see 
FIGURE 23, A, C). 
As previously observed, WJABs/We/ODM turned darker and seemed less 
transparent (see FIGURE 23, G) in osteogenic medium. This change in color and 
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transparency was higher when WJABs/HARV/ODM were observed (see FIGURE 
23, I). The Calcein AM/Propidium iodide double staining assay at day 21 showed 
that cells were vital in all conditions (see FIGURE 23, B, D, H, J), but darkfield 
aspects of beads were different considering fluorescence amount. Despite the 
same number of PBS rinses after Calcein AM/Propidium iodide staining, it 
appeared like aspecific staining wasnʼt able to be washed out from WJABs/HARV/
ODM sample (see FIGURE 23, J). Cells were all vital, and merging images didnʼt 
evidence the presence of any dead cell in beads. 
The mineral deposition within beads was measured by  Alizarin Red staining assay, 
that showed unstained WJABs in control conditions (see FIGURE 23, E, F), as 
well as red color was seen within WJABs after 21 days of osteogenic 
differentiation (see FIGURE 23, K, L), with more intense red coloration for WJABs/
HARV/ODM (see FIGURE 23, L).
RUNX2 expression level was evaluated after 21 days of control and osteogenic 
conditions for WJABs in 4 conditions. This analysis was done for 2 samples and 
results are shown (see FIGURE 24, samples 1 and 2).  Samples showed an 
higher RUNX2 level in osteogenic conditions (see FIGURE 24, samples 1 and 2, 
green columns). On the other hand Col I expression levels seemed to vary more 
than RUNX2, despite of osteogenic differentiation (see FIGURE 25, samples 1 
and 2, yellow columns).
Considering PDLABs, PDLABs/We/CCM, as well as PDLABs/HARV/CCM cells 
after 21 days of culture in control medium didnʼt show any change in beads 
morphology, size or shape.  PDLABs were still transparent and easy to observe in 
brightfield (see FIGURE 26, A, C). 
As previously observed, also this experiments resulted in turning dark for both 
PDLABs/We/ODM and PDLABs/HARV/ODM in osteogenic medium. They seemed 
less transparent too (see FIGURE 26, G, I). This change in color and transparency 
RESULTS
119
was higher when PDLABs/HARV/ODM were observed (see FIGURE 26, I). The 
Calcein AM/Propidium iodide double staining assay at day 21 showed that cells 
were vital in all conditions (see FIGURE 26, B, D, H, J). As happened for WJABs/
HARV/ODM, darkfield aspects of beads was different considering fluorescence 
amount. PDLABs/HARV/ODM appeared like aspecific staining wasnʼt able to be 
washed out from WJABs/HARV/ODM sample (see FIGURE 23, J). Cells were all 
vital, and merging images didnʼt evidence the presence of any dead cell in beads. 
The mineral deposition within beads was measured by  Alizarin Red staining assay, 
that showed unstained PDLABs in control conditions (see FIGURE 26, E, F), as 
well as red color was seen within PDLABs after 21 days of osteogenic 
differentiation (see FIGURE 26, K, L), with more intense red coloration for 
PDLABs/HARV/ODM (see FIGURE 26, L).
Comparing results for WJABs and PDLABs in osteogenic conditions (see FIGURE 
23, K and L, and see FIGURE 26, K and L), both cell populations were able to 
differentiate in osteogenic lineage, with an increased mineralization for PDLABs 
samples. Therefore, the presence of continuous medium flow in HARVTM vessels 
conditions provided a different environement where both WJABs and PDLABs 
underwent a stronger mineral deposition (see (see FIGURE 23, L and FIGURE 26 
L, respectively).
RUNX2 expression level was evaluated after 21 days of control and osteogenic 
conditions for PDLABs in 4 conditions. This analysis was done for 2 samples and 
results are shown (see FIGURE 27, samples 1 and 2).  Samples showed an 
higher RUNX2 level in osteogenic conditions (see FIGURE 27, samples 1 and 2, 
green column). On the other hand Col I expression levels seemed to vary more 
than RUNX2, despite of osteogenic differentiation (see FIGURE 28, samples 1 
and 2, yellow columns).
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GRAPHIC CONTENTS
The umbilical cord (UC) in cross section. The three round structures are vessels.   The two 
smallest are the umbilical arteries, and the largest is the umbilical vein. the wall of the vein is 
much thicker than the walls that you find in other veins. The material surrounding the vessels is 
so-called mucoid connective tissue, better known as Whartonʼs jelly. (modified from http://
www.med.uio.no/dlo/mikro/Images/img03748.jpg)
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At least six distinctive zones are now recognized based on the structural and functional studies: (a) 
surface epithelium (amniotic epithelium, UC epithelium), (b) UC blood,  (c) subamniotic stroma, (d) 
intervascular stroma , (e) perivascular stroma, ( (c), (d) and (e) recognized as Whartonʼs jelly) and 
(f) vessels.
FIGURE 1 
UMBILICAL CORD: OVERVIEW
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FIGURE 2 
NON ENZYMATIC ISOLATION OF WHARTONʼS JELLY (WJ) MSCs
The umbilical cord (A), cut longitudinally (B), was incised with a scalpel (C). WJ small pieces were 
washed several time before direct culture into flasks (D). WJ, Whartonʼs jelly.
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After 5 to 7 days of direct culture in tissue flasks (A), the outgrowth of spindle shape fibroblast-like 
cells was observed (B).  After 2 weeks WJ pieces were removed, and medium was changed, 
allowing colonies expansion and subconfluence (C). WJ, Whartonʼs jelly.
FIGURE 3
NON ENZYMATIC ISOLATION OF WHARTONʼS JELLY (WJ) MSCs
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Cells from the dental follicle give rise to the periodontal ligament (PDL).  These fibroblasts secrete 
collagen, which interacts with fibers on the surfaces of adjacent bone and cementum. The periodontal 
ligament is a group of specialized connective tissue fibers that essentially attach a tooth to the alveolar 
bone within which it sits. These fibers help  the tooth withstand the naturally substantial compressive 
forces which occur during chewing and remain embedded in the bone.
modifed by: Ten Cate, A. R. [1980] (1998). Oral Histology: development, structure, and function, 5th ed., St. 
Louis: Mosby. ISBN 0-8151-2952-1.
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FIGURE 4
PERIODONTAL LIGAMENT: OVERVIEW
modifed by: http://www.studiodentaire.com/en/glossary/tooth.php
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FIGURE 5 
NON ENZYMATIC ISOLATION OF PERIODONTAL LIGAMENT (PDL) CELLS
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Gently PDL was separated from the middle third of the tooth root surface using forceps and a size 
15 surgical blade (A), then washed and placed direclty in 6-well plate with culture medium (B). After 
4 to 6 days cells outgrowth was observed next to tissue pieces (C). Subconfluence was generally 
reached within 2 weeks (D). 
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FIGURE 6
CHARACTERIZATION OF WHARTONʼS JELLY (WJ) MSCs
Phenotype characterization of WJMSCs. I) Flow cytometric histograms showing the immunophenotype of WJMSCs 
(representative experiment). Open histograms represent the isotype control antibody, dotted histograms represent 
anti-CD3,  -CD14, -CD31, -CD34, -CD45, -CD73, -CD90, -CD105, -CD146 antibodies. X-axis, mean fluorescent 
channel;  Y-axis,  number of events. Lower part of panel I:  (A) representative fluorescence photomicrograph of 
WJMSCs monolayer  after Calcein-AM staining (magnification: 20x); (B, C) optical micrographs of hematoxylin 
counterstained WJMSCs (after 2 weeks of  culture),  showing a fibroblast-like morphology (Magnification:  20x and 
40x,  in panel B and C respectively). Bar corresponds to 20 μm. II) Schematical distribution of the cell surface 
parameters of the samples analyzed. 
%
 C
D
90
 p
os
iti
ve
-C
D
45
 n
eg
at
iv
e 100!
0! 10! 20! 30! 40! 50! 60!
70!
85!
!
B!A! C!
CD 3! CD 14! CD 31!  CD 34! CD 45! CD 73! CD 90! CD 105! CD 146!
!!
samples
131
FIGURE 7
CHARACTERIZATION OF PERIODONTAL LIGAMENT (PDL) CELLS
Phenotype characterization of PDLMSCs. I) Flow cytometric histograms showing the 
immunophenotype of PDLMSCs. The gated cells were negative for the hematopoietic line marker 
CD45 and CD34, partially positive for CD105 and STRO-1, and positive for the mesenchymal stem 
cells marker CD90. (A) Periodontal ligament cells STRO-1 expression. Binding of STRO-1 antigen to a 
cytospin preparation was detected by using FITC-conjugated secondary antibody on human 
PDLMSCs cultured for 7 days in standard medium. II) A,B: Representative fluorescence and brightfield 
photomicrographs of PDLMSCs monolayer  after Calcein-AM staining (magnification 10x).
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Adipogenic and osteogenic differentiation potential. The capacity of mesenchymal stem cells to 
generate stromal tissues including those similar to which they were derived from is recognized as a 
hallmark feature of these cells. The ability of WJMSCs and PDLMSCs to differentiate into osteblastic 
cell lineages in vitro can be investigated by culturing under inductive conditions. After 21 days of 
specific induction WJMSCs (see panel I) and PDLMSCs (see panel II) exhibited lipidic (A) and 
osteogenic (B) phenotype (magnification: 20x and 4x, in panel A and B respectively).
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FIGURE 8 
WJMSCs AND PDLMSCs DIFFERENTIATION POTENTIAL
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FIGURE 9
SCRATCH WOUND MIGRATION ASSAY: siRNA SILENCING STRATEGY FOR 
WJMSCs AND PDLMSCs PHENOTYPE MODULATION
Analysis of WJMSCs migration by in vitro scratch assay. 
(A) WJMSCs were transfected with 30 nM siSlug or a nonrelevant siRNA (scr) as negative control. 
Slug expression was determined at mRNA level. Knockdown of Slug expression was verified by Real-
Time RT-PCR.
(B) 72h after silencing treatment, WJMSCs monolayers were scratch wounded with a pipet tip (0h), 
and observed over the indicated time periods, 0h, 24h, and 48h (4X magnification). Images show 
siSlug treated cells exhibited a reduced capacity to cover the scratch if compared to untreated (ctr).
This set of experiments had the aim to investigate the effectiveness of wound assay in pointing out 
effect of cells phenotype modification, through the direct observation of different cells behaviour when 
comparing siSlug treated cells to control.
WJMSCs exibited a rapid modification of wound margin, due to active proliferation and migration 
ability.
ctr! siSlug!scr!
0 h!
24 h!
48 h!
!
"
0!
2!
4!
6!
Re
la
tiv
e 
Sl
ug
 m
RN
A 
le
ve
l!
ctr! scr! siS
lug
!
*!
#
134
FIGURE 9 (continued)
SCRATCH WOUND MIGRATION ASSAY: siRNA SILENCING STRATEGY FOR 
WJMSCs AND PDLMSCs PHENOTYPE MODULATION
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Analysis of PDLMSCs migration by in vitro scratch assay. 
(A) PDLMSCs were transfected with 30 nM siSlug or a nonrelevant siRNA (scr) as negative control. 
Slug expression was determined at mRNA level. Knockdown of Slug expression was verified by Real-
Time RT-PCR.
(B) 72h after silencing treatment, WJMSCs monolayers were scratch wounded with a pipet tip (0h), 
and observed over the indicated time periods, 0h, 24h, and 48h (4X magnification). Images show 
siSlug treated cells exhibited a reduced capacity to cover the scratch if compared to untreated (ctr).
as done for WJMSCs, observations went on for more 24 hours, showing that cellsʼ  Slug knockdown 
affected cells motility, avoiding any closure of the wound. These findings could lead to the speculation 
of an important role of SLUG also during tissue reparation and/or tissue regeneration,  as well as for 
PDL and PDLMSCs.
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FIGURE 10
OSTEOGENIC POTENTIAL OF WJMSCS: VARIABILITY BETWEEN SAMPLES
In the table (A) clinical parameters, RUNX-2 expression and  Alkaline Phosphatase activity (ALP) basal 
level (mmol/min/mg protein)  are reported. As indicated, the  samples were divided in two subgroups: 
subgroup  I, premature birth; subgroup II, full term birth.  F(female), M(male), CS(Caesarian delivery), 
SP(spontaneous delivery).
(B)The advance of the mineralization status (0d, 14d, 21d) for one representative sample of each 
subgroup is reported. The two samples  mineralized differently, according to the clinical parameters.
(C) The  analysis of the relationship  between the mineralization status (+, -) of the selected WJMSCs 
samples and, respectively, the basal level  (at day “0”) of RUNX-2 expression (on the left) and ALP 
activity (on the right) is reported. WJMSCs mineralize after 21 days in osteogenic conditions 
preferentially with high  basal level of RUNX-2 and ALP activity (* = P <0.05). 
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FIGURE 11
RELATIONSHIP BETWEEN MOLECULAR AND OSTETRIC PARAMETERS IN 
WJMSCs
Relationship between molecular and obstetric parameters. Basal levels of RUNX-2 expression and 
ALP activity were related to mother's age, weeks of pregnancy and birth weight in 20 WJMSC 
samples.
Motherʼs age at delivery had a significant impact on the basal ALP activity but didnʼt affect RUNX-2 
expression level. Interestingly, birth weight of the infant was shown to significatively impact on 
RUNX-2 basal expression level which decreases with the decreasing of the babyʼs weight. The same 
relationship  was found for the duration of pregnancy. In fact, it was found that WJMSCs from babies 
born before the 37 weeks of gestation express lower basal level of RUNX-2 than the full term borns. 
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FIGURE 12
POLYMERIC MICELLES (PMs)
Panel I) A micelle (A) is an aggregate of surfactant molecules dispersed in a liquid colloid. A typical 
micelle in aqueous solution forms an aggregate with the hydrophilic "head" regions in contact with 
surrounding solvent, sequestering the hydrophobic single tail regions in the micelle centre (B).
Panel II) (A) Scheme of microfluidic reactor. instead of traditional batch procedure to generate PMs, 
microfluidic reactor was chosen, with three inlets creating a hydrodynamic flow, focusing where the 
central stream is polymer Pluronic solution in DMSO. (B) The width of the focusing central stream, wf, 
is controlled by varying the volumetric flow rates of the three inlets.
MICELLES
-Aggregate of surfactant molecules (unimers) 
-Spontaneous self-assembling (CMC, hydrophobic 
effect)
-Hydrophilic block generally PEG
-Hydrophobic block (poly-ester, poly L-aminoacid, 
poly-ethers)
-Spherically shaped core–shell structures
-Size between 10 and 200 nm (freely circulate in the 
blood stream)
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MTT analysis was performed after 72 hours on cells exposed to the different PMs. Values are 
expressed as percentage of viable cells respect culture condition without osteogenic induction 
(DMEM High Glucose supplemented with 10% FCS). Data represent the average of 3 independent 
experiments, conducted in triplicate. Empty PMs were used as negative control.
Proliferation rate and viability of the PDLMSCs were compared. As shown, all different culture 
conditions exhibited no appreciable cytotoxicity (cells viability was higher than 75%).
Instead of traditional batch method for PMs, microfluidic synthesis of M-PMs was carried out. 
FIGURE 13
CITOTOXICITY OF PMs ON PDLMSCs: MTT ASSAY
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Cells  were cultured for 21 days in different conditions: (C) control medium (DMEM HG supplemented with 10% 
FCS); (ODM) osteogenic differentiation medium was supplemented with inducers (0.1 μM dexamethasone;  10 mM 
β-glycerophosphate;  50 μg/mL L-ascorbic acid-2-phosphate); (PMs) PMs medium (10% FCS DMEM HG) 
supplemented with 10 mM β-glycerophosphate and PMs containing 0.1 μM dexamethasone and 50 μg/mL L-
ascorbic acid-2-phosphate (working solution 100 μL/1 mL). PMs were realized with batch technique (B-PMs) or 
microfluidics (M-PMs). Mineralization status and viability  (with Alizarin Red Staining Assay and double staining with 
Calcein-AM and propidium bromide respectively) were tested at day 7, 14 and 21. Cells viability wasnʼt affected by 
PMs, that provided osteogenic differentiation of PDLMSCs either. Pattern of  mineralization was different for each 
condition.
FIGURE 14
EFFECT OF PMs-MEDIATED OSTEOGENIC DIFFERENTIATION ON PDLMSCs: 
VIABILITY AND MINERALIZATION.
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FIGURE 15
ALGINATE MICROBEADS: ENCAPSULATION DEVICE
Schematic representation of the encapsulation device. Monodisperse alginate beads containing 
WJMSCs were prepared using an encapsulation device which is based on a vibrating-nozzle 
(Encapsulator Research Inotech, Dottikon Switzerland) according to the experimental procedure 
previously described.33,34 The encapsulator is composed by a 2-liter glass reaction vessel with 
stainless steel top and bottom plates. The top  plate contains a feed-line connected to a syringe and a 
vibrating nozzle. A nozzle with an internal diameter of 300 μm was used. The flow of alginate to the 
nozzle is achieved by a precision syringe pump. 
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FIGURE 16
ALGINATE MICROBEADS GENERATION
Panel I): The production of alginate microbeads was optimized by changing different experimental 
parameters.
Panel II): Effect on alginate microbeads concentration of the dimensional and production rate of Ba-
alginate microbeads. (left column) Samples of microbeads produced with an alginate concentration of 
0.5, 1.0, 1.5 and 2.0% were analyzed for morphology, size and size distribution. Table showes that 
microbeads produced with an alginate concentration comprised between 1.0-2.0% (w/v) were spherical 
in shape and characterized by a smooth surface. Lowering the alginate concentration down to 0.5% (w/
v) caused partial broke-up  of beads resulting in particles with an irregular shape. This behaviour was 
attributed to the mechanical stress caused by the landing in the hardening barium chloride solution. 
TABLE 3. EFFECT OF ALGINATE CONCENTRATION ON THE DIMENSIONAL 
AND PRODUCTION RATE OF BA-ALGINATE MICROBEADS 
Alginate 
Conc. 
(%, w/v) 
Mean 
diameter 
±SD (mm) 
Skewne
ss Kurtosis 
Max. Production 
Rate*(g/s) Photo 
0.5 685.3±114.7 0.09 0.20 0.5 
 
 
1.0 586.4±84.4 2.84 10.70 1.7 
 
 
1.5 630.4±63.7 1.40 1.06 2.8 
 
 
 
2.0 645.8±66.5 1.28 4.53 4.2 
 
 
 
Data represent the average of three independent batch 
determinations. *Calculated n the dry weight of the alginate powder 
 
!!
! TABLE 1. PRODUCTION OF ALGINATE MICROCAPSULES BY VIBRATIONAL ENCAPSULATION PROCEDURE: THE INVESTIGATED EXPERIMENTAL PARAMETERS AND 
THEIR RANGE OF VARIATION 
 
Parameter Abbreviation Meaning Range 
frequency freq frequency of the vibration of the nozzle 100.0-140.0 hz 
amplitude amp amplitude of vibration of the nozzle 1.0-6.0 mm 
pump pump polymer pumping rate 7.5-9.5 mL/min 
height height distance from nozzle to surface of gelling bath  100.0-140.0 mm 
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FIGURE 17
ALGINATE MICROBEADS ENCAPSULATION OF WJMSCs
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Panel I): Optical (A, B) and fluorescence photomicrographs (C,D) of freshly prepared alginate 
microbeads containing WJMSCs. Dark field (C) photomicrographs were taken after double staining with 
Calcein-AM and propidium bromide. Cumulative size distribution analysis (E, F) of microbeads prepared 
for experiments.
Panel II): Viability of WJMSCs encapsulated in alginate microbeads (WJMSCs alginate beads, WJABs) 
after determination with the double staining assay with Calcein-AM and propidium bromide (panels A-
D). Bar corresponds to 200 μm. (E) The percentage of viable cells, by Calcein AM/Propidium iodide 
double staining, at “3”and “6”  day is reported in the graph (WJABs were cultured in in 6 well-plate (We) 
“control” culture medium (CCM) (WJABs/We/CCM). Adherent WJMCs: dashed bars; WJABs: white 
bars. (F) Determination by MTT assay of the viability of adherent WJMCs (dotted line) and 
encapsulated WJMCs (unbroken line) after 0, 3, 6 and 9 days of culture. Values are expressed as 
percentage of viable cells respect to day “0” (rated to 100%). Data represent the mean of two 
independent samples in quadruplicate ±SD.
 
!
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Secreted 
protein
Protein amount (pg/ml/mg ± S.D.) 
Adherent WJMSCs Encapsulated WJMSCs
IL-1α n.d. n.d.
MIG n.d. n.d.
IL-18 n.d. n.d.
β-NGF n.d. n.d.
SCF n.d. n.d.
TNF-β n.d. n.d.
LIF n.d. n.d.
IFN-α 4.83 ± 0.67 1.78 ±0.30
IL-2Rα 1.78 ± 0.73 0.75 ±0.32
CTACK 4.90 ±1.65 1.86 ±0.28
IL-16 0.83 ± 0.36 n.d.
VCAM 1.80 ± 0.40 0.80 ±0.30
IL-3 0.96 ± 0.41 n.d.
TRAIL 6.70 ±1.20 2.60 ±1.40
M-CSF 12.70 ±2.50 3.90 ±0.60
SDF1α 5.80 ±1.50 3.80 ±1.20
IL-12 11.20 ±2.16 4.60 ±0.95
ICAM-1 29.50 ±5.60 13.10 ±3.70
SCGF-β 959.00 ±209.00 289.60 ±98.20
GRO-α 4.20 ±1.70 25.70 ±8.60
MCP3 6.10 ±2.00 19.60 ±5.00
HGF 46.70 ±10.90 78.60 ±18.60
MIF 13.00 ±2.80 13.50 ±3.60
FIGURE 18
MSCs SECRETIVE PROFILE BEFORE AND AFTER ENCAPSULATION: BIOPLEX® 
ANALYSIS FOR WJMSCs
Data represent the average of four independent experiments conducted in triplicate.
WJMSCs, Whartonʼs jelly mesenchymal stem cells; IL-1a, interleukin- 1alpha; n.d., not detectable; b-NGF, 
beta-nerve growth factor; SCF, stem cell factor; TNF-b, tumor necrosis factor-beta; IFN-a, interferon- 
alpha; SCGF-b, stem cell growth factor-beta; HGF, hepatocyte growth factor; MIG, monokine induced by 
IFN-Gamma; LIF, leukemia inhibitory factor; CTACK, cutaneous T-cell-attracting chemokine; VCAM-1, 
vascular cell adhesion molecule-1; TRAIL, tumor-necrosis-factor related apoptosis inducing ligand; M-
CSF, macrophage colony stimulating factor; SDF-1a, stromal cell-derived factor 1a; ICAM-1, intercellular 
adhesion molecule-1; GRO-a, growth regulated oncogene-alpha; MCP3, monocyte chemotactic protein-3; 
MIF, macrophage migration inhibitory factor.
Adherent WJMSCs and alginate-encapsulated WJMSCs secretions were subjected to Bio-Plex 
analysis. Both secretive profiles are sumarized. Data is presented as normalization of the amount of 
factors (in pg/ml) released in culture medium for the cellular protein content. The panel of analyzed 
factors includes members of interleukins and chemokines families, growth factors and adhesion 
molecules soluble form. All the proteins analyzed have a molecular weight lower of the molecular weight 
cut off of the microbead membrane.
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WJMSCs in alginate beads (WJABs) after 21-day experimental period of osteogenic induction. Medium 
was changed every three days. WJABs were  cultured in 6-well (We) plate in osteogenic differentiation 
medium (ODM) (WJABs/We/ODM). 10%FCS supplemented DMEM LG  was chosen as “control” 
culture medium (CCM) condition (WJABs/We/CCM). 
Optical (A, B) photomicrographs of WJABs after 21 days of culture. Beads morphology was still regular 
and shape wasnʼt affected. Beads in osteogenic medium (B) seemed opaque, if compared to control 
ones (A). The Calcein AM/Propidium iodide double staining assay at day 21 showed that cells were vital 
in both conditions (C, D).The mineral deposition within beads was measured by Alizarin Red staining 
assay (E, F). (magnification 4x)
 
FIGURE 19
ALGINATE MICROBEADS ENCAPSULATION OF WJMSCs INDUCED TO 
OSTEOGENIC DIFFERENTIATION
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FIGURE 20
ALGINATE MICROBEADS ENCAPSULATION OF PDLMSCs INDUCED TO 
OSTEOGENIC DIFFERENTIATION
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PDLMSCs in alginate beads (PDLABs) after 21-day experimental period of osteogenic induction. 
Medium was changed every three days. PDLABs were  cultured in 6-well (We) plate in osteogenic 
differentiation medium (ODM) (PDLABs/We/ODM). 10%FCS supplemented DMEM LG  was chosen as 
“control” culture medium (CCM) condition (PDLABs/We/CCM). 
Optical (A, B) photomicrographs of PDLABs after 21 days of culture. Beads morphology was still 
regular and shape wasnʼt affected. Beads in control medium (A) appeared brighter if compared to the 
differentiated ones (B). Brown shade were recognized inside the beads, without affecting beads 
morphology or size. The Calcein AM/Propidium iodide double staining assay at day 21 showed that 
cells were vital in both conditions (C, D). The mineral deposition within beads was measured by Alizarin 
Red staining assay (E, F). (magnification 4x) 
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ALP activity and RUNX-2 expression level were evaluated after 21 days of cuture of alginate 
microbeads (WJABs and PDLABs) in control (We/CCM) and osteogenic conditions (We/ODM). 
Samples showed an increase of ALP and RUNX-2 levels after osteogenic induction. 
the increase of markers was significant (* p< 0.05) except for RUNX2 in PDLABs.
ALP activity
RUNX2
FIGURE 21
ALGINATE MICROBEADS ENCAPSULATION OF WJMSCs AND PDLMSCs 
INDUCED TO OSTEOGENIC DIFFERENTIATION: OSTEOBLASTIC MARKERS
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FIGURE 22 
ROTARY CELL CULTURE SYSTEMTM  (RCCS-4TM BIOREACTOR) WITH HIGH 
ASPECT RATIO VESSEL (HARVTM )
Panel I) Rotary Cell Culture SystemTM . A cell suspension bioreactor is a closed stirred vessel where it is 
possible to inline monitor and control some culture parameters. One approach to maintain 
homogeneous environment with low stress, is the use of rotating wall vessels (RWV).  The National 
Aeronautics and Space Administration (NASA) developed the Rotary Cell Culture SystemTM (RCCS-4TM 
bioreactor, SyntheconTM, Inc., Houston, TX, U.S.A.), with 2 different systems:  High Aspect Ratio Vessel 
(HARVTM).
Panel II) High aspect ratio vessel: side view (left) and front view (right). With HARVTM  system gas 
exchange is provided by a 31.4 cm2 gas exchange membrane at the inner concentric cylinder. On 
Earth, this reactor is often rotated at a speed of approximately 15–30 rpm as the tissues grow, so the 
constructs in the reactor are maintained ʻʻstationaryʼʼ in a state of continuous free-fall. Solid body 
rotation of the constructs at higher rotating speeds is also reported in space and Earth experiments. 
Both the inner and outer cylinders can be independently rotated [Martin & Vermette 2005].
The high aspect ratio vessel (HARV) allows high level of gas exchange. It is enhanced by the presence 
of a large gas exchange membrane at one end of the vessel.
Panel III) RCCS-4TM bioreactor with 10 mL HARVTM vessel inside incubator. Cells culture can be easy 
maintained at 5% CO2 and 37°C.
!
!!!
!!
148
FIGURE 23
ALGINATE MICROBEADS ENCAPSULATION OF WJMSCs INDUCED TO 
OSTEOGENIC DIFFERENTIATION:  EFFECT OF ROTARY CELL CULTURE 
SYSTEMTM  (RCCS-4TM BIOREACTOR) WITH HIGH ASPECT RATIO VESSEL 
(HARVTM ).
WJMSCs in alginate beads (WJABs) after 21-day of osteogenic induction. WJABs were  cultured in 6-
well (We) plate in osteogenic differentiation medium (ODM) (WJABs/We/ODM),and in “control” culture 
medium (CCM) condition (WJABs/We/CCM). WJABs were also cultured in Rotary Cell Culture 
SystemTM (RCCS-4TM bioreactor) with High Aspect Ratio Vessel (HARVTM), in osteogenic 
differentiation medium (ODM) (WJABs/HARV/ODM). 10%FCS supplemented DMEM LG  was chosen 
as “control” culture medium (CCM) condition (WJABs/HARV/CCM). 
Optical (A, C, G, I) photomicrographs of WJABs after 21 days of culture. Beads morphology was still 
regular and shape wasnʼt affected. Beads in osteogenic medium (G, I) seemed opaque, if compared to 
control ones (A, C). The Calcein AM/Propidium iodide double staining assay at day 21 showed that cells 
were vital in 4 conditions (B, D, H, J).T The mineral deposition within beads was measured by Alizarin 
Red staining assay. It showed unstained cells (E, F) in both control conditions, and intense red color fot 
both osteigenic conditions, within and out of HARVTM vessel (K, L), suggesting that the cells underwent 
osteogenic differentiation despite encapsulation .
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FIGURE 24 
ALGINATE MICROBEADS ENCAPSULATION OF WJMSCs INDUCED TO 
OSTEOGENIC DIFFERENTIATION: EFFECT OF ROTARY CELL CULTURE 
SYSTEMTM  WITH HARVTM VESSEL ON RUNX2 EXPRESSION.
RUNX2
sample 1
sample 2
0!
5!
10!
7,5!
2,5!
Day 0! Day 21!
WJABs/WE! WJABs/HARV!
0!
5!
10!
7,5!
2,5!
Day 0! Day 21!
WJABs/WE! WJABs/HARV!
RUNX2 expression level was evaluated after 21 days of cuture of WJMSCs encapsulated in alginate 
microbeads (WJABs). Levels  were compared before osteogenic induction (Day 0) and after 21 days 
of culture in both conditions (6-well plate culture, WE, and HARVTM vessels, HARV) in control (We/
CCM and HARV/CCM, white columns) and osteogenic conditions (We/ODM and HARV/ODM, green 
columns).  Samples showed an higher RUNX2 level in osteogenic conditions.
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FIGURE 25 
ALGINATE MICROBEADS ENCAPSULATION OF WJMSCs INDUCED TO 
OSTEOGENIC DIFFERENTIATION: EFFECT OF ROTARY CELL CULTURE 
SYSTEMTM  WITH HARVTM VESSEL ON COL I EXPRESSION
COL I
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COL I expression level was evaluated after 21 days of cuture of WJMSCs encapsulated in alginate 
microbeads (WJABs). Levels  were compared before osteogenic induction (Day 0) and after 21 days 
of culture in both conditions (6-well plate culture, WE, and HARVTM vessels, HARV) in control (We/
CCM and HARV/CCM, white columns) and osteogenic conditions (We/ODM and HARV/ODM, yellow 
columns).  Samples showed an higher Col I level in control conditions.
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FIGURE 26 
ALGINATE MICROBEADS ENCAPSULATION OF PDLMSCs INDUCED TO 
OSTEOGENIC DIFFERENTIATION:  EFFECT OF ROTARY CELL CULTURE 
SYSTEMTM  (RCCS-4TM BIOREACTOR) WITH HIGH ASPECT RATIO VESSEL 
(HARVTM ).
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PDLMSCs in alginate beads (PDLABs) after 21-day experimental period of osteogenic induction. 
Medium was changed every three days. PDLABs were  cultured in 6-well (We) plate in osteogenic 
differentiation medium (ODM) (PDLABs/We/ODM). 10%FCS supplemented DMEM LG  was chosen 
as “control” culture medium (CCM) condition (PDLABs/We/CCM).  PDLABs were also cultured in 
Rotary Cell Culture SystemTM  (RCCS-4TM   bioreactor) with High Aspect Ratio Vessel (HARVTM), in 
osteogenic differentiation medium (ODM) (PDLABs/HARV/ODM). 10%FCS supplemented DMEM LG 
was chosen as “control” culture medium (CCM) condition (PDLABs/HARV/CCM). 
Optical (A, C, G, I) photomicrographs of PDLABs after 21 days of culture. Beads morphology was still 
regular and shape wasnʼt affected. Beads in osteogenic medium (G, I) seemed opaque, if compared 
to control ones (A, C). The Calcein AM/Propidium iodide double staining assay at day 21 showed that 
cells were vital in 4 conditions (B, D, H, J).T The mineral deposition within beads was measured by 
Alizarin Red staining assay. It showed unstained cells (E, F) in both control conditions, and intense red 
color fot both osteigenic conditions, within and out of HARVTM vessel (K, L), suggesting that the cells 
underwent osteogenic differentiation despite encapsulation .
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FIGURE 27 
ALGINATE MICROBEADS ENCAPSULATION OF PDLMSCs INDUCED TO 
OSTEOGENIC DIFFERENTIATION: EFFECT OF ROTARY CELL CULTURE 
SYSTEMTM  WITH HARVTM VESSEL ON RUNX2 EXPRESSION.
RUNX2 expression level was evaluated after 21 days of cuture of PDLMSCs encapsulated in alginate 
microbeads (PDLABs). Levels  were compared before osteogenic induction (Day 0) and after 21 days 
of culture in both conditions (6-well plate culture, WE, and HARVTM vessels, HARV) in control (We/
CCM and HARV/CCM, white columns) and osteogenic conditions (We/ODM and HARV/ODM, green 
columns). Samples showed an higher RUNX2 level in osteogenic conditions.
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FIGURE 28 
ALGINATE MICROBEADS ENCAPSULATION OF PDLMSCs INDUCED TO 
OSTEOGENIC DIFFERENTIATION: EFFECT OF ROTARY CELL CULTURE 
SYSTEMTM  WITH HARVTM VESSEL ON COL I EXPRESSION
COL I expression level was evaluated after 21 days of cuture of PDLMSCs encapsulated in alginate 
microbeads (PDLABs) Levels  were compared before osteogenic induction (Day 0) and after 21 days 
of culture in both conditions (6-well plate culture, WE, and HARVTM vessels, HARV) in control (We/
CCM and HARV/CCM, white columns) and osteogenic conditions (We/ODM and HARV/ODM, yellow 
columns). 
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DISCUSSION
Better quality of life ask, together with progressive population aging, are increasing 
bone tissue transplant cases and needings. Bone defects repair, with attention to 
replacement with funcitional healthy bone, is a significant question in everyday 
clinical work. 
Autogeneous bone is still the most effective bone graft substitution material (“gold 
standard”), fulfilling all essential physico-chemical and biological properties, 
despite its inherent limitations (availability, morbility, postoperative pain).
The most common alternatives to the auto-graft material are allografts (human) or 
xenografts (animal, e.g., bovine). Allografts have the disadvantages of limited 
supply  and potential infectivity, while the use of xenografts could lead to 
unfavorable immune response and also infectivity. 
Considering problem list connected to few donors availability, possible infections 
and rejection of heterologous tissue implanted, bone tissue engineering is having 
in these years particolar impulse.
Tissue-engineered bones with excellent biocompatibility  are common alternatives 
to autogeneous bone, xenograft, or allograft materials. 
In this scenario, scientific community is paying attention (i) to cellular and 
molecular research fields, to discover new factors that potentially can improve or 
stimulate the production of bone within the defect, and (ii) to biomaterials field, to 
create effective “combined systems” (combinations of cells/biomolecules/
biomaterials). 
In vitro cultures of osteoblasts and chondrocytes progenitors (mesenchymal stem 
cells, MSCs) and adult cells (osteoblasts and chondrocytes) together in vivo 
animal models are traditionally used to study cell physiology and development. In 
the last years the employment of different strategies of differentiation induction are 
designed giving to researchers useful information in field of regenerative medicine 
DISCUSSION
155
too. Particularly, a lot of studies appraised the interactions between progenitors or 
mature cells and biomaterials for the development of orthopedic devices, with the 
aim of treating bone defects that can affect skeletal system as well as dental root 
support tissues.
In vitro studies have been dedicated to screening new scaffolds for use in vivo, 
with particular attention to their ability in supporting infiltration of host cells 
(osteoconductive) and enhance bone regeneration (osteoinductive). 
More recently, tissue-engineered bone constructs based on scaffold-cells 
combinations benefit from the use of dynamic cell culture system represented by 
bioreactors. The benefits from these technological innovations in the form of 
“multidimensional systems” implantable in vivo to form bone are numerous. In fact, 
biodegradable polymer scaffolds permit cells to maintain or differentiate their 
phenotype, provide a three-dimensional framework for tissue regeneration; 
bioreactors provide control over the conditions of cell seeding and tissue 
cultivation and affected construct structures and compositions [Jin et al. 2010]. 
In situ engineered constructs containing in vitro expanded autologous cells could 
be used to regenerate tissue within the defect. The key technique for 
bioengineering tissue passes necessarily  through the developing of in vitro 
strategies to achieve plenty  of functional seeded cells. A theoretical way to achieve 
this goal would be to provide a “stimulatoryʼʼ environment for cells to expedite 
tissue engineering.
Bone tissue engineering using MSCs is one of the most promising alternatives to 
estabilish treatment for bony defects. This approach has all of the advantages of 
an autograft, but is not subject to supply  limitations due to its self-renewal capacity 
[Jin et al. 2010]. 
All these considerations are subjected to several matters. Bone tissue 
regeneration and repair obtained through cell-based therapy requires special 
attention to at least four major issues:
- the definition of optimal osteoprogenitor sources; 
- the definition of innovative strategies for the commitment of human cultured 
MSCs towards osteogenic lineage; 
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- the search for new suitable scaffolds, in consideration of which defect has to be 
repaired;
- the knowledge of the molecular networks implicated in osteogenic 
differentiation, and, at the same time, the identification of the role of specific 
transcription factors in mediating the fate and maturation of human MSCs.
During last years many different efforts have been and still are being made to 
solve and overcome problems concerning these major issues. Unfortunately, 
current therapies, including tissue regeneration strategies and their combination 
with various bone substitutes, do not always yield a satisfactory clinical outcome. It 
is therefore important to develop new strategies that can increase the reliability 
and effectiveness of tissue regeneration. 
Recently, biological approaches have emerged as interesting alternatives to 
existing treatments for the repair and regeneration of the lost bone, or 
periodontium too [Froum et al. 2002; Elangovan et al. 2009]. Such approaches 
have included protein-based, cell-based, and gene-based therapies, as well as the 
local application of biocompatible scaffolds containing selected growth factors. 
Each approach has its own advantages and disadvantages, and all of them are 
suitable only for some defects, laking of universal characteristics and hallmark that 
can make the suggested models useful for any bone defect, in any anatomic 
district. 
This thesis focused on developing the concept borrowed from updated literature 
on engineered tissue regeneration and the use of human MSCs for in vitro and in 
vivo studies. The main aims were (i) to understand, control and influence all 
processes and biomolecular interactions between cells and environment, (ii) to 
modulate most useful cell phenotype characteristics during tissue regeneration, 
(iii) to contribute to treat tissue defect, particulary periodontal or bone defects, with 
appropriate MSCs transplant. 
This can be achieved only through several pre clinical experiments, considering 
and investigating factors that can affect cell differentiation and proliferation, 
mimicking in vitro, as accurately as possible, conditions of in vivo environment.
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Considering the four major issues previously  cited, this thesis work focused on the 
development of experiments and strategies useful for model applicable in tissue 
engineering and regenerative medicine field, through the employment of two 
different human cell populations, Whartonʼs jelly mesenchymal stem cells 
(WJMSCs) and periodontal ligament mesenchymal stem cells (PDLMSCs).
Along with the ease of accessibility, lack of ethical concerns, and abundant cell 
number, WJMSCs was shown to be an attractive, alternative source of progenitor 
or stem cells for basic research. On the other hand periodontal ligament has been 
recognized as a reliable adult source of MSCs. 
Due to this consideration, the chance to extract MSCs from an easy to reach 
tissue was considered by our group, with the aim to investigate characteristics of 
this cell population and compare them to WJMSCs.
In both cases, our findings demonstrated the successful isolation and 
characterization of undifferentiated progenitor cells from both examined tissues, 
the umbilical cord Whartonʼs Jelly  and the periodontal ligament of extracted teeth: 
these cells can be expanded in vitro, providing a unique reservoir of stem cells 
obtained with minimally invasive procedures from otherwise discared tissues. 
Therefore, these cells displayed both important hallmarks for our research 
purposes:
-  easy samples recruitment;
-  lack of ethical controversies;
-  easy culture and ex vivo expansion;
-  reliable and consistent osteogenic potential and differentiation
-  relatively homogeneous populations and superimposable characteristics.
The way we chose to explore these features and answer to major issues is 
reported.
Because of WJMSCs properties, umbilical cord was confirmed to be a 
noncontroversial and feasible source of mesenchymal stem cells, with high 
potential in term of viability, adhesion, proliferation before and after 
cryopreservation. This study showed that the WJMSCs could be easily isolated 
and expanded without morphological and characteristic changes.
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The data on WJMSCs are promising, and there may be important therapeutic uses 
for these cells. Even if further studies are required to better understand the precise 
nature of umbilical cord matrix-derived cells and to explore their potential clinical 
applications, nevertheless, along with the ease of accessibility, lack of ethical 
concerns, and abundant cell number, WJMSCs may be an attractive, alternative 
source of progenitor or stem cells for basic research.
Within all WJMSCs samples recruited, we characterized WJMSCs from different 
donors for their osteogenic potential, trying to establish predictable elements to 
discriminate the cells with most promising osteoprogenitor cell potential.
The comparative study between the presence of osteoblastic markers and 
different obstetric parameters, including babyʼs gender and birth weight, motherʼs 
age at delivey, gestational stage at parturition and mode of delivery was 
performed. We found that osteoblastic potential was not influenced by babyʼs 
gender, motherʼs age at delivey, and mode of delivery. On the contrary, the highest 
degree of osteoblastic potential has been shown by WJMSCs with RUNX-2 
transcription factor high basal levels, selected from umbilical cords of the heaviest 
term babies.
Even if further evaluation is required, our hypothesis is that our findings may help 
in selecting the optimal umbilical cord donors and in collecting high potential 
Whartonʼs jelly-derived osteoprogenitors efficiently. The analysis of the basal level 
of RUNX-2 and ALP activity could allow to quickly  test an high number of 
mesenchymal precursors cultured in vitro and select the more suitable to 
potentially use for bone tissue engineering application. In addition, for the same 
aim, our results suggest that it is preferred to recruit the samples from full term 
borns without paying attention to motherʼs age.
These observations suggested that it may be possible to discriminate among 
different WJMSC samples those will have a positive outcome towards osteoblastic 
differentiation.
Our findings also demonstrated the successful isolation and characterization of 
undifferentiated progenitor cells contained in human PDL, that can be expanded in 
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vitro, providing a unique reservoir of stem cells obtained with minimally invasive 
procedures from discared tissue. 
When MSCs hallmarks are investigated, the in vitro-obtained data are overly 
dependent on culture conditions for isolation and expansion of MSC populations 
and, therefore, are unlikely to be extrapolated to the native cells. Moreover the 
optimal combination and concentration of soluble and molecular factors to treat 
MSCs, to preserve the stem state, or optimize cells differentiation, has not been 
yet established.
To overcome these problems, i.e. the cytotoxic effects of some molecules 
necessary to dissolve inducers in medium, we developed alternative strategies for 
osteogenic differentiation.
A first set of experiments considered PDLMSCs useful to analyze and observe 
effects of entrapped inducers, like dexamethasone and ascorbic acid, in polymeric 
micelles (PMs), reducing the use of DMSO to dissove them in culture medium for 
osteogenic differentiation. 
During in vitro experiments efforts to modify  environment in terms of composition 
and soluble molecules revealed a different osteogenic potential for PDLMSCs 
population tested than what expected, confirming that collateral events (i.e. culture 
medium flow inside the well, presence of higher concentration of toxic molecules 
than expected, like DMSO) cas affect cells characteristics in term of proliferation 
and differentiation. The use of the PMs as delivery systems increased the 
osteogenic potential of the cells, allowing to control in terms of space and time the 
release of inducers, avoiding uncontrolled presence of DMSO and all its well 
known side effects.
It is important to underline that delivery system of bioactive factors to target cells 
or tissues is a very  critical aspect in tissue engineering [Richardson et al. 2001]. 
Since tissue repair or regeneration is a complicated cascade of the multiple events 
in which a large number of growth factors or hormones are associated, a finely 
controlled release system, like the one investigated by our group, based on PMs, 
of specific growth factors or drugs is one of the pivotal strategies in achieving the 
goal of tissue engineering.
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During in vitro osteogenesis, the molecular and cellular mechanisms underlying 
the sequential differentiation of mesenchymal stem cells into osteogenic lineages 
have been the object of numerous studies. Several factors have been identified 
influencing these processes. To date, there have been several successful 
approaches to direct osteogenic differentiation of MSCs from different sources as 
well as success in the fabrication of bone-like tissue using 3-D supporting matrixes 
and culture systems. 
This approach has the potential advantage of transplanting a preformed functional 
“combined systems”. However, cells tend to retain their differentiated phenotype in 
vitro only if cultured under conditions that resemble their natural in vivo 
environment. 
Both cell attachment and incorporation in vitro, as well as subsequent tissue 
maturation during in situ regeneration, are crucial features of tissue engineering. 
Therefore, the supporting 3-D structure plays a crucial role that need to be taken 
into consideration when designing tissue-engineering scaffolds [Boyan et al. 
1996].
These considerations drove our group  to develop and set of experiments aimed at 
defining cells behaviuor after modification of environment from a traditional 2-D 
culture condition to a 3-D one. The 3-D systems tested were: alginate microbeads 
and cell culture in bioreactor.
The produced barium-alginate microbeads were characterized by excellent 
morphological characteristics as well as a very narrow size distribution. The 
microencapsulation procedure did not alter the morphology and viability of the 
embedded WJMSCs. The described encapsulation procedure represents a 
promising strategy to use WJMSCs for possible in vivo applications in tissue 
engineering and biomedicine.
The same protocol for encapsulation was chosen for WJMSCs and PDLMSCs, 
due to similar cells characteristics. The use of barium ions (instead of more often 
used calcium ions) resulted in the formation of mechanically stable microbeads 
DISCUSSION
161
with an extremely high biocompatibility, preserving the in vitro and in vivo viability 
of the embedded cells. 
When induced to osteogenic differetiation, embedded cells showed also an 
increase of the expression of osteoblastic markers such as Runx2, and ALP 
activity. Presence of mineralization was detected, and these results suggested that 
despite encapsulation the cells underwent osteogenic differentiation.
In addition, we investigated the functional properties, in term of secretive profiles 
of both free and encapsulated WJMSCs. The analyzed factors were members of 
the family of interleukins, chemokines, growth factors and soluble form of adhesion 
molecules These experiments showed that upon encapsulation, most of the 
proteins analyzed were secreted both by the free and encapsulated cells, even if 
in a different extent. 
Without forcing the speculations on these data, nevertheless some considerations 
may be done. The decrease of SCGF-β production by encapsulated WJMSCs 
may be correlated with their cytostaticity. In fact, SCGF-β is a cytokine of the C-
type lectin family acting on hematopoietic stem/progenitor cells to support their 
proliferation. In addition, an appreciable decrease in the production of factors 
strictly associated with the immune response including IFN-α (-63%), IL-12 (-60%) 
51,52 was observed in encapsulated cells. IL-3 and IL-16 became undetectable 
after encapsulation. This should be interpreted as a benefit in consideration of an 
effective role of alginate in the protection of the cells from the hostʼs immune 
response. In this respect it should be underlined that the optimized microbeads 
have shown an excellent biocompatibility  and immunoprotection skills, as 
demonstrated by  in vivo studies conducted up to 8 months of transplantation in the 
peritoneal cavity of NOD mice [Luca et al. 2007]. The microbeads hardened with 
barium chloride were freely floating in the peritoneal cavity and morphologically 
intact, with the majority of the microbeads free of fibrotic tissue overgrowth. In 
addition at 8 months of transplantation, the encapsulated cells were extraordinarily 
viable [Luca et al. 2007].
At present time, we donʼt know the correlation between the functionality of 
encapsulated WJMSCs and the over-production of two important chemokines 
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(GRO-α and MCP3) involved in mesenchymal stem cell chemotaxis and a 
pleyotropic cytokine of mesenchymal origin (HGF, hepatocyte growth factor) 
promoting migration and survival of MSCs. Nevertheless it is interesting to 
underline that HGF is one of the factors with therapeutic potential in regenerative 
medicine. In addition, many researchers are looking for the best approach to 
maintain the therapeutic level of HGF at the repair site for endogenous stem cell 
recruitment [Neuss et al. 2004].
These results pointed out that the extracellular matrix can control stem cell fate, 
inducing seeded MSCs towards osteogenesis depending on its physical 
properties. These findings opened up avenues for the regulation of MSCs 
differentiation using physical factors, combining these conditions with the use of 
biomolecules too. Consequently, biological features of cells in different conditions, 
in term of proliferation and differentiation rate, gene expression and sensitivity  to 
specific biological response modifier, were strongly modify.
Bioreactors have been proven to be able to provide cell a new tool for the study of 
three-dimensional (3-D) cell growth and differentiation. 
With the aim to verify if differentiation could be enhanced through the improvement 
of cells exchanges with culture environement, we performed experiments in Rotary 
Cell Culture SystemTM (RCCS-4TM bioreactor, SyntheconTM, Inc., Houston, TX, 
U.S.A.) with High Aspect Ratio Vessel (HARVTM) 
The rotational motion of the system chosen prevented sedimentation, creating an 
optimized suspension culture able of supporting living cells in alginate microbeads. 
The HARVs used in the RCCS-4TM provide two essential components of the 
optimized suspension cell culture system:
- the solid body rotation (minimal shear stress and mechanical damage to the 
microbeads)
- diffusion-mediated oxygenation (oxygenation occurs as a result of a silicon 
membrane that allows appropriate diffusion of gases preventing hypoxic 
conditions and turbulence inducing air space or bubbles.
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In the preliminary study  reported in this thesis, the microgravity hydrodynamic 
conditions during in vitro cultivation of alginate microbeads was costant, with use 
of rotating vessels.
Fluid flow and mixing markedly affected the aspect and composition (in term of 
presence of Alizarine-positive mineral deposits) of alginate microbeads containing 
MSCs. In the rotating vessels, the associated fluctuations in fluid velocity 
appeared to permit the MSCs to maintain their differentiated phenotype and to 
depose mineral extracellular components.
Despite different results and findings coming from literature (due to the big amount 
of differences and experimental designs for each kind of mammalian cells 
examined), this dynamic system provided a useful in vitro model to understand 
and control the effects on proliferation, differentiation, and MSCs osteogenic 
potential in hydrodynamic conditions. Regulation of these parameters in 
bioreactors could modulate the composition, morphology, and function of 
“combined systems” (combinations of cells/biomolecules/biomaterials). 
In particular, enhanced rates of mass transfer and hydrodynamic effects 
associated with dynamic laminar flow patterns in rotating vessels were expected to 
stimulate MSCs to differentiate and  regenerate a functional extracellular matrix. 
Based on findings obtained, new studies in dentistry  could be designed to identify 
and characterize dental-derived stem cells populations, aiming at developing more 
predictable regenerative approaches for lost tissues as consequence of disease 
and/or trauma. Considering oral defects, the bone loss around teeth is due to a 
combined loss of hard and soft tissues, that all together form the periodontal 
ligament complex. Thus regeneration of all these tissues is the ultimate goal of 
clinical periodontal therapy [Yang et al. 2010].
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CONCLUSIONS AND FUTURE WORK
Our study  encourages the development of alternative strategies to induce efficient 
differentiation for clinical use of hMSCs in bone and cartilage tissue engineering 
and repair.
Considering present knowledge, reseachers efforts and developing technologies, 
there are several main objectives that need to be addressed for the development 
of effective cellular-based therapies for regenerative medicine: 
- Development of new strategies to select most potential cells donors/sites could 
be helpful in expanding and obtaining larger cell population, overcoming the 
problem connected to the small number of stem cells in adult tissue stem cell 
niche;
- In vitro manipulation of MSCs could allow the maintenance of their proliferative 
phenotype, meant as “characterized by  stemness”. On the other hand, 
strategies to prevent and avoid MSCs transformation have to be developed, in 
order to ensure safe use in short and long term terapies with these cells;
- Upregulation or downregulation of proper gene expression, could modify 
permanently or not cells characteristics, easing their use for both investigation 
of cell-based therapy.
All these efforts and increasing knowledge around MSCs during basic research 
experiments will be of considerable clinical significance, especially in terms of 
developing novel mechanisms of achieving tissue regeneration.
Within regenerative medicine field, the idea to realize, through the smart 
combination of biomolecules and cells in a system useful also "in vivo" for bone 
disease therapy, it is tightly linked to availability of proper biomaterials and 
scaffolding strategies.
Considering the specific biomaterials field, recently, a variety of systems has been 
proposed for matrix and membrane with immunoisolation devices with different 
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physio-chemical properties and geometries, including vascular perfusion devices, 
avascular diffusion chambers, macrocapsules, microcapsules and conformal 
coating. 
The needing for vascular surgery, and associated risks of surface-induced 
thrombosis, has largely limited the development of vascular perfusion devices. 
Although notable exceptions exist, clinical application of macrocapsules and 
avascular diffusion chambers has been hampered because of insufficient oxygen 
and nutrient transport to cells in the center of such devices. Consequently, largest 
part of immunoisolation strategies employed microcapsules, consisting of cells or 
cell clusters entrapped within a spherical semi-permeable membrane, an 
inherently favourable geometry for diffusive nutrient transport, that can be 
implanted with minor surgery. Cell encapsulation/entrapment represents a 
technique for the entrapment of viable cells within a semi-permeable polymeric 
membrane or 3-D scaffolds.
These matrices are usually formulated to allow small molecules, such as nutrients, 
growth factors and pro-differentiating agents, to freely permeate through 
microcapsules, while blocking larger molecules (antibodies) and cells. 
Encapsulation allows both (i) the transplant of xenogenic or allogenic cells into a 
host to repair or replace damaged or diseased tissue without the need of 
immunosupressive regimens as well as (ii) to co-cultivate cells of different origin 
and/or histotype without the needing of a physical separation between the cells. 
Most cell immobilization matrix are usually composed of biopolymers such as 
alginate, carrageenans, collagen, chitosan, cellulose and agar/agarose. 
Despite technological advancements, just described, it must be underlined that the 
use of immunoisolated cells for transplantation is rather limited because of the 
scarce viability, functionality and tissue-integration of the transplanted cells.
All these aspects, could be improved through the use of developed biomaterials, 
using new concept of "multicompartimental scaffolds".
The biomaterials for cell transplantation would be improved, including inside stubs 
polymeric molecules able (i) to avoid immune system answer toward installed 
cells, (ii) to dispatch a function of "scavenger", to inhibit or to metabolize cytotoxic 
molecules, (iii) to influence the proliferation and differentiation through gene 
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expression modulation (i.e. RNA interference) and finally (iv) to promote cells 
adhesion of polymeric scaffold to damaged tissue.
A further application of the concept of multicompartimental scaffolds is the 
realization of new scaffold with different matrix and functions.
Thus, alginate or agarose in combination with adhesion proteins such as 
fibronectin, vitronectin and laminin could be proposed to promote cell anchorage 
and interaction of cells within the multicompartimentali scaffold.
The smart choice of biomaterials has to consider also the characteristics of the 
defect, in terms of anatomic shape and size.  An interesting approach to combine 
these efforts could be given by MSCs embedded in alginate microbeads and 
transplanted in vivo.  Considering that stem cells exhibit the ability to sense and 
move in the direction of a chemoattractant, the elective secretion of pleyotropic 
cytokine of mesenchymal origin, promoting migration and survival of MSCs, could 
be useful for cells homing strategies, i.e. through the implant of beads in the defect 
area.
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